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Abstract  
Atopic eczema is a common, complex trait that is highly heritable. This thesis 
describes a body of research over 5 years, from 2014 to 2019, highlighting six key 
publications. These are described on a background of intense activity within the field 
of atopic eczema genetic research, stimulated by the discovery, in 2006, of loss-of-
function mutations in the gene encoding filaggrin (FLG). FLG null mutations play a 
major role in eczema and other atopic diseases and my work has built on this seminal 
discovery. I described, for the first time, transcriptomic features of FLG 
haploinsufficiency (Cole et al. J Allergy Clin Immunol 2014). I tested the effect of 
FLG null mutations on the skin’s response to ultraviolet-induced erythema in vivo 
(Forbes et al. J Allergy Clin Immunol 2016). I optimised a well-established organoid 
model, using primary human keratinocytes and fibroblasts to recapitulate aspects of 
human skin for functional testing of specific genetic effects. Quantitative global 
proteomic analysis of the organoid model with FLG knockdown has replicated 
findings from previous transcriptome analyses and showed evidence of keratinocyte-
immune cell cross-talk and disordered axon guidance (Elias et al. Wellcome Open 
Research 2019). Detailed analysis of the organoid model with knockdown of the 
transcriptional repressor EMSY has shown, for the first time, that this protein is a 
master-regulator of multiple aspects of skin barrier formation (Elias et al. J Allergy 
Clin Immunol 2019). Taking a statistical approach driven by a clinical question, 
longitudinal latent class analysis applied to two independent populations identified 
distinct subgroups of eczema (Paternoster et al. J Allergy Clin Immunol 2018) in 
which the most long-lasting phenotypes show the greatest genetic risk, including 
FLG null genotype. Finally, leveraging the similarities and differences between 
eczema and psoriasis, a genome-wide comparative analysis identified opposing 
genetic mechanisms in these common inflammatory skin diseases (Baurecht et al. 
Am J Hum Genet 2015) providing a theoretical rationale for therapies designed to 
rebalance the skin’s tendency to atopic versus psoriatic inflammation. Together this 
body of work has substantially increased understanding of genetic mechanisms in 
atopic skin, with important clinical applications and opportunities for much-needed 
therapeutic development.  
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CHAPTER ONE: Introduction 
 
Atopic eczema 
Nomenclature 
Atopic eczema is a term used synonymously with ‘atopic dermatitis’ and ‘eczema;’1 
the nomenclature has continued to be a topic for debate in the field over several 
decades.2-17 For the purposes of this thesis I will use the term ‘atopic eczema’ when 
there is evidence of some knowledge relating to an atopic (IgE-mediated) immune 
response and ‘eczema’ as an umbrella term, in keeping with the World Allergy 
Organisation nomenclature,1 where specific atopic features are not clearly defined.  
 
Clinical features 
Atopic eczema is an itchy inflammatory skin condition associated with significant 
morbidity.11,15,18 It is characterised by skin barrier impairment, cutaneous and 
systemic inflammation.18 
Eczema is highly prevalent, affecting up to 25% of school-aged children (with a 
range from 0.2% to 24.6% worldwide)19,20 and up to 10% of adults.21 It 
characteristically presents in childhood and 70% of cases show onset before 5 years 
of age.15 However eczema follows a chronic relapsing and remitting course with over 
10% of cases persisting into adult life or recurring in adulthood.15 A subset of 
eczema cases develop for the first time in adult life22,23 and it is not clear whether 
they may be atopic eczema, irritant contact or allergic dermatitis, or a combination of 
these disorders. Approximately 40% of patients with eczema have extra-cutaneous 
atopic co-morbidities including asthma, allergic rhinitis and IgE-mediated food 
allergies.15,24 Other co-morbidities have been suggested from epidemiological 
studies,25 including depression,26 attention-deficit hyperactivity disorder,27 
rheumatoid arthritis and inflammatory bowel disease,28 hypertension and obesity.29,30 
The shared risk factors and pathomechanisms of this diverse range of co-morbidities 
are currently unclear. 
 
Importance 
Eczema creates a substantial burden of disease with physical, psychological and 
social impact;18 suffering is compounded by the multiple atopic31 and non-atopic32 
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co-morbidities. In the UK, eczema is the most common condition affecting children 
aged 0 to 9 years33 with a period prevalence of ~33%33 and dermatitis is the most 
prevalent skin disorder in age groups from 20 to >80 years.33 The total annual UK 
expenditure on atopic eczema was approximately £465 million in the mid-1990s34 
and this cost is projected to rise considerably with the increasing demand for new 
treatments including biologic agents (described below). On a global scale, dermatitis 
is the most prevalent skin disease, accounting for an estimated 11 million years lived 
with disability.35 Eczema accounts for more disability-adjusted life-years than other 
common inflammatory diseases, including psoriasis, rheumatoid arthritis and 
inflammatory bowel disease.35 The rising prevalence of eczema, its chronicity and 
multi-morbidities indicate that primary prevention and developments in treatment are 
important goals for improving global public health. 
 
Diagnosis 
Eczema is diagnosed on the basis of clinical features: ill-defined, erythematous, scaly 
and pruritic lesions with a clinical history characterised by childhood onset, flexural 
inflammation, a background of generalised skin dryness (xerosis and/or ichthyosis 
vulgaris) and associated atopic disease in the patient and/or first degree relatives.15 
Eczema can occur at any body site and non-flexural sites are usually involved in 
early infancy. However in atopic patients the skin as a whole organ shows 
impairment in barrier function and a predisposition to inflammation, even in 
clinically un-inflamed sites. Barrier dysfunction also manifests as skin dryness (in 
part because of increased water-loss) and susceptibility to viral and bacterial 
infections.36 
 
Treatment 
The main principles of eczema management are allergen and irritant avoidance, 
emollient use37 and topical or systemic anti-inflammatory treatment.36 Secondary 
infection with bacteria (most frequently S aureus) is commonly associated with 
eczema exacerbations and should be treated concomitantly. Eczema herpeticum is an 
infection of herpes simplex virus within areas of skin affected by eczema36 and this 
requires urgent anti-viral treatment.  
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The most common allergens leading to sensitisation in childhood are house dust 
mite, grass pollen, milk, egg and peanut. These allergens induce a type 1, IgE-
mediated immediate hypersensitivity reaction rather than eczema itself, but there is 
evidence that reducing exposure in the subset of sensitised patients can improve 
eczema control.38 The most common irritants encountered in every-day life are soap 
and detergents. Clinical experience demonstrates the utility of soap substitutes 
(emollients) when bathing,37 but a recent clinical trial of emollient bath additives 
showed they have no significant effect when added to the standard management of 
paediatric eczema.39 Topical corticosteroids should be applied to areas of active 
eczema at a potency aimed to induce remission, and a steroid of lower potency or 
less frequent application used to maintain remission.15 
Second- and third-line treatments include topical calcineurin inhibitors, ultraviolet 
radiation (principally narrow band UVB phototherapy), oral corticosteroids and 
systemic immunosuppressants, principally ciclosporin, azathioprine, methotrexate 
and mycophenolate mofetil. However, only ciclosporin is currently licensed in the 
UK for adults; systemic treatment for eczema in children is currently unlicensed, but 
ciclosporin, azathioprine and methotrexate are each used by dermatology specialists 
in the UK and internationally to treat paediatric eczema cases.40,41  
Many new treatments for atopic eczema have emerged in the last 5 years, including 
small molecules and novel biologic treatments, targeting specific aspects of atopic 
inflammation.42 Dupilumab, the first biologic treatment to be licensed for eczema, is 
a human monoclonal antibody that binds to the alpha-chain of the interleukin (IL)-4 
receptor, inhibiting both the IL-4 and IL-13 pathways.43 It is highly effective in 
some, but interestingly not all, patients.43-45 A recent analysis of systematic reviews 
concluded that there is a paucity of evidence for complementary eczema treatments 
and non-pharmacological interventions such as specialist clothing; further well-
designed clinical trials are needed.46 
 
Pathogenesis 
Despite the high prevalence of eczema, the pathogenesis of this condition remains 
incompletely understood. Atopic eczema results from the interplay of skin barrier 
impairment and immunological dysfunction, both of which are determined by 
multiple genetic and multiple environmental factors (Figure 1).   
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Figure 1. Diagrammatic representation of factors contributing to the 
pathogenesis of atopic eczema. 
Eczema is a complex trait but its high heritability demonstrates the importance of genetic mechanisms 
in pathogenesis; skin barrier dysfunction and maladaptive immune activation occur as a result of the 
interactions of multiple genetic and environmental factors; skin barrier and immune activation are 
themselves closely inter-related. 
Atopic eczema is a strongly heritable disease, shown by twin studies and familial 
clustering. ‘Heritability’ is defined as the proportion of variation within a clinical 
feature that is attributable to genetic factors.47 Twin studies show 72–86 % 
concordance in monozygotic pairs and 21–23 % in dizygotic twins.48,49 A family 
history of atopic disease is the strongest risk factor for eczema: atopic disease in one 
parent increases a child’s risk of developing eczema 1.5-fold and the risk is increased 
~3-fold if one parent has eczema and ~5-fold if both parents have eczema.50,51 The 
genetic contribution to the development of eczema is 70-80%,52,53 which represents 
high heritability for a complex trait.54   
This high heritability demonstrates the importance of genetic mechanisms in eczema 
pathogenesis, but the rapid rise in prevalence over recent decades worldwide 
indicates the importance of environmental factors.55-59 The notably heterogeneous 
phenotype of atopic eczema18,36 indicates that different aspects of pathogenesis – 
genetic and environmental, barrier impairment and immune dysfunction – may each 
play a role to different extents in different cases and at different times in the life-
course of disease. 
 
SKIN 
BARRIER 
FUNCTION
IMMUNE 
ACTIVATION
Environmental 
effects
Genetic factors
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Importance of understanding genetic mechanisms in eczema 
Genetic studies have played a major role in transforming the understanding of atopic 
eczema from a disease seen as an immune-mediated disorder to one that may arise 
from a primary or secondary skin barrier impairment. Genetic studies have identified 
a central role for skin barrier impairment in eczema predisposition and 
perpetuation;24 this brought about a paradigm shift in understanding atopic disease.60 
The role of Th2-mediated immune dysfunction is also central to atopic inflammation 
and has proven to be a powerful target for biological therapy in atopic eczema. 
Genetic mechanisms controlling skin barrier function remain to be targeted and a 
more detailed understanding of eczema genetic mechanisms will be required for the 
era of personalised medicine.61 Strategic developments in drug discovery will allow 
the application of genetic insight to the development of novel targeted treatments62 
and in return a better understanding of genetic mechanisms will facilitate patient 
stratification in this heterogeneous phenotype. A recent electronic Delphi process 
defined the ten highest priority research questions for inflammatory skin disease, of 
which three related specifically to genetic risk mechanisms in eczema.63  
 
Approaches to studying genetic risk in the complex trait of eczema 
Atopic eczema is a complex trait (Figure 1); strategies for investigating risk have 
included the study of candidate genes and extreme phenotypes as well as genome-
wide analyses, exome and genome sequencing. Mouse models have provided some 
valuable insights, as reviewed elsewhere,64 but murine models are limited in their 
representation of human skin structure and immune function65 and this thesis will 
focus on human genetic studies. 
 
Candidate gene studies 
Many candidate genes have been selected for investigation in relation to eczema 
pathogenesis because of their theoretical roles in epidermal differentiation, skin or 
systemic immunity.66 Notable findings include a role for variants in the genes 
encoding IL-4, the IL-4 receptor and IL-13;67,68 these associations have been 
replicated in candidate gene studies and subsequently supported by genome-wide 
association loci (discussed further, below).  
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The strongest association and most widely replicated single gene affecting atopic 
eczema is the gene encoding filaggrin (FLG).24,69,70 Filaggrin is expressed in the 
granular layer of the upper epidermis; it is a multifunctional protein contributing to 
epidermal differentiation and multiple aspects of barrier function.71 Filaggrin 
aggregates keratin filaments, contributing to the compaction of corneocytes; filaggrin 
breakdown releases amino acids that are hygroscopic and acidic and have anti-
staphylococcal activity.72 Filaggrin deficiency was reported in the common dry skin 
condition ichthyosis vulgaris (IV) in the mid-1980s73-75 and IV is known to be a risk 
factor for atopic eczema. However, because of technical difficulties in sequencing 
this large and repetitive gene,72 loss-of-function mutations in FLG were not 
identified until 2006.76 FLG null mutations are present in up to 10% of the general 
population; they cause IV with a semi-dominant mode of inheritance,76 such that 
homozygous (or compound heterozygous) individuals have the full phenotype of dry 
scaly skin, hyperlinear palms and keratosis pilaris, whilst individuals heterozygous 
for FLG null mutations have a milder dry (xerotic) and/or ichthyotic skin 
phenotype.77 The same null mutations are found in up to 40% of patients with 
moderate-severe atopic eczema24,78 and meta-analysis has shown the risk for eczema 
in an individual carrying one or more FLG loss-of-function mutation(s) to be 
increased 3-fold (odds ratio 3.12, 95% confidence interval 2.57-3.79).70 This 
illustrates a remarkably strong effect for a single gene in the context of a complex 
trait. The central effect of filaggrin in skin physiology has been further demonstrated 
by my work showing a dose-dependent effect of copy number variation within this 
repetitive gene sequence79 and by the effect of atopic inflammatory cytokines which 
suppress filaggrin expression in the skin resulting in additional barrier 
impairment.80,81  
 
Study of extreme phenotypes 
Atopic eczema varies from a mild, self-limiting skin disease to a severe, chronic 
disorder affecting the entire skin surface, with multisystem involvement and life-long 
morbidity. However, severe phenotypes with monogenic inheritance have also 
offered insight into mechanisms giving rise to atopic skin inflammation. Netherton 
syndrome (OMIM #256500) is an autosomal recessive condition caused by 
mutations in SPINK5, encoding a serine protease inhibitor, LEKTI. Features of 
Netherton syndrome include an ichthyotic (dry, scaly) and eczematous skin 
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phenotype and markedly raised IgE. Several independent studies have shown an 
association between SPINK5 variants and atopic eczema.82-84 This indicates the 
importance of the protease-antiprotease balance in maintaining an optimal skin 
barrier function. The control of proteases by protease inhibitors is crucial in the co-
ordinated differentiation and desquamation of the outer epidermis85 and also plays an 
important role in the cutaneous response to allergens, many of which are, or contain 
proteases.86 
Another extreme phenotype of atopic skin disease is the syndrome of severe 
dermatitis, multiple allergies and metabolic wasting (SAM), for which the genes 
DSG1 (encoding desmoglein 1) and DSP (encoding desmoplakin) have each been 
implicated.87,88 Desmosomes are intercellular junctions which provide mechanical 
strength to the skin and are degraded in a controlled way during physiological 
desquamation;85 they also play a key role in cell signaling.89 The finding of 
mutations in DSG1 and DSP causing SAM indicates the importance of desmosomal 
proteins in protecting against local and systemic atopic inflammation. Other ‘human 
knock-out’ models include CARD11 mutations (causing systemic atopic 
inflammation), DSG1 and DSP mutations (causing severe dermatitis, multiple 
allergies and metabolic wasting) and various immunodeficiency syndromes with 
atopic eczema-like skin inflammation, such as Wiskott-Aldrich, caused by mutations 
in WAS.65 
Importantly, there are forms of more extreme skin barrier impairment which do not 
appear to predispose to atopic inflammation, such as epidermolysis bullosa. 
Furthermore, recent molecular profiling of patients with several different rare 
monogenic ichthyoses has suggested they may share the feature of Th17 immune 
activation.90 This illustrates the complex and specific role of transcutaneous 
sensitization in allergic disease. 
 
Genome-wide analyses 
A genome-wide association study (GWAS) aims to identify regions of the genome 
that are associated with a specific trait or disease. The technique compares the 
frequency of single nucleotide polymorphisms (SNPs) between cases and controls, 
similar to a massive case-control study. Large numbers (one-two million) of SNPs 
are assessed, sampling regions across the whole genome and large numbers 
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(thousands - tens of thousands) of cases and controls are needed to achieve sufficient 
statistical power. Results are summarized in the form of a Manhattan plot. GWAS is 
most effective in defining genetic risk loci for common complex traits, because a 
sufficient sample size can be obtained. It is important to note that the effect sizes 
detected by GWAS can range from odds ratio (OR) >2 (ie risk more than doubled) to 
very small effect sizes (OR 1.1 or lower ie <10% increased risk) because complex 
traits are a result of multiple genetic effects. 
The first genome-wide association study (GWAS) for atopic eczema was published 
in 2009, representing the white European population.91 This identified the locus on 
chromosome 1q21.3 (the epidermal differentiation complex which includes FLG) as 
well as a locus on chromosome 11q13.5, in an intergenic region of unknown 
function; subsequent GWAS analyses have replicated these findings. A meta-
analysis combining published and previously unpublished data was completed in 
201592 which included over 15 million genetic variants in >20,000 cases and 
>95,000 controls from populations of European, African, Japanese and Latino 
ancestry, followed by replication in >250,000 eczema cases and controls. This 
powerful meta-analysis detected 10 additional risk loci, bringing the total number of 
eczema risk loci identified to date to 31. The majority of GWAS loci are in 
intergenic or intronic regions for which the function remains unclear, but where 
functions can be inferred these have largely been attributed to skin barrier 
development, innate and acquired immunity. The most recently identified loci have 
been proposed to identify genes with roles in the regulation of innate host defence 
and T cell function, supporting a possible role for autoimmune mechanisms in 
eczema pathogenesis.92,93 
Whole exome sequencing (WES) has contributed to the diagnosis of extreme 
phenotypes in rare diseases (including SAM, described above88) and has offered 
greater detail in the search for rare variants causing common diseases. To date only 
one small WES study has been reported for eczema, in which 22 Ethiopian patients 
with ichthyosis vulgaris and atopic eczema were sequenced. This identified possible 
disease-causing variants in FLG and related genes as well as some novel candidate 
genes in a heterogenous pattern of risk.94 Exome sequencing data has been reported 
for FLG and related genes95 as well as for the HLA region,96 but larger studies will 
be required to systemically identify rare variants contributing to atopic eczema. 
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Further, whole genome sequencing and painstaking functional studies will be 
required to fully assess the complex contribution of non-coding genetic variants, 
which is anticipated to be substantial.97,98 
 
Transcriptome analyses 
The accessibility of skin tissue has allowed the detailed comparison of gene 
expression patterns in lesional (active eczematous skin) compared with non-lesional 
(uninflamed skin on a patient with eczema) and normal skin (from a non-atopic 
individual). Whole transcriptome analyses, using RNA sequencing techniques 
provide more comprehensive assessment and more detailed quantification of mRNA 
than previous microarray studies. Several studies have identified networks of 
differentially expressed genes involved in keratinocyte differentiation in the 
epidermis, innate and acquired immune responses as well as lipid metabolism.99-101 
Laser capture microdissection has recently been used to separate the dermal and 
epidermal gene expression signatures, identifying some novel immune and barrier 
genes102 which require further validation. 
 
Single cell analysis  
Most of the molecular analyses on skin to date have been carried out using whole 
skin biopsies, or epidermal samples. However single cell analysis is now feasible for 
DNA and RNA sequencing, as well as protein analysis.103 These techniques offer the 
prospect to study individual cells, define new cell types and gain insight into the 
functional and structural heterogeneity of skin as a complex organ. The Human Cell 
Atlas is an international collaboration to make single cell analytical data available to 
researchers104 and the skin component of this atlas is eagerly awaited. Several 
research laboratories have already released data and tools to allow the interrogation 
of skin transcriptome analysis, for example murine data from the Kasper lab.105  
 
In vitro modelling of genetic effects 
Knockdown of candidate genes using RNA inhibition (RNAi) 
Small interfering RNA (siRNA) can be used to bring about a selective reduction in 
gene expression based on complimentary base pairing. siRNA is a double-stranded 
molecule 20-25 nucleotides in length. When transfected into the cell type of interest 
 
 
Page 17 
(principally primary human keratinocytes for eczema studies) siRNA binds with a 
complex of proteins to form an RNA-induced silencing complex (RISC) in which the 
double-stranded siRNA disassociates to become single-stranded. The single stranded 
siRNA can then bind to complementary mRNA, bringing an Argonaut protein into 
proximity to catalyse the cleavage of this mRNA. Translation is prevented, hence 
silencing the gene expression.  
siRNA-mediated knockdown can be carried out in primary cells of low passage, 
using chemically-enhanced transfection, to minimise interference with physiological 
conditions. There is, however, still an innate immune response to the siRNA and 
scrambled or non-targeting siRNA is an essential control condition. The duration of 
knockdown is short-lived (hours-days, depending on the rate of mRNA turnover) and 
this can be a limitation to the technique. 
Short hairpin RNA (shRNA) is another method for RNAi. shRNA is a synthetic 
double-stranded RNA molecule with a tight hairpin turn; it is synthesised in the cell 
type of interest using a plasmid introduced by viral or bacterial vector transfection. 
The vector integrates into host DNA and shRNA is transcribed in the nucleus, 
processed by dicer and loaded into the RISC. The sense strand is degraded and the 
antisense (guide) strand directs RISC to mRNA that has a complementary sequence 
where RISC cleaves or represses translation of the mRNA. An advantage of shRNA 
knockdown is the longer lasting duration of effect compared to siRNA; a 
disadvantage is the need for vector transfection and integration, producing a less 
physiological condition in primary cells or cell lines.  
 
CRISPR-cas9 gene editing 
CRISPR (clustered regularly interspaced palindromic repeat) sequences are found in 
bacterial DNA and form part of their immune response to phage infection. Cas9 
(CRISPR-associated protein 9) is an enzyme that cleaves DNA selectively at 
sequences containing the CRISPR motif. In 2012 it was reported that this mechanism 
can be exploited for genetic engineering;106,107 guide-RNAs are used to direct the 
cas9 enzyme to cleave DNA in precisely-targeted editing. Application of CRISPR-
cas9 allows the effects of genetic variation to be tested directly and the technique has 
revolutionised molecular biology. This cost-effective and relatively easy-to-use 
technology has allowed researchers to precisely and efficiently target, edit, modify 
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and mark genomic loci in a wide range of cells and organisms.108 Within 
dermatology, CRISPR-cas9 can be used to investigate candidate genes in vitro, 
allowing the study of their effect on replicated samples with a controlled genetic 
background. 
 
Gene over-expression 
Over-expression of candidate genes is a key technique to assess their effect. Stable 
over-expression of a gene of interest can be achieved using plasmid transfection, 
lentivirus transduction or CRISR-cas9 editing. 
 
In vitro models 
Keratinocyte culture in vitro was first established by Rheinwald and Green in 
1975,109 opening up the opportunities for detailed study of this cell type. Multi-
layered keratinocyte cultures recapitulate many features of human epidermis 
including morphology, spatiotemporal expression of terminal differentiation markers 
and lipid content.110,111 Multiple different two-dimensional (keratinocyte culture) and 
three-dimensional (organoid) models of skin and eczema have been described, as 
recently reviewed.65 Some organoid models are epidermal-only whereas others 
include a model dermis as well as epidermis. The model dermis includes fibroblasts; 
these cells may be suspended in a fibrin or collagen gel, or an artificial matrix; 
alternatively, a de-epidermalised dermis may be used. Co-culture with T cells and 
neurons has been piloted but these models are not yet well validated.65 
Explanted whole skin has also used been used for ex vivo experimentation. Explanted 
skin has the advantage of including intact skin adnexae and a compliment of resident 
cell types, but it is tissue that is inevitably beginning a process of demise.  
Two main approaches can be used to model eczema pathophysiology in vitro: 
culturing normal human keratinocytes with eczema-relevant cytokines (IL-13 and 
IL-4);112 alternatively gene silencing or FLG mutant keratinocytes can be used to 
model a filaggrin-deficient state.113 Organoid models deficient in filaggrin show a 
lack of keratohyalin granules, increased paracellular permeability114,115 and 
proteomic features consistent with eczema.116  The use of normal keratinocytes (as 
opposed to cells extracted from eczema biopsies) allows the investigation of specific, 
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selected genetic mechanisms without the complex and confounding effects of 
multiple genetic and epigenetic risk variants that are co-inherited in atopic eczema.  
Organoid models allow the investigation of tissue-specific genetic effects and the 
opportunity for testing specific eczema candidate genes, by knockdown, over-
expression, or CRISPR-cas9 editing of genes of interest. Three-dimensional organoid 
models of human skin (epidermis and dermis, Figure 2) offer a unique opportunity 
to investigate genetic effects in a tissue context. 
 
 
 
Figure 2. Workflow showing methods used to produce skin organoid model for 
candidate gene analysis in vitro in the Brown laboratory. 
This human skin organoid takes a total of 3 weeks to produce, but it recapitulates gene expression 
patterns, biochemical and functional features of epidermis in vivo. In this model candidate genes are 
knocked down using siRNA transfection of primary keratinocytes and the effect may be observed in 
mature organoids 10 days later. This figure has been reproduced from Elias et al. 2019.117  
 
 
Page 20 
Functional analyses in vitro 
Organoid skin grown at the air-liquid interface develops a competent epidermal 
barrier with biophysical properties analogous to human skin. This allows the 
quantitative measurement of functional parameters, including hydrophilic dye 
penetration, water content in the stratum corneum (measured by transepidermal 
electrical resistance, or capacitance) and water evaporation from the surface 
(equivalent to transepidermal water loss, TEWL, in vivo).65,114,118,119  
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CHAPTER TWO: Genetic risk in atopic eczema 
 
FLG null mutation creates a strong genetic risk for atopic eczema 
Filaggrin haploinsufficiency affects risk of mild, moderate and severe eczema 
The identification of genetically-determined skin barrier dysfunction in eczema 
pathogenesis 10 years ago69 brought about a paradigm shift in understanding atopic 
disease. The strong and highly significant association of FLG null mutations with 
atopic eczema has subsequently been replicated in numerous independent studies, 
including case-control studies, family studies and unselected population cohorts. 
Two independent meta-analyses carried out in 2009 estimated the odds ratio of 
developing atopic eczema in association with FLG null genotype to be 4.78120 and 
3.1270 i.e. individuals with one or more FLG loss-of-function mutations have a 3-5 
times greater risk of developing atopic eczema.  
The eczema sub-phenotypes that are most strongly associated with FLG null 
mutations are early-onset, severe, and persistent disease121,122 and eczema with the 
associated ‘extrinsic’ features of raised total IgE and allergic sensitization.123,124 
These patients are most frequently referred to secondary care. However, population 
cohort studies include atopic eczema of milder severity and this phenotype has also 
demonstrated significant association with FLG null mutations.19,31,125 Mild-to-
moderate eczema shows a lower odds ratio than severe disease and its association 
with FLG null mutations may be significant only in individuals carrying two null 
mutations.19  
 
Filaggrin deficiency also increases risk of irritant and allergic contact dermatitis 
Following on from the strong association of atopic eczema with FLG null mutations, 
several other subgroups of eczema were investigated for their link with filaggrin. 
There is a well-recognized genetic susceptibility to contact dermatitis,126 but it is 
often difficult to distinguish the subgroups of irritant and allergic contact dermatitis 
from atopic eczema; hence, these genetic studies are difficult to interpret.127-129 
Studies on FLG genotype as a risk factor for experimentally-induced irritant 
dermatitis have given somewhat conflicting results,130,131 and this may be because of 
methodological differences in the concentration of irritant. Subsequent studies 
reported no association of FLG genotype with allergic contact dermatitis defined by 
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a positive patch test result to one or more substance,132 nor with a subset of patients 
having both atopic eczema and contact allergy.133 In contrast, FLG null genotype has 
shown significant association with nickel sensitization, but only in a subgroup of 
cases reporting intolerance to costume jewellery134 and in a subgroup of women who 
had not had their ears pierced.135 This illustrates the importance of environmental 
exposures in allergy development, as well as the need for careful phenotype 
definition in genetic studies. 
 
FLG null mutations contribute to risk of multiple atopic disorders 
The term ‘atopic march’136-138 refers to the observation that atopic eczema may 
precede the development of food allergies, asthma, and allergic rhinitis in a temporal 
sequence, although it is now recognised that this sequence and trajectory are far from 
inevitable.137,139-141 FLG null mutations represent a risk factor for each step in the 
atopic march: atopic eczema;78 allergic sensitization;120 the subgroup of asthma in 
association with eczema;19,31,142 allergic rhinitis;142,143  and IgE-mediated peanut 
allergy.144 FLG null alleles are therefore a significant risk factor for all aspects of 
atopy, with differing odds ratios for each specific phenotype. The odds ratio (OR) for 
eczema is ~1.3, whilst allergic rhinitis is ~2.8, atopic asthma ~1.5 and peanut allergy 
~3.8. These studies have brought new understanding about the need to address skin 
barrier dysfunction as a driver of allergic disease. 
 
Pathomechanisms associated with filaggrin-deficiency are identified by in vitro 
studies 
As described above, filaggrin and its precursor profilaggrin are multifunctional 
proteins and it is unclear which of these functions are most relevant to eczema 
pathogenesis. The precise molecular pathways leading from filaggrin 
haploinsufficiency to atopic diathesis have been the focus of a large amount of 
research work over recent years. The accessibility of human skin and established 
methods for the culture of primary cells and immortalised cell-lines, in addition to 
organoid modelling has facilitated progress considerably.65  
One promising line of enquiry is the role of aryl hydrocarbon receptor (AhR) 
signalling in increasing filaggrin expression145,146 but the control of keratinocyte 
differentiation is complex and some aspects of the AhR signalling pathway are 
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detrimental to skin health.147 The cytokines most prominent in atopic inflammation, 
IL-4 and IL-13, have been shown to reduce FLG expression.148 TNF-alpha81 and IL-
17149 may also downregulate filaggrin expression. Caspase-14 is required for 
filaggrin breakdown, to release amino acids as part of the natural moisturising factors 
in the stratum corneum150 and an mTORC1/AKT1/Cathepsin H axis has been 
described, playing a role in the control of filaggrin expression and processing in 
skin.151 There is evidence that hypoxia-inducible factors regulate filaggrin 
expression152 and filaggrin-deficiency itself promotes an inflammatory phenotype.116 
It is, however, salutary to note that multiple gaps in knowledge persist, including 
questions about the control of filaggrin expression, the relative role of filaggrin and 
its breakdown products in structural versus microbiological and immunological 
barrier functions. Despite the reported opportunities for therapeutic targeting, no 
treatments are currently available that can directly upregulate filaggrin expression for 
the treatment or prevention of eczema. 
 
FLG null mutations predispose to some, but not all, forms of inflammatory 
disease   
FLG mutations in other inflammatory conditions 
The strong effect of filaggrin on atopic inflammation does not extend to all 
inflammatory disease. Psoriasis shows association with the 1q21 locus in genome-
wide studies153 and this locus is within the epidermal differentiation complex (EDC), 
a dense cluster of over 60 genes, including FLG.154 Filaggrin shows increased 
expression in psoriasis, but FLG mutations (loss- or gain-of-function) are not 
associated with psoriasis in the multiple European populations studied to date.155-160 
Variants in FLG have been associated with psoriasis in Chinese populations161,162 but 
the functional effect of these variants has not been defined, therefore an association 
with other genetic effects in linkage disequilibrium remains a possibility.  The 
psoriasis-chromosome 1q21.3 association appears more likely to be driven by a 
deletion affecting two of the late cornified envelope genes (LCE3C to LCE3B) within 
the EDC.163,164 
In one report FLG null mutations showed a possible protective effect against acne 
vulgaris165 but a larger and more adequately powered study in the Singaporean 
Chinese population effectively excluded an association.166 Other inflammatory 
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barrier diseases, including Crohn’s disease, ulcerative colitis, and sarcoidosis, share 
common susceptibility loci with atopic eczema167 but do not show association with 
FLG null mutations.168,169 This indicates that additional genetic mechanisms are 
responsible for barrier perturbations in these diseases.  
 
Filaggrin haploinsufficiency in autoimmune skin disease 
Autoantibody formation to citrullinated profilaggrin is a sensitive and specific 
serological marker for rheumatoid arthritis170 and can predate the onset of joint 
disease.171 Levels of anti-filaggrin antibody may also correlate with arthritis 
activity.172 However, filaggrin is not expressed in articular tissues and these 
autoantibodies appear to be produced as a result of cross-reaction between 
deiminated peptide sequences, which are present within fibrin chains in the 
synovium and deiminated sequences produced during the post-translational 
processing of profilaggrin. Anti-filaggrin antibodies are therefore not believed to be 
pathogenic.173 FLG null mutations R501X, 2282del4, and 3702delG have been 
studied in rheumatoid arthritis patients and controls,174 and FLG mutation carriers 
showed no increased risk of developing rheumatoid arthritis. However, in a separate 
study, FLG heterozygotes did show significantly elevated levels of autoantibodies to 
citrullinated peptides compared with controls173 and FLG null mutations may 
therefore contribute to the development of humoral autoimmunity in early 
rheumatoid arthritis174 by an as yet undefined mechanism. Alopecia areata is a tissue-
specific autoimmune disease and genetic factors make a significant contribution to 
its aetiology.175 Alopecia areata is known to be associated with atopic disease and it 
has been shown that comorbidity with atopic eczema, as well as prevalent FLG null 
variants (R501X and 2282del4), predict a more severe form of alopecia areata.176,177 
The specific mechanism remains unknown. 
 
FLG null mutations and chronic photosensitivity 
Another inflammatory condition associated with atopic eczema is chronic actinic 
dermatitis (CAD). CAD is a photosensitivity dermatitis in which individuals show 
abnormal reactions to UVB, UVA and in severe cases to visible light, plus an 
increased incidence of contact sensitivity to airborne allergens. Whilst FLG 
mutations may obviously contribute to the underlying atopic eczema, they are not 
strongly associated with CAD.178 
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Taken together, these observations indicate that filaggrin deficiency creates a 
pathogenic tissue environment in which atopic inflammation predominates, but the 
propensity to other forms of non-atopic inflammation is also of importance. 
 
Genome-wide association studies have identified eczema risk loci giving 
mechanistic insight 
GWAS loci confirm and extend knowledge 
GWAS have been performed in large populations sampled from European and Asian 
ethnicities. Some eczema risk loci have confirmed pre-existing knowledge, including 
the role of skin barrier and type 2 inflammation in the pathogenesis of this disease: 
the epidermal differentiation complex on chromosome 1q21.3 includes FLG and the 
cytokine cluster on chr5q31.1 includes genes encoding IL-13 and IL-4. Other loci 
have provided newer insights, including evidence for auto-immunity 92 and a role for 
Langerhans cells, indicated by variants in a locus on 2p13.3 which affect the 
expression levels of CD207/langerin in skin.92  
An extension to GWAS, focusing on protein-coding variants, used exome genotype 
and skin transcriptome data.179 This study identified an additional 12% of AD 
heritability explained by rare protein-coding variation in genes including IL4R, IL13, 
JAK1, JAK2 and TYK2 (current therapeutic targets in the IL-13 pathway) and novel 
candidate genes DOK2 and CD200R1 for which eczema susceptibility mechanisms 
remain to be defined.179  
GWAS of multiple atopic traits has shown considerable overlap in genetic risk 
profiles for eczema, asthma and allergic rhinitis180,181 attributed predominantly to 
lymphocyte-mediated immunity. It is interesting to note that only two loci indicate 
eczema-specific effects and these are both within the epidermal differentiation 
complex on chromosome 1q21.3, attributed to FLG and HRNR-RPTN.180 
The GWAS performed to date have been conducted in white European and selected 
Asian populations. The lack of ethnic diversity in genetic research has been 
highlighted as a critical weakness in the field, in terms of equity in access to medical 
and scientific knowledge and also as a missed opportunity for genetic discovery.182 
Eczema GWAS studies in more diverse ethnicities are ongoing. 
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Epistatic effects are likely to be common but most remain undefined 
Genetic risk loci are likely to have multiple interactions in their contributions to 
complex traits,183 but the identification of these interactions using a statistical 
approach is challenging, because of the burden of multiple testing. One epistatic 
interaction that appears to occur is the effect of FLG null mutations in the context of 
a variant on chromosome 11q13.5: the effects of these two GWAS peaks are 
multiplicative at a population level.184 This indicates that an interaction or overlap in 
the molecular pathogenesis is likely. Another epistatic effect has been demonstrated 
in variants of the high affinity IgE receptor gene FCER1A185 indicating that multiple 
variants may have synergistic effects on this pathomechanism. 
 
Relevance of genetic risk mechanisms for clinical practice 
FLG null mutations produce a recognisable clinical phenotype 
Ichthyosis vulgaris in an individual with two FLG null mutations (i.e. homozygous 
or compound heterozygous) is a triad of ichthyosis with fine scaling, palmer 
hyperlinearity and keratosis pilaris. These features indicate FLG null genotype 
without the need for genetic testing.77 Furthermore, when combining all the milder 
clinical signs that may be attributable to FLG haploinsufficiency (atopic eczema, 
ichthyosis, xerosis, palmar hyperlinearity, and keratosis pilaris), FLG null mutations 
are seen to be highly penetrant.77 Careful clinical examination of patients and their 
relatives can therefore be used to implement understanding of FLG-related genetic 
risk in the clinical setting. However, there are likely to be multiple other genetic 
effects of relevance to clinical practice which we cannot yet apply in clinic. 
 
Skin barrier impairment is a central pathomechanism 
The filaggrin story demonstrates how the study of a monogenic disorder can provide 
insight into complex trait disease, and the striking significance of FLG null 
mutations as a genetic risk factor for atopic eczema has placed a new focus on the 
role of barrier impairment in eczema pathogenesis. This offers the opportunity for 
therapeutic intervention – simple emollients to protect and improve skin barrier 
function – and also a rationale for patient education, encouraging the use of 
emollients, through an explanation of skin barrier impairment. 
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In light of the strong association between atopic eczema and peanut allergy, it was 
important to consider whether the association of FLG genotype with peanut allergy 
occurs through atopic eczema on the skin,186 or whether the risk occurs as a genetic 
mechanism independent of eczema, in order to target prevention appropriately. It is 
likely that both mechanisms are active, but there are various sources of evidence 
favouring an effect of FLG null genotype that is independent of eczema. In a study 
that I co-led144 the association of FLG genotype with peanut allergy was not 
dependent on co-existent eczema. A separate study showed a dose-dependent effect 
of environmental peanut exposure on children with FLG null mutations, after 
adjustment for infantile eczema, supporting the hypothesis that peanut allergy can 
develop through transcutaneous sensitization even without eczema.187 Therefore it 
appears that risk of peanut allergy is mediated via the FLG genetic risk 
independently, or at least it is not dependent on, the presence of eczema. 
 
Stratification of patients in clinical trials 
Given the strong and central effect of FLG genotype on eczema, this has been used 
to stratify clinical trials, to assess whether patients with filaggrin haploinsufficiency 
may be more or less likely to benefit from a specific treatment. There is some 
evidence that FLG wild-type genotype is associated with a more favourable response 
to omalizumab therapy for atopic eczema.188 In contrast there was no difference in 
response to silk clothing for the treatment of eczema in a carefully designed 
randomised controlled trial.189,190   
 
Opportunities for therapy development 
Many of the novel biologics and small molecule drugs for treating atopic eczema 
have been designed to target specific aspects of the atopic immune response.42 These 
pathways were previously identified by research in the field of immunology, but 
their importance has been supported by GWAS hits.  
Novel therapies targeting aspects of skin barrier formation or function are yet to 
show a transformative effect on eczema management. Conventional simple emollient 
formulations transiently improve water retention properties of skin in vivo.191 Novel 
emollients aiming to replace physiological doses of ceramides and amino acids to the 
stratum corneum have been developed. These complex preparations show a more 
long-lasting increase in hydration parameters in paediatric eczema192and elderly 
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xerotic skin.193 The position for these more expensive emollients in atopic eczema 
management remains to be defined. 
An attractive opportunity arising from the application of knowledge of genetic risk 
mechanisms is the possibility of primary prevention of eczema and other atopic 
diseases, which would have an enormous public health benefit. This will be 
considered further in the critical appraisal in Chapter Four.     
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CHAPTER THREE: Body of work to be considered for PhD  
 
Selected publications from a five-year period, 2014 to 2019 
The publications that I wish to be considered within this thesis are as follows: 
 
[1] Cole C, Kroboth K, Schurch NJ, Sandilands A, Sherstnev A, et al., Watson RM, 
McLean WHI, Barton GJ, Irvine AD and Brown SJ. Filaggrin-stratified 
transcriptome analysis of paediatric skin identifies mechanistic pathways in 
atopic dermatitis. J Allergy Clin Immunol. 2014; 134(1):82-91. 
 
[2] Forbes D, Johnston L, Gardner J, MacCallum SF, Campbell LE, Dinkova-
Kostova A, McLean WHI, Ibbotson SH, Dawe RS and Brown SJ. Filaggrin 
genotype does not determine the skin's threshold to UV-induced erythema. J 
Allergy Clin Immunol 2016;137(4):1280-2. 
 
[3] Elias MS, Wright SC, Nicholson WV, Morrison KD, Prescott AR, Ten Have S, 
Whitfield PD, Lamond AI and Brown SJ. Functional and proteomic analysis of a 
full thickness filaggrin-deficient skin organoid model. Wellcome Open Res. 2019, 
4:134. 
 
[4] Elias MS, Wright SC, Remenyi J, Abbott JC, Bray SE, Cole C, Edwards S, 
Gierlinski M, Glok M, McGrath JA, Nicholson WV, Paternoster L, Prescott AR, 
Have ST, Whitfield PD, Lamond AI and Brown SJ. EMSY expression affects 
multiple components of skin barrier with relevance to atopic dermatitis. J Allergy 
Clin Immunol. 2019 Aug;144(2):470-481. 
 
[5] Paternoster, L Savenije OEM, Heron J, Evans DM, Vonk JM, Brunekreef B, 
Wijga AH, Henderson AJ, Koppelman GH* and Brown SJ*. Identification of 
atopic dermatitis subgroups in children from two longitudinal birth cohorts. J 
Allergy Clin Immunol 2018;141(3):964-971. [* denotes equal contribution] 
 
[6] Baurecht H,* Hotze M,* Brand S, Büning C, Cormican P, Corvin A, Ellinghaus 
D, Ellinghaus E, Esparza-Gordillo J, Fölster-Holst R, Franke A, Gieger C, 
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Hubner N, Illig T, Irvine AD, Kabesch M, Lee Y AE, Lieb W, Marenholz I, 
McLean WHI, Morris DW, Mrowietz U, Nair R, Nöthen MM, Novak N, 
O’Regan GM, PAGE consortium, Schreiber S, Smith C, Strauch K, Stuart PE, 
Trembath R, Tsoi LC, Weichenthal M, Barker J, Elder JT, Weidinger S,* Cordell 
HJ* and Brown SJ.* Genome-wide comparative analysis of atopic dermatitis 
and psoriasis gives insight into opposing genetic mechanisms. Am J Hum Genet. 
2015; 96(1):104-20. [* denotes equal contribution] 
 
 
The contributions made by each of these publications to the understanding of atopic 
eczema are summarised in Figure 3. The rationale, key aspects of study design and 
main findings for each publication will be considered in turn. 
 
 
 
Figure 3. Diagrammatic summary of key features of atopic eczema pathogenesis 
and my contributions to understanding its pathogenesis.  
The diagram of epidermal structure is modified from a diagram created by M. Elias; the contributions 
from each of my publications selected for this PhD thesis101,117,194-197 are listed in the right half of the 
figure. 
Atopic eczema is: 
Heterogeneous
but highly 
heritable
A complex trait 
arising from genetic 
and environmental 
effects
My work has: 
Defined the atopic skin transcriptome
Investigated erythemal response 
to UV radiation
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as a transcriptional regulator   
controlling skin barrier formation
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skin barrier 
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inflammation 
Compared and contrasted eczema  
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[1] Filaggrin genotype has a global effect on skin transcriptome, with relevance 
to atopic eczema 
Single molecule direct RNA sequencing of skin samples 
Having previously described the clinical phenotype of filaggrin haploinsufficiency in 
detail as part of a population-based study,77 I proceeded to study this at a molecular 
level. I chose to use a forefront technique at the time, single molecule RNA 
sequencing, because this allows analysis of a small quantity of RNA (such as that 
available from paediatric skin biopsies). The technology captures and sequences 
mRNA from the poly-A tail. Digital quantitative analysis is facilitated by counting 
each messenger RNA (mRNA) molecule.198  
The skin transcriptome varies considerably in different body sites, in different sexes 
and at different ages, as demonstrated on a macroscopic scale by the clinical features 
and on a biochemical and molecular genetic level.199,200 I therefore recruited 
volunteers specifically for control sampling, to allow the closest possible match in 
age, sex and body site. The 26 eczema cases were aged between 6 and 16 years; 
controls were aged 16-19 years. 
 
Stratification by FLG genotype 
Transcriptome analysis creates a large and complex dataset and this is further 
complicated by the inter-individual variation that is inherent in clinical samples. 
Since FLG genotype has the single greatest genetic effect on eczema phenotype, 
18,24,70,72,77,201 this was used to stratify the transcriptome data. In this study, because of 
the relatively small numbers of cases and controls, it was possible to carry out very 
comprehensive FLG genotype analysis, including next generation sequencing of all 
coding regions in FLG and confirmation of mutations by Sanger sequencing. 
 
Main findings 
2430 genes were differentially expressed (false discovery rate (FDR) P<0.05) of 
which 211 genes were upregulated and 490 downregulated >2-fold. The gene 
ontology terms ‘extracellular space’ and ‘defence response’ were enriched, whereas 
‘lipid metabolic processes’ were downregulated. The subset of FLG wild-type cases 
showed dysregulation of genes involved with lipid metabolism, whereas filaggrin 
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haploinsufficiency affected global gene expression and was characterized by a type 1 
interferon-mediated stress response. 
 
[2] Filaggrin haploinsufficiency does not affect the skin's threshold to UV-
induced erythema 
Evidence for filaggrin breakdown products contributing to skin photoprotection in 
vitro requires testing in vivo 
A role for filaggrin breakdown products in photoprotection is suggested on the basis 
of their biochemical and physicochemical properties.72 Filaggrin is a histidine-rich 
protein75 and histidine is metabolized to trans-urocanic acid (trans-UCA). The 
photoisomerization of trans-UCA to cis- UCA202 produces a molecule with an action 
spectrum of 280–310nm,203 which is within the UVB range. There is evidence from 
in vitro studies that cis-UCA has immunomodulatory actions in human keratinocytes 
and leukocytes.203,204 There is also in vitro evidence from an organotypic siRNA 
FLG knockdown model that lack of filaggrin leads to a reduction in UCA 
concentration and an increased sensitivity to UV-induced apoptosis.114 Histidinaemic 
mice, deficient in cutaneous UCA because of a mutation in Hal, the gene encoding 
histidase, show increased propensity to UVB-induced DNA damage.205 However, 
evidence of a photoprotective effect in humans in vivo was lacking. 
 
Detailed phototesting of healthy volunteers 
In collaboration with expert photobiologists (Drs Robert Dawe and Sally Ibbotson) 
in Dundee, I gained access to detailed monochromator phototesting data that had 
previously been generated for 71 adult volunteers with clinically normal skin, as part 
of a drug phototoxicity study. All participants were of white European ethnicity; this 
was required to minimise inter-individual variation in photo-response and to 
standardise FLG genotyping as far as possible. All of the participants were requested 
to provide saliva samples to allow testing for the 6 most prevalent loss-of-function 
mutations in FLG in this white European population (R501X, 2282del4, R2447X, 
S3247X, 3673delC, and 3702delG) using previously published methodology.19,206 
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Main findings 
Contrary to expectations, there was no significant effect of FLG genotype on UV-
induced skin erythema. This study was sufficiently powered to exclude a large effect 
of FLG genotype on photosensitivity (>1.8-fold difference in MED) at any of the 
wavebands tested. Furthermore, monochromator phototesting did not indicate a 
differential erythemal sensitivity within the wavelengths representing UVB, as would 
be predicted from the known absorption spectrum of UCA.  
 
[3] The filaggrin-deficient skin organoid is a valuable model  
Opportunities to investigate genetic mechanisms in skin 
Skin is more amenable than the many other human organs to modelling and genetic 
manipulation in vitro; organoid cultures facilitate a bridge in understanding from 
genetic and cellular level to physiological effects and potential therapeutic targets. A 
skin organoid created from adult stem cells207 (primary fibroblasts and basal 
keratinocytes) forms stratified layers, recapitulating the structure and gene 
expression patterns of human skin.117,195,208 This avoids some of the limitations of 
mouse models that are most pertinent to inflammatory skin disease, including the 
limited numbers of cell layers in the epidermis, frequent hair follicles and variation 
in genetic effects on different background strains.65  
 
Optimisation of model for assessment of molecular and functional parameters in skin 
barrier 
Primary human keratinocytes and donor-matched primary fibroblasts from healthy 
individuals were used to create skin organoid models with and without siRNA-
mediated knockdown of FLG. Biological and technical replicate sets of organoids 
were assessed using histological, functional and biochemical measurements. 
Quantitative global mass spectrometry proteomics was used to identify >8000 
proteins per sample. The model was optimised to produce sensitive, reproducible 
functional and biochemical measurements.117  
 
Main findings 
FLG knockdown led to subtle changes in histology and ultrastructure. Immature 
organoids showed evidence of barrier impairment with FLG knockdown, but the 
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mature organoids showed no difference in transepidermal water loss, water content 
or dye penetration. Gene ontology (GO) and pathway analyses identified an increase 
in transcriptional and translational activity but a reduction in proteins contributing to 
terminal differentiation, including caspase 14, dermokine, AKT1 and TGF-beta-1. 
The GO term ‘axon guidance’ and aspects of innate and adaptive immunity were 
represented in both the up-regulated and down-regulated protein groups. This work 
provides further evidence for keratinocyte-specific mechanisms contributing to 
immune and neurological, as well as structural, aspects of skin barrier dysfunction. 
All methods and data were shared in detail, as a resource for the field. 
 
[4] An EMSY-deficient organoid model reveals effects on multiple components 
of skin barrier formation and function 
EMSY is the nearest gene to the risk locus on chr11q13.5 and it has no known 
function in skin 
The chr11q13.5 locus, identified in multiple GWAS, lies in a large (~104kb) 
intergenic region between EMSY and LRRC32 in one topologically-associated 
domain. This locus has also been associated with other immune-mediated barrier 
disorders including atopic sensitisation180,209 and inflammatory bowel disease.210 
EMSY encodes a BRCA2-interacting protein, implicated in nuclear hormone 
regulated transcription and repression211 but it has not previously been studied in 
skin. The organoid model, optimised for barrier assessment, is therefore an ideal 
platform with which to assess a role for this candidate gene in atopic eczema. 
 
EMSY knockdown and over-expression, with functional and biochemical analyses 
The commercially available antibodies for EMSY required time-consuming testing 
and careful validation. Knockdown of EMSY in primary keratinocytes was achieved 
using siRNA; importantly, persistence of knockdown was demonstrated at day 10 in 
organoid culture. mRNA showed a mean 36% reduction and EMSY protein was 
reduced to ~50% compared to a nontargeting control. Detailed analyses included 
histological, ultrastructural, functional (water content, water evaporation, dye 
penetration) proteomic and lipid mass spectrometry. Over-expression of EMSY was 
achieved by viral vector transfection of primary keratinocytes, to compare the effect 
with EMSY knockdown. 
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Main findings 
EMSY acts as a transcriptional repressor in human keratinocytes. Knockdown leads 
to a marked change in skin organoid phenotype, including acceleration of barrier 
formation and upregulation of multiple aspects of skin barrier function. Over-
expression in cells shows opposite effects. EMSY knockdown is therefore a novel 
therapeutic target for eczema treatment and/or prevention. 
 
[5] Longitudinal latent class analysis identifies distinct subgroups of paediatric 
eczema in two independent populations 
Rationale 
Atopic eczema is a highly heterogeneous disorder, with variation in age of onset, 
chronicity, severity and comorbidities. One approach to sub-classify eczema cases is 
to define ‘atopic’ (extrinsic) and ‘non-atopic’ (intrinsic) forms, based on the presence 
or absence of IgE elevation.  It is well recognised that the majority of eczema cases 
present within the first two years of life and most resolve during childhood,15 but 
some persist into adulthood.212 The heterogeneity of longitudinal disease course is 
relatively un-studied, but it could offer valuable insight into eczema sub-phenotypes.   
 
Latent class analysis applied to longitudinal birth cohorts with detailed phenotype 
data 
Longitudinal latent class analysis (LLCA) is a statistical technique which can be used 
to model distinct subgroups within a dataset to identify different longitudinal patterns 
of disease, where the aim is to identify distinct subgroups in longitudinal multivariate 
categorical data. LLCA is somewhat similar to cluster analysis, but it allows for 
assignment based on mathematical probability, rather than definitive partitioning of 
individuals into classes. Starting with a single latent class, additional classes are 
added until measures that estimate the degree of model fitting are optimised. 
Statistical criteria (including a low Bayesian Information Criterion) are used to 
determine the optimal number of classes within the data. 
This work applied LLCA to data from two independent longitudinal cohort studies: 
The Avon Longitudinal Study of Parents and Children (ALPSAC) in the UK and 
Prevention and Incidence of Asthma and Mite Allergy (PIAMA) in The Netherlands. 
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Main findings  
The independent cohorts gave remarkably similar results, offering confidence in this 
mathematical modelling approach. Six distinct subtypes of eczema were defined (one 
of which was essentially unaffected), including a previously unrecognised class with 
peak onset at the age of 5-6 years, associated with male sex and asthma. The classes 
of early onset and persistent or late-resolving eczema showed the strongest 
association with eczema risk variants from GWAS. 
 
[6] Genome-wide comparative analysis of atopic dermatitis and psoriasis gives 
insight into opposing genetic mechanisms 
Comparing and contrasting two common inflammatory skin diseases 
Eczema and psoriasis are highly prevalent inflammatory skin disorders but they very 
rarely co-exist.213 Clinically, these diseases have similarities as well as differences. 
They are both erythematous and scaly; both sometimes itchy; both may be 
generalised, but eczema is characteristically flexural whilst psoriasis affects some 
flexures (e.g. umbilicus, groin, axillae and retro-auricular) but is classically extensor; 
eczema has atopic co-morbidities whilst both share the co-morbidities of 
cardiovascular disease30,214,215 and psychological/psychiatric burden.32,216 On a 
genome-wide level the two diseases show considerable overlap in risk loci, including 
the epidermal differentiation complex (chromosome 1q21.3), the Th2 locus control 
region (chromosome 5q31.1) and the major histocompatibility complex 
(chromosome 6p21-22). 
These observations provide the rationale for a genome-wide comparative analysis, to 
investigate shared and opposing mechanisms leading to eczema or psoriasis.197 
 
Collaborative work and statistical method development 
Genome-wide genotype data were obtained on samples from six case-control cohorts 
(three each of eczema and psoriasis), totalling 2,262 eczema cases, 4,489 psoriasis 
cases and 12,333 controls. Meta-GWAS was performed on each disease using 
standard methodologies. Novel meta-analysis techniques were developed, in 
collaboration with an expert in statistical genetics (Heather Cordell, Newcastle upon 
Tyne. UK) and applied to the datasets to compare and contrast genetic effects 
between the two diseases.  
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Main findings 
Opposing risk variants were identified within the epidermal differentiation complex, 
the Th2 locus control region and the major histocompatibility complex. Previously 
unreported pleiotropic alleles with opposing effects on eczema and psoriasis risk 
were also identified in PRKRA and ANXA6/TNIP1. In contrast, there were no shared 
loci with effects operating in the same direction on both diseases. Atopic eczema and 
psoriasis therefore appear to have distinct genetic mechanisms with opposing effects 
in pathways influencing epidermal differentiation and immune response.   
 
 
Page 38 
CHAPTER FOUR: Critical appraisal 
 
Contributions to the field of knowledge 
Each of the six publications featured in the thesis have contributed knowledge to the 
field of eczema genetic research. The main contributions are summarized in turn 
below. 
 
First global transcriptomic analysis of atopic skin101 
Patients with atopic eczema have a generalised abnormality in skin biology that is 
not restricted to the areas affected by eczematous inflammation. Atopic skin 
demonstrates a greater transepidermal water loss and greater penetration of external 
allergens and irritants.21 A subset of patients with eczema also show greater 
susceptibility to bacterial15 and viral217 infection. Furthermore, FLG 
haploinsufficiency is a specific risk factor for eczema herpeticum,218 a complication 
in which herpes simplex infection spreads rapidly in areas of skin affected with 
active eczema, causing a severe and sometimes life-threatening condition.36 The 
molecular mechanisms underpinning these abnormalities are not fully understood. 
I was fortunate to have the opportunity to collect, with ethical approval, skin biopsies 
from a series of children who had been cared for in Our Lady’s Children’s Hospital 
Crumlin, Dublin, for their lifelong atopic eczema. These precious samples warranted 
very careful analysis. At that time, previous studies had investigated the skin 
transcriptome using microarray and quantitative PCR. These had identified 
abnormalities in epidermal differentiation,219,220 inflammation221,222 and lipid 
structures.223 However, microarray analysis is limited by the requirement to preselect 
genes for inclusion in an array, hence RNA-sequencing has become the method of 
choice for global transcriptome analysis. Single-molecule direct RNA sequencing 
(DRS)224,225 was used as the optimal methodology for quantification of the small 
amounts of mRNA available from the paediatric skin biopsies. ‘Uninvolved’ skin 
(i.e. skin that appears normal on clinical examination) was studied to avoid the 
confounding effects of inflammation and secondary infection. My work represented 
the first comprehensive analysis of primary molecular abnormalities in atopic skin.  
One striking finding was the global effect of FLG genotype on skin transcriptome, 
illustrating the central role that filaggrin plays in epidermal biology. Analysis of the 
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whole dataset (all cases compared to all controls) showed significantly differentially 
expressed genes, when classified by gene ontology (GO) in keeping with previous 
micro-array studies – an important proof-of concept. However, GO analysis stratified 
by FLG genotype revealed key differences in FLG mutant and wild-type cases 
compared with controls: FLG wild-type cases showed dysregulation of genes 
involved with lipid metabolism and upregulation of extracellular matrix genes whilst 
FLG mutant cases displayed upregulation of a functional network of proteins in the 
type 1 interferon–mediated defence response. I have speculated that this network of 
‘defence response’ might relate to the dysfunctional cutaneous response to viral 
infection in patients with eczema, or it may represent the reduced threshold for 
inflammation that is apparent clinically in many atopic patients.226,227  
Together these transcriptomic analyses provided insight into the mechanistic 
pathways in atopic skin, which are both dependent and independent of FLG 
genotype, including the importance of extracellular space, lipid metabolic pathways, 
apoptotic pathways, innate and acquired immunity. Together these findings 
contribute to the future development of stratified and personalised medicine. 
 
FLG genotype has no substantial effect on photo-response in normal skin194 
This study was designed to address a widely-quoted hypothesis stating that the 
filaggrin breakdown product trans-UCA contributes to skin photoprotection by its 
absorption of UVB to produce cis-UCA, which in turn has immunomodulatory 
effects.72 There is evidence of these effects in human cells in vitro and in mice in 
vivo, but no previous studies in human skin in vivo. The response of skin to UV 
radiation ranges from erythema and oedema, to blister formation and necrosis. The 
molecular mechanisms are complex and multifaceted, but they include DNA damage 
and apoptosis. This study aimed to use erythemal response as a quantitative 
parameter of clinical relevance; clinically-relevant wavebands and doses of UV 
radiation were used, including the UVA and UVB wavelengths used for eczema 
treatment.  
Somewhat surprisingly, there was no difference in erythemal sensitivity between the 
FLG heterozygous and wild-type volunteers, even in the UV wavelengths known to 
be absorbed by UCA as it undergoes trans to cis isomerisation. Importantly, our 
post-hoc power estimation showed that the sample size (71 individuals, including 10 
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FLG heterozygotes) was sufficient to exclude an effect size of >1.8-fold difference in 
MED; a smaller effect could not be excluded. However, there was no differential 
effect in the wavebands expected to be absorbed by trans-UCA and those not known 
to be absorbed by this photochemical, suggesting that the hypothesized mechanism 
of photoprotection does not have an impact on erythemal sensitivity.   
This work represents an important negative finding. The fact that observations of 
UVB-induced damage in murine and in vitro models have not been supported by 
clinical data suggests that different mechanisms lead to cutaneous erythema in vivo. 
This is perhaps un-surprising, given the more complex and multifaceted mechanisms 
of photoprotection versus photodamage in human skin in vivo compared to in vitro. 
Epidemiological studies by other research groups have shown an increase in actinic 
damage in patients with FLG null mutations228 and it is possible that the 
photoprotective effect of the FLG wild-type genotype might be attributable to a 
mechanical filtering of UV by the stratum corneum, rather than by photo-
immunosuppression. However, it is not clear whether the observational association 
of FLG mutant genotype and actinic damage is the result of filaggrin deficiency or 
confounding factors, for example sun-seeking behavior by patients with chronic 
eczema or their use of immunosuppressant medications. 
Another important impact of these findings is that they demonstrate the need for 
future work to define predictors of patient response to phototherapy for eczema. The 
treatment dose of UV radiation is currently based on reported skin phototype and 
cutaneous response to MED testing. There are no reliable predictors of response to 
UVA or UVB phototherapy for atopic eczema. A greater understanding of factors 
predicting response would clearly be superior to the current approach of using a 
therapeutic trial, with the inherent risk in UV exposure. 
 
Skin organoid models allow detailed functional and molecular assessment of 
eczema GWAS loci117,195 
Multiple independent research groups have developed skin organoid models with 
important technical differences, including the presence or absence of a model dermis 
and the source(s) of keratinocytes for model epidermis. Immortalised cell lines or 
primary human keratinocytes from patients with normal skin (from foreskin or other 
surgical waste tissue, pooled or single-donor), active eczema or FLG mutant skin 
 
 
Page 41 
samples have each been used. This diversity of modelling has produced a range of 
findings, summarised by Niehues et al.113 and listed in a review that I co-authored.65 
The somewhat conflicting findings in skin barrier assessment in vitro may be 
accounted for, at least in part, by methodological differences in organoid culture as 
well as details with respect to the measurement of barrier function. The duration of 
dye exposure, for example, may affect sensitivity to detect barrier impairment. In our 
model, the immature organoids showed some limited evidence of barrier impairment 
with FLG knockdown, but the mature organoids showed no difference in 
transepidermal water loss, water content or dye penetration. The concordance of 
these three sensitive measurements gives confidence to the findings. 
Our work used a model developed and optimised for barrier assessment, informed by 
a detailed protocol shared by Mildner et al.114 I chose to use primary human 
keratinocytes from normal skin donors, allowing matched controls and technical 
replicates, in addition to multiple biological replicates to allow for inter-individual 
variation.  
The filaggrin-deficient phenotype in vitro had previously been studied in detail.116 
Elias et al. used pooled foreskin keratinocytes and shRNA knockdown, in an 
epidermal-only model; each of these aspects are likely to reduce, to some degree, the 
physiological relevance of the model. In contrast, the siRNA knockdown in my work 
allowed the use of low passage keratinocytes which produce organoid histology that 
more closely resembles skin in vivo. The use of single donor tissue also allowed 
separate biological replicate experiments for comparison and the matching of 
keratinocytes and fibroblasts for the epidermal and dermal compartments.  
My work added greater detail in the mass spectrometry proteomic analysis: 
Fractionation to increase the sensitivity allowed detection of more than 8000 proteins 
compared to 1640 proteins by Elias et al.116 The findings from my work are 
complimentary to those of Elias et al. and have replicated the finding that filaggrin 
deficiency affects the abundance of multiple proteins of relevance to eczema 
pathophysiology, even in the absence of inflammation. However, the greater detail 
and closer physiological relevance of my work offered additional insights, including 
evidence of mechanisms contributing to immune and neurological, as well as 
structural, aspects of skin barrier dysfunction.  
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This work in vitro is complimentary to previous studies of eczema skin biopsies in 
my own work described above101 and carried out by other groups.100,229 The nature of 
our model and analysis of isolated epidermal tissue means that the mechanisms are 
keratinocyte-specific and cannot be confounded by differential components of 
immune cells, neural tissue, blood vessels etc that may be present in whole skin 
biopsies to differing degrees. Furthermore, the skin organoid model is important in 
that it provides an opportunity to study keratinocyte-specific mechanisms in isolation 
from other cell types. This gives unique insight into skin-specific genetic 
mechanisms as well as opportunities for the development of treatments which may 
be most effective when applied topically in direct contact with keratinocytes. My 
work was published in Wellcome Open Research117 because this journal allowed 
sharing of detailed methodology as well as data. The detailed proteomic data have 
been shared in raw and processed form using the open access platform provided by 
the European Bioinformatics Institute (EMBL-EBI) PRIDE 
(https://www.ebi.ac.uk/pride/) as a resource for the field. 
Mass spectrometry lipidomic analysis of the filaggrin-deficient skin organoid model 
was also carried out, using spiked-in standards to aid identification of ceramide 
subsets. This work produced findings in keeping with previous lipid analyses in 
vitro230,231 and in vivo232 providing further proof of concept that the skin organoid 
provides an effective recapitulation of skin barrier physiology.   
I next applied the organoid model to the investigation of a novel eczema candidate 
gene – EMSY – which had not previously been studied in skin. siRNA knockdown of 
EMSY led to a marked phenotype change. An acceleration of the skin barrier 
formation was observed, with upregulation of multiple proteins involved in skin 
differentiation, as well as lipid components of the stratum corneum. These findings 
demonstrate an important role for EMSY in transcriptional regulation and skin 
barrier formation.  
To investigate the relevance for clinical disease, I studied EMSY expression in 
eczema and control skin biopsies. Here, the intensity of nuclear expression at the 
basal layer and throughout the epidermis, was a marker of active eczema. In 
subsequent work, I have shown a correlation between the risk SNP genotype and 
EMSY expression in primary keratinocytes (unpublished data) which further 
validates the link between EMSY and the GWAS risk locus. 
 
 
Page 43 
Together these findings strongly support EMSY inhibition as a novel therapeutic 
approach for atopic eczema. Recent therapeutic advances have effectively targeted 
atopic inflammation and therapies specifically aiming to increase skin barrier 
function are not currently available. I am now working in collaboration with experts 
in the fields of high-throughput screening and drug discovery to assess the feasibility 
of targeting EMSY as a treatment for eczema and other skin barrier defects. 
 
There are distinct subgroups of atopic eczema within the human population196 
Atopic eczema is a very diverse phenotype in clinical appearance, age of onset, co-
morbidities, response to therapy and disease trajectory. Loss-of-function mutations in 
FLG are known to be a risk factor for early-onset, persistent and severe disease; the 
presence of elevated total and specific IgEs are also associated with more severe 
disease, but this may be an epiphenomenon, rather than a true marker of 
pathophysiological process. There are well-recognised clinical subsets of eczema, 
with remission in infancy, later childhood, or evolution into a life-long chronic 
disease. However, it was not clear whether the observed differences represent a 
continuum, or distinct subgroups, since the definition of longitudinal disease subsets 
had not previously been studied.  
Collaboration with two large, well designed, longitudinal birth cohort studies 
allowed the technique of longitudinal latent class analysis to be used to test for 
distinct subgroups. This was the first application of LLCA to atopic eczema. 
Adjustment of the modelling parameters defined 6 groups as providing the optimal 
balance between fitting and over-fitting the data. Findings from each of the 
independent populations gave remarkable replication, supporting the validity of these 
latent classes. 
The majority of eczema cases in the birth cohorts were, as expected, in a large class 
of early onset and resolving disease. The cases with FLG mutations (and other 
GWAS risk SNPs) were most strongly associated with classes of persistent or late-
resolving eczema; this was also as expected from previous knowledge. Novel 
findings included evidence for distinct subgroups of atopic eczema in childhood, and 
the presence of a previously unrecognised class with onset at 5-6 years of age, 
associated with atopic asthma and male sex.  
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The finding of distinct latent classes provides support for the future application of 
personalised medicine tailored to the specific subsets of eczema. However, this 
LLCA is observational. Further research is needed to apply our findings for the 
prediction of eczema trajectory (rather than the retrospective definition supplied by 
the longitudinal data) before pro-active personalised care can be made available.  
 
Eczema and psoriasis show opposing genetic mechanisms in epidermal 
differentiation and immune response197 
It has long been recognised that eczema and psoriasis rarely co-occur, but the 
molecular mechanisms for this exclusivity are not well defined. It is a striking 
observation that atopic eczema and psoriasis share genetic risk loci, and these have 
been attributed to both immune and skin barrier mechanisms.233 Previous work 
investigated whether SNPs reported to be associated with psoriasis were also 
associated with atopic eczema.234 Of the 13 risk variants in the overlapping loci 
reaching statistical significance, approximately two-thirds showed opposing effects 
on eczema and psoriasis (consistent with the diseases being mutually exclusive) 
whilst one-third of variants contributed risk to both diseases. This may be 
representative of the shared features of the two inflammatory skin diseases.234 
My work took a more systematic exploratory approach, using statistical analysis to 
compare and contrast genetic risk for eczema and psoriasis across the whole genome.  
Our results confirm shared regions of genetic risk on chromosomes 1, 5 and 6, 
representing the epidermal differentiation complex, Th2 locus control region and the 
major histocompatibility complex (MHC). Within these regions there were variants 
with shared and opposing effects on eczema and psoriasis, but the variants increasing 
risk of both diseases were not statistically significant, emphasising the divergence of 
these conditions.  
There were 6 loci associated with both diseases (with genome-wide significance) and 
each showed opposing effects. A variant within the antisense transcript FLG-AS1 
may mediate opposing effects on epidermal differentiation through transcriptional 
regulation of nearby genes, as has been described for other long non-coding RNA 
species.235,236 Opposing effects at 5q31.1 are within RAD50 and IL13, therefore likely 
to reflect the divergent immune signalling in eczema versus psoriasis. Two other loci 
(2q31.2, 5q33.1) had not previously been reported as showing co-association with 
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eczema and psoriasis. The pleiotropic alleles in these two loci with opposing effects 
on eczema and psoriasis risk lie in exon 6 of PRKRA and in an intergenic region in 
linkage disequilibrium with ANXA6 and TNIP1. PRKRA encodes protein kinase 
interferon-inducible double-stranded RNA-dependent activator (PACT), a cellular 
dsRNA-binding protein originally identified as a binding partner and activator of 
PKR in response to extracellular stress.237 More recently, it has been shown to be an 
essential factor in the PKR-independent initiation of RIG-I-induced antiviral 
response.238 This may be of relevance to the differential susceptibility of individuals 
with eczema and psoriasis to viral skin infections.239 ANXA6 encodes a calcium-
dependent membrane and phospholipid binding protein that is upregulated in atopic 
skin compared to control skin but expression is decreased in skin with active 
psoriasis. Since calcium signalling is important in epidermal differentiation this may 
contribute to differential susceptibility to the inflammatory skin diseases, but further 
fine mapping and functional testing is required. TNIP1 is involved in TNF signalling 
and regulation of the transcription factor NF-kB and it has previously been 
implicated in psoriasis risk240 but not eczema. TNIP1 shows increased expression in 
both eczema and psoriatic lesions compared to control skin, which supports this 
mechanism as an opposing effect in these disorders. It is tempting to speculate that 
the reported observations of eczematous eruptions or paradoxical psoriasis 
developing in patients receiving anti-TNF biologic therapies241 and psoriatic 
eruptions in response to dupilumab for eczema242 may all be manifestations of the 
balance that is required in healthy skin to maintain an immune homeostasis to avoid 
either eczema or psoriasis. Greater understanding of this immunological balance may 
be applied to therapeutic optimisation in the future. 
Looking outside Dermatology, the statistical analysis methods developed in the 
conduct of this study are likely to be applicable to the investigation of the genetic 
basis of other complex traits with overlapping and distinct clinical features. 
 
 
Impact on clinical guidelines and randomised controlled trials 
The role of FLG null mutations in causing dry skin, barrier dysfunction and eczema 
has informed the development of therapeutic guidelines. The National Institute for 
Health and Care Excellence (NICE) guidelines state: ‘Atopic eczema often has a 
genetic component that leads to the breakdown of the skin barrier. This makes the 
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skin susceptible to trigger factors, including irritants and allergens, which can make 
the eczema worse’.243 The NICE guideline on treatment emphasises the importance 
of emollient use to improve skin barrier function, now a key quality statement: 
‘Children with atopic eczema are prescribed sufficient quantities (250-500 g weekly) 
from a choice of unperfumed emollients for daily use.’ The Scottish Intercollegiate 
Guidelines Network (SIGN) also quote filaggrin research in their rationale for a 
guideline: ‘…defects in epithelial barrier function arising from abnormalities in 
structural proteins such as filaggrin [make] the skin both excessively permeable and 
more prone to damage from environmental irritants and allergens.’244 This new 
understanding has been conveyed in undergraduate and postgraduate teaching as well 
as lay health education including the NHS educational web pages `NHS inform' and 
`NHS choices'.   
The strong effect of FLG null genotype has also been used for patient stratification in 
randomised controlled clinical trials, including therapeutic silk clothing190 and 
emollients for eczema prevention.245 
 
Strengths and weaknesses 
Many of the strengths and weaknesses of my published research have been discussed 
in relevant sections above; additional key points will be summarised here.  
 
Atopic skin transcriptome analysis 
A major strength of direct RNA sequencing (DRS) is that it offers accurate 
quantification of polyadenylated RNA, avoiding the bias that is introduced by the 
steps of reverse transcription, ligation, and amplification in other forms of RNA 
sequencing. In addition, DRS provides information on the DNA strand from which 
the mRNA is transcribed, allowing more accurate alignment of reads to genes in 
complex regions. The disadvantages of DRS are that relatively short reads are 
produced, hence the technique is better for accurate quantification than novel 
sequencing. However, the main aim of my analysis was to quantify the transcriptome 
in the most sensitive, accurate and comprehensive way, rather than to detect novel 
transcript sequences, therefore DRS was the optimal method for this detailed study 
of tissue-specific gene expression data from small amounts of tissue. 
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Another strength of the skin transcriptome study was the very thorough FLG 
genotyping by full sequencing, rather than selected mutation analysis. This identified 
several mutations that would otherwise have been overlooked. The application of 
FLG genotype – known to have a functional effect on skin biology – for stratification 
was a strength allowing more information to be leveraged from the large dataset. 
This is illustrated by the differing but complimentary findings obtained from analysis 
of the whole dataset compared with FLG genotype subgroups.101 
A weakness of the skin transcriptome analysis was that I did not have sufficient 
tissue to allow protein quantification to investigate correlation with mRNA levels. 
This was a limitation because of the biopsy size (3 or 4mm diameter punch) which 
was the maximum that could be requested from our paediatric patients. I made the 
decision to use the entire sample for optimal RNA extraction, since my pilot data 
from similar sized skin samples showed that attempts to bisect the sample or 
protocols to extract RNA and protein simultaneously compromised the quality and 
quantity of RNA. 
 
Erythemal response to UV radiation 
A major strength of this study was the use of clinically-relevant wavebands and 
physiological doses of UV radiation. A relative weakness was the sample size with 
detailed phototesting data, meaning that the study was only powered to detect a 
modest-large effect size (>1.8-fold difference in MED). Another possible weakness 
of the study was the lack of FLG homozygous or compound heterozygous 
individuals; this was not unexpected since the prevalence of FLG -/- is only ~1:100 
within the normal population. We therefore have not excluded the possibility that 
FLG homozygous (or compound heterozygous) subjects might show greater 
erythemal sensitivity than wild-type subjects. However, FLG null heterozygosity has 
a significant effect on filaggrin expression in vivo,101,126 therefore I would anticipate 
an effect to be detectable in this study (within the parameters of the posthoc power 
calculation) reducing the likelihood of a false negative finding. 
 
Organoid modelling of genetic effects in skin 
The skin organoid model optimised in my laboratory uses low passage primary 
human keratinocytes and donor-matched primary fibroblasts; this is a major strength 
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in obtaining as near to physiological conditions as possible in vitro. Other important 
cell types, notably resident and circulating immune cells of the haematopoietic 
lineage are absent; supportive and adnexal structures including blood vessels, 
neurons, sweat glands etc are also absent. The reductionist model may clearly be a 
weakness but it can also be viewed as a strength. My approach focuses on epidermal 
keratinocytes because there is clear evidence of specific genetic effects in 
keratinocytes in disorders of cornification with atopic features78,195,246 and barrier 
epithelial cells are crucial in determining the outcome of allergen-encounter.247 
Keratinocyte biology is likely to play a central role in eczema risk and resolution. 
Studying keratinocytes in a tissue model without other immune cells offers the 
opportunity to identify initiating mechanisms in eczema, as well as keratinocyte-
specific contributions to barrier function.78,195,248 The potential weaknesses in using 
the keratinocyte and fibroblast organoid model are further circumvented by 
validation of key findings in whole skin biopsies from eczema patients.117,195 
 
Longitudinal latent class analysis defining eczema subgroups 
A major strength of this study is the use of data from two large and complimentary 
longitudinal epidemiological studies. Despite the large sample size, a limitation 
inherent in latent class analysis is that the dataset is divided into smaller subsets, 
which lowers the statistical power to detect association. The similarity in case 
definitions, using prospective questions to capture diagnostic features of eczema 
from infancy to later childhood and the similar high frequency of eczema in 
ALSPAC and PIAMA are strengths. However, these studies were limited in their 
inclusion of data relating to atopic traits, comorbidities and important environmental 
factors. Another limitation inherent in LLCA was the fact that the analysis is not 
designed to test for causality of direction of effect. This is pertinent because some of 
the risk factors in this study did not unequivocally precede the onset of disease. 
Therefore further work is needed to investigate causality (discussed below). 
 
Comparative analysis of eczema and psoriasis  
A major strength of this work was the large sample sizes, but weaknesses included 
the different platforms used for genotyping in different cohorts, meaning that 
imputation and careful integration of data were needed. These steps may have 
introduced bias. A further limitation in the interpretation and application of key 
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findings is that genome-wide analysis identifies loci and variants in association with 
disease, but not a mechanism of effect. Further work is therefore needed to fine-map 
and validate key findings by demonstrating functional effects in vitro or in vivo. 
Work is now on-going in my lab to investigate one of the loci showing an opposing 
effect within the FLG-AS1 transcript. Preliminary (unpublished) findings show an 
effect of FLG-AS1 on the expression levels of FLG and FLG2.  
 
Genetic diversity 
The lack of ethnic diversity in all six publications arose because of study design, in 
which genetic homogeneity was needed to allow screening for FLG null mutations 
that are prevalent in white European populations and to reduce inter-individual 
variation to some extent. However, this lack of diversity is a weakness that has been 
highlighted as a widespread problem in the field of genetic research.182 An increasing 
number of studies are investigating eczema genetic risk in more ethnically diverse 
populations249 including African people-groups.94,250-253 
Sex-differences are also an important consideration in genetic research. Participant 
sex has been matched or controlled for throughout my work wherever possible. An 
exception is in the skin organoid work, since the primary cells for these studies are 
harvested from predominantly female skin, reflecting the plastic surgical procedures 
(breast and abdominal reduction surgery) that most frequently supply excess tissue. 
Ideally future work would test for replication using XY cells and tissues. 
 
Complimentary approaches 
A variety of complimentary experimental approaches are used in my work and this 
is, I believe, an important strength. Complimentary approaches offer a more 
comprehensive understanding of the very complex and diverse disease, atopic 
eczema. The integration of different perspectives obtained from clinical observation, 
epidemiological and population-based studies, molecular and genetic analyses has 
provided opportunities to inform and direct future research. For example, the skin 
transcriptome findings from DRS have informed the FLG knockdown in vitro and 
clinical studies in vivo; GWAS findings led to assessment of EMSY in skin models in 
vitro and validation of EMSY expression in clinical biopsy samples, leading to a 
phenotypic screen for drug discovery. 
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Outstanding questions and future perspectives 
Despite rapid progress in the field of eczema genetic research there remain important 
gaps in knowledge and understanding. 
 
Molecular mechanisms attributable to filaggrin  
Some fundamental questions remain to be answered in relation to the filaggrin 
molecule, profilaggrin and the constituent amino acids with respect to how filaggrin 
deficiency leads to eczema and other atopic diseases. More specific understanding of 
the relative importance of different aspects of the profilaggrin-filaggrin-amino acid 
pathways and their control mechanisms could allow for more effective targeting of 
this central pathomechanism for treatment and/or prevention. My work and others’ 
has shown that filaggrin plays a role in skin biology beyond the mechanical barrier 
function of filament aggregation to susceptibility to infection, threshold for 
inflammation, control of apoptosis and neurological abnormalities. Effective 
therapeutic application may require specific targeting of one or more of these aspects 
of skin biology. 
 
Insights from GWAS  
Multiple GWAS studies and meta-analyses have identified risk loci, emphasizing the 
importance of genetic risk mechanisms controlling both the skin barrier and immune 
responses in eczema, but for the majority of risk loci the mechanisms leading to 
atopic skin inflammation remain unknown. Furthermore, many of the loci are 
intergenic, therefore detailed molecular studies, carried out in cells and tissues of 
relevance to eczema are needed to characterise the relevant functional effects. The 
threshold for statistical significance is necessarily stringent in GWAS because of the 
extreme multiple testing that occurs (Figure 4). Larger GWAS studies, including 
hundreds of thousands of cases and controls could reveal additional risk loci, but 
each new effect size is likely to be small. GWAS findings to date account for <20% 
of AD heritability 92 and even with the additional risk attributed to protein-coding 
variants, ~70% of heritability remains to be explained 254. Considerable further work 
is therefore needed to fully understand individual risk and functional effects. 
In addition to the main GWAS ‘hits’, multiple gene–gene and gene-environment 
interactions that are likely to contribute to the heritability that remains to be 
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explained in atopic eczema (Figure 4). Gene-gene interaction analysis is statistically 
challenging because of the issues of multiple testing and similarly gene-environment 
interactions, whilst likely to be of importance in eczema, are challenging to detect on 
a genome-wide level. These mechanisms therefore require alternative, more targeted 
functional assessment.  A clearer understanding of gene–environment interaction is 
needed in order to explain the significant rise in incidence of atopic disease in 
industrialized nations over the recent decades. This will require careful 
epidemiological study of human populations, but the use of mouse models of atopic 
disease will also be useful in allowing experimental manipulation of both genetic and 
environmental effects. Gene–environment interactions are key to future preventative 
strategies, with the ultimate aim of preventing atopic eczema and halting the atopic 
march. 
 
 
Figure 4. Annotated Manhattan plot showing information displayed and 
outstanding questions. 
A Manhattan plot is the conventional method for displaying results from GWAS. Each SNP is 
represented by a dot on the plot, and its position is determined by genomic location and a statistical 
test of association with the trait of interest. Figure reproduced from an invited commentary that I have 
written, currently under review for J Invest Dermatology 2020. 
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Causal effects 
Population genetic studies including GWAS and LLCA identify association but do 
not test for causal effects. Causality can be tested in vitro using skin organoid models 
(as described above), but this detailed work is very time-consuming. An alternative 
statistical approach is Mendelian randomisation (MR), a technique that uses genetic 
risk variants, single or groups of SNPS from GWAS, as a proxy for phenotype or 
exposures. Genetic variants are inherited randomly at conception, therefore they are 
less prone to the confounding and reverse causation which limit the usefulness of 
observational epidemiology.255 MR studies in eczema have previously investigated 
causal links with prenatal alcohol exposure256 and vitamin D levels,257 each of which 
have no causal effect on eczema. Another approach has combined MR and multiple-
trait colocalization to define cell-specific inflammatory drivers of autoimmune and 
atopic disease.258 A recent MR study has shown that there is a causal effect of 
obesity on psoriasis, but conversely psoriasis does not cause an increase in obesity.259 
We have recently completed a similar MR analysis to investigate a causal effect of 
obesity on eczema, or vice versa (manuscript in press, J Allergy Clin Immunol). 
 
Therapeutic targets 
It is known that drugs targeting molecules or pathways informed by human genetic 
studies have a greater chance of clinical success than targets defined using other 
experimental or theoretical approaches.260 GWAS hits and variants in protein-coding 
regions have identified multiple proteins in the IL-13 pathway, all of which have 
been successfully targeted in novel AD treatments.254 In contrast, specific molecular 
targets to improve skin barrier function remain elusive and, as discussed above, in 
this respect EMSY is a particularly promising discovery. The distinct genetic 
mechanisms in atopic eczema and psoriasis include opposing effects in pathways 
influencing epidermal differentiation and immune response, suggesting that both 
may need to be targeted simultaneously to achieve optimal disease control. Further 
investigation of disease mechanisms will offer the opportunity to understand not only 
inflammatory skin disease but also the substantial burden of co-morbidities. 
Translational genomics, drug development and personalised medicine are closely 
inter-dependent and will progress together.61,261 Dermatological research is poised to 
be at the forefront of these exciting developments in clinical care. 
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Another area of intensive research interest is the complex interaction of skin and gut 
microbiome with cutaneous inflammation.262 These studies have been made possible 
by modern sequencing technologies to circumvent the need for selective bacterial 
cultures.263 The approach has illustrated a reduction in microbial diversity in active 
eczema in addition to the well-established over-growth of S aureus.262 Further work 
is needed to match genetic risk effects in human skin with microbial diversity or 
overgrowth232 and to date these interactions have not been targeted for therapy. 
 
Can eczema be prevented? 
There is considerable interest in the possibility that eczema and other atopic diseases 
may be amenable to primary prevention through targeted intervention early in life. 
Hope was raised by two independent studies which both showed an ~50% reduction 
in eczema prevalence in high-risk infants treated with intensive emollient 
therapy.264,265 However, a recent more definitive study (the BEEP study, Barrier 
Enhancement for Eczema Prevention), including 1394 newborns in a randomised 
controlled study, has shown no protective effect.245 This study included planned 
subgroup analysis based on FLG genotype (for which I co-ordinated the genotyping). 
It could be hypothesised that either filaggrin-deficient or filaggrin-replete skin would 
benefit more from emollient therapy: filaggrin-deficient because this skin stands to 
derive greater benefit from the hydration provided by emollient therapy; filaggrin-
replete because these infants’ skin does not have an inherent predisposition to 
inflammation. The fact that neither of these genetic subgroups showed a protective 
effect from emollient application provides further support for the whole study’s 
negative result.  
A similar study from Sweden, including 2397 newborn infants has replicated the 
finding that emollient therapy does not protect against atopic eczema.266 These are 
both well-designed, sufficiently powered and carefully conducted studies. Possible 
reasons behind the negative results include: true lack of effect in emollient for 
eczema prevention, since the independent studies gave strikingly similar results; 
inadequate emollient application, although there was adherence to emollient use in 
>70% of the intervention group in the BEEP study; delayed commencement, 
possibly after a critical early window for eczema initiation; or an insufficiently 
complex intervention to improve skin barrier.  
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Interestingly, analysis of side effects and secondary effects of emollient showed 
some evidence of increased skin infection (adjusted incidence rate ratio 1.55 (95% 
confidence interval 1.15 to 2.09) and a non-significant increase food allergy.245 
Therefore intensive emollient application may not be entirely harm-free. Further 
work is needed to identify the most effective way to improve skin barrier early in life 
and assess whether this can safely be used to prevent eczema or other atopic 
diseases. 
 
Concluding remarks 
The work comprised in these six selected publications illustrates a program of 
research that has contributed substantially to understanding genetic risk mechanisms 
in atopic eczema. The field has shifted from a focus on atopic inflammation to a 
broader understanding of skin barrier-immune dysregulation as a complex interplay, 
with multiple genetic as well as environmental effects. Much has been learned from 
genetic studies, allowing a detailed interrogation of the primary mechanisms in 
atopic skin disease and there is great potential for this knowledge to be applied in 
future therapeutic development. 
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Filaggrin-stratified transcriptome analysis of paediatric skin identifies 
mechanistic pathways in atopic dermatitis. 
Atopic dermatitis and skin disease
Filaggrin-stratified transcriptomic analysis of pediatric skin
identifies mechanistic pathways in patients with atopic
dermatitis
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by a widespread abnormality in cutaneous barrier function and
propensity to inflammation. Filaggrin is a multifunctional
protein and plays a key role in skin barrier formation.
Loss-of-function mutations in the gene encoding filaggrin (FLG)
are a highly significant risk factor for atopic disease, but the
molecular mechanisms leading to dermatitis remain unclear.
Objective: We sought to interrogate tissue-specific variations in
the expressed genome in the skin of children with AD and to
investigate underlying pathomechanisms in atopic skin.
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82Uninvolved skin biopsy specimens from 26 pediatric patients
with AD were compared with site-matched samples from 10
nonatopic teenage control subjects. Cases and control subjects
were screened for FLG genotype to stratify the data set.
Results: Two thousand four hundred thirty differentially
expressed genes (false discovery rate, P < .05) were identified,
of which 211 were significantly upregulated and 490
downregulated by greater than 2-fold. Gene ontology terms for
‘‘extracellular space’’ and ‘‘defense response’’ were enriched,
whereas ‘‘lipid metabolic processes’’ were downregulated. The
subset of FLG wild-type cases showed dysregulation of genes
involved with lipid metabolism, whereas filaggrin
haploinsufficiency affected global gene expression and was
characterized by a type 1 interferon–mediated stress response.
Conclusion: These analyses demonstrate the importance of
extracellular space and lipid metabolism in atopic skin
pathology independent of FLG genotype, whereas an aberrant
defense response is seen in subjects with FLG mutations.
Genotype stratification of the large data set has facilitated
functional interpretation and might guide future therapy
development. (J Allergy Clin Immunol 2014;134:82-91.)
Key words: Atopic dermatitis, direct RNA sequencing, eczema,
filaggrin, gene expression, singlemolecule, skin, tissue, transcriptome
Atopic dermatitis (AD; atopic eczema or eczema) is an itchy
inflammatory skin disease with a spectrum of clinical skin
phenotypes.1,2 The pathology of eczematous skin is characterized
by epidermal intercellular edema and a barrier dysfunction
resulting in increased transcutaneouswater loss and increasedpene-
tration of external allergens and irritants.3 A subset of patients with
AD show greater susceptibility to bacterial4 and viral5 infection.
Previous studies have investigated the transcriptome in atopic
and eczematous skin by using microarray technologies and
quantitative PCR, identifying a variety of pathomechanisms,
including abnormalities in epidermal differentiation,6-8 inflam-
matory pathways,9-14 and lipid homeostasis.12,15,16 However,
microarray analysis is intrinsically restricted by preselection of
genes represented on an array and by annotations from which
gene expression is quantified.17 Sequencing RNA is now an
established methodology to study gene expression without the re-
striction of gene preselection.18 We chose to use single-molecule
direct RNA sequencing (DRS)19,20 as the optimal methodology
for quantification of the relatively small amounts of mRNA
available from pediatric skin biopsy samples. DRS offers accurate
quantification of polyadenylated RNA, avoiding bias that might
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amplification in other forms of RNA sequencing. In addition,
DRS provided information on the DNA strand from which the
mRNAwas transcribed; this facilitates more accurate alignment
of reads to genes in the complex overlapping regions that are
common in the human genome.21
The finding that loss-of-function mutations in the skin barrier
gene encoding filaggrin (FLG) are strongly and significantly
associated with AD risk22,23 has focused attention on skin
barrier dysfunction as a primary pathogenic mechanism.
Filaggrin deficiency appears to play a central role in the
pathogenesis of AD. Filaggrin expression can be downregulated
by TH2 cytokines
24-26 and atopic inflammation,27,28 whereas FLG
intragenic copy number variation influences AD risk in a
dose-dependent fashion, even in the absence of FLG null
mutations.29 Filaggrin is expressed initially as a long insoluble
polyprotein, profilaggrin, which is cleaved to produce
functional monomers that aggregate and align keratin filaments.30
Filaggrin is thereafter degraded in amultistep proteolysis to release
hygroscopic amino acids, contributing to the skin’s ‘‘natural mois-
turizing factor.’’31,32 Themechanisms bywhich themultifunctional
profilaggrin/filaggrin proteins lead to AD, as well as atopic asthma,
allergic rhinitis, food sensitization, and peanut allergy, have been
the focus of intense study over recent years.33
We sought to undertake a comprehensive analysis of the
primary molecular abnormalities in atopic skin using accurate
quantification of the transcriptome in pediatric patients with AD
compared with nonatopic teenage control subjects. FLG geno-
type was used to define subphenotypes for the stratification of
this large data set. Uninvolved skin was chosen to study the
underlying pathomechanisms of AD without the confounding
effects of secondary inflammation or infection. Our strategy for
analysis was stepwise, as follows: (1) all cases compared with
all control subjects, (2) case-control comparison stratified by
FLG genotype, and (3) case-case comparison stratified by FLG
genotype (Fig 1).METHODS
Study subjects: Patients with AD
This study was reviewed and approved by the research ethics board at
Our Lady’s Children’s Hospital, Dublin, Ireland (reference: SAC/119/09
26). Pediatric patients with AD of Irish ethnicity attending the dermatology
department were invited to participate. Twenty-six children aged 6 to 16
years and their parents/guardians provided written informed consent; 19
were male, and 7 were female (Table I). Each child had a history of
chronic relapsing AD diagnosed by experienced pediatric dermatologists
(G.M.O’R., R.M.W., A.D.I., and S.J.B.) and moderate or severe disease,
as defined according to the Nottingham Eczema Severity Score.34 Children
with a history of current or previous treatment with systemicimmunomodulatory medication were excluded. The area of biopsy was
not treated with topical steroids for 4 weeks before sampling, and emol-
lients were not applied for 2 days before biopsy. A single punch biopsy
specimen of 3 to 4 mm in diameter was taken from each child after local
anesthetic injection and standard aseptic technique from the upper outer
buttock skin. Clinically uninvolved skin was sampled and protected skin
on the buttock was chosen to minimize differences resulting from UV
exposure and variation in environmental humidity.35 Batch effects and
RNA degradation were minimized because samples were collected by 2
clinicians (G.M.O’R. and S.J.B.), and the biopsy specimens were immedi-
ately snap-frozen in liquid nitrogen before storage in a single 2808C
freezer before simultaneous processing. The study subjects had previously
provided blood samples for DNA extraction as part of the ongoing Na-
tional Children’s Research Centre AD Case Collection.36
Study subjects: Nonatopic control subjects
The collection of samples from healthy volunteers was reviewed and
approved by the East of Scotland Research Ethics Service, United Kingdom
(LR/11/ES/0043). Nonatopic teenage volunteers with 4 grandparents of Irish
or Scottish descent were recruited. Skin biopsy specimens were collected in
the same way as for the patients with pediatric AD, and 5 mL of venous blood
was collected for DNA extraction.
RNA extraction and quality control
The protocol for extraction of total RNA of greater than 200 nucleotides
in length from tissue by using the Qiagen RNeasy Mini Kit (Qiagen,
Manchester, United Kingdom) was modified and optimized, as follows.
Working on dry ice, subcutaneous fat was trimmed from the skin biopsy
specimen, and the remaining sample was placed in a 2-mL sample tube RB
(Qiagen, UK) with 600 mL of Buffer RLT (Qiagen, UK) and one 7-mm
stainless steel bead (Qiagen, UK). The sample was disrupted and homog-
enized at 48C in a Qiagen TissueLyser LT for 5 minutes at 50 oscillations
per second. RNA extraction then proceeded according to a standard
protocol with 2 final elution steps each using 30 mL of RNase-free water
and centrifuged at 12,000 rpm for 90 seconds. Spectrophotometry (Nano-
Drop ND-1000 spectrophotometer; Thermo Scientific, Uppsala, Sweden)
and a microfluidics platform for size analysis and quantification (Agilent
2100 Bioanalyser; Agilent Technologies, Santa Clara, Calif) were used for
quality control. This protocol yielded 2.5 to 10.8 mg per sample of RNA
with an A260/280 ratio of 1.9 to 2.1.
FLG genotyping
Genomic DNA samples extracted from blood were initially screened for
FLG null mutations with TaqMan allelic discrimination assays (TaqMan,
Applied Biosystems 7700 sequence detection system; Applied Biosystems,
Foster City, Calif), as previously described.37 Next-generation deep
sequencing of 25 cases and all 10 control subjects identified additional
mutations that were confirmed by using Sanger sequencing.Measurement of global transcript abundance
DRS was performed on a HeliScope Sequencer (Helicos, Cambridge,
Mass) with 500 ng of extracted RNA, as previously described.19 RNA mole-
cules are captured by the poly-A tail, and the single molecule of mRNA is
directly sequenced from the 39 end, producing reads up to 70 bp in length (me-
dian, 32 bp).DRS read processing
Details of sequence alignment and analysis are presented in the Methods
section in this article’s Online Repository at www.jacionline.org. DRS re-
sulted in 480 million reads across all 36 samples, providing gene expression
data for 11,259 genes. The raw data are deposited at the European Genome-
Phenome Archive (EGAS00001000823/EGAC00001000200); processed
data are available at polyAdb (http://www.compbio.dundee.ac.uk/polyAdb)
FIG 1. Flow diagram summarizing study design and analysis strategy. het, Heterozygous.
TABLE I. FLG genotype and demographic data for 26 pediatric
patients with moderate-to-severe AD and 10 nonatopic control
subjects
Phenotype FLG genotype No. (%)
Mean age
(y [range; SD])
Male sex,
no. (%)
Cases Wild-type 7 (27) 12.3 (9-15; 2.8) 7 (100)
Heterozygous 12 (46) 11.6 (6-16; 3.4) 8 (67)
Compound
heterozygous
7 (27) 10.7 (6-13; 3.4) 4 (57)
Total 26 11.5 (6-16; 3.2) 19 (73)
Control subjects Wild-type 8 (80) 17.9 (16-19; 0.8) 4 (50)
Heterozygous 2 (20) 18.0 (18-18; 0.0) 2 (100)
Compound
heterozygous
0 (0) NA 0 (0)
Total 10 17.9 (16-19; 0.7) 6 (60)
Cases were diagnosed by experienced pediatric dermatologists (G.M.O’R., R.M.W.,
A.D.I., and S.J.B.), and severity was defined by using the Nottingham eczema severity
score.34 Heterozygous mutations in the cases were p.R501X (n 5 6) and c.2282del4
(n 5 6), and those in the control subjects were p.R501X (n 5 1) and c.5690delA
(n 5 1). Compound heterozygous genotypes (each n 5 1) were p.R501X/c.2282del4,
p.R501X/p.S3247X, p.R501X/p.G1139X, p.R501X/p.S1280X, c.2282del4/p.R1474X,
p.S1040X/c.10885delC, and p.S608X/p.Y2092X.
NA, Not applicable.
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ensembl.org. Scripts for performing analysis and generating the figures that
accompany this article are available at polyAdb (http://www.compbio.
dundee.ac.uk/polyAdb).Differential gene expression and FLG correlation
analyses
EdgeR (version 2.6.12 in R version 2.15.1) analysis was performed with
generalized linear models to control for sex bias between comparisons. Unless
otherwise stated, genes were called as significantly differentially expressed if
the Benjamini-Hochberg corrected false discovery rate (FDR) was less than
0.05.38 All-against-all correlation of gene expression across individual sam-
ples was performed with the Pearson method. Further details are presented
in the Methods section in this article’s Online Repository.
Gene ontology analysis and functional protein
network analysis
Gene ontology (GO) has been developed to provide a controlled vocabulary
of terms to describe the characteristics of genes and gene products with
standardization across species and between databases. This allows the
bioinformatic analysis of GO terms in large data sets for thematic classifica-
tion. GO analyses were performed with AmiGO gene ontology version 1.8
(http://amigo.geneontology.org/cgi-bin/amigo/search.cgi?action5advanced_
query). Functional protein association networks were investigated in silico by
using STRING9.05 (http://string-db.org/).
Quantitative PCR analysis
RNA (1.4 ng) was converted to cDNA by using the High Capacity cDNA
Reverse Transcription Kit (Applied Biosystems), according to a standard
protocol. Aliquots of RNA extracted from atopic skin samples were analyzed
in triplicate by using real-time quantitative PCR performed according to
standard protocols with the TaqMan 7900HT Fast (Applied Biosystems) with
normalization to glyceraldehyde-3-phosphate dehydrogenase (GAPDH).
FIG 2. Scatterplots showing correlation of gene expression levels with FLG expression. The fold change of
significantly differentially expressed genes (FDR P < .05) is plotted against the Pearson correlation
coefficient for correlation with FLG expression. Each point represents expression of a single gene. FLG is
marked in orange. A, Correlation of FLG wild-type (n 5 7) compared with FLG heterozygous (n 5 12)
samples. B, Correlation of FLG wild-type (n 5 7) versus FLG compound heterozygous (n 5 7) samples.
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Seventy-three percent of patients with AD carry 1 or
more FLG null mutations
Our comprehensive screen for FLG null mutations revealed a
high proportion of mutation carriers (19/26 [73%] of cases,
Table I), reflecting the severity of disease and enrichment for
coexisting ichthyotic skin phenotype. One heterozygous
mutation, p.Y2092X, is reported for the first time. Two (20%)
of 10 control subjects were heterozygous for an FLG null
mutation (Table I).FLG genotype affects global gene expression
Gene expression between samples was highly correlated
(Pearson r 5 0.81-0.99, see Fig E1 in this article’s Online
Repository at www.jacionline.org), and comparison of the control
samples with AD cases revealed no obvious clustering by
phenotype or FLG genotype (see Fig E2 in this article’s Online
Repository at www.jacionline.org). This highlights the subtlety
of changes in gene expression in uninvolved atopic skin. The
samples do not cluster according to age, providing some
assurance that the use of samples from older subjects in the
control group does not result in bias to account for the observed
differences in transcriptional profile. However, in contrast,
correlation with FLG gene expression showed a striking global
change between samples of different FLG genotypes (Fig 2).‘‘Defence response’’ and ‘‘extracellular region’’
genes are overexpressed in atopic skin, whilst ‘‘lipid
metabolic processes’’ and ‘‘small molecule
metabolic processes’’ are downregulated
Comparing all 26 cases with all 10 control subjects showed
2430 differentially expressed geneswith an FDR of less than 0.05,including 211with a fold change of greater than 2.0 and 490 genes
with a fold change of less than 0.5. The full list is shown in
Table E1 in this article’s Online Repository at www.jacionline.
org. GO analysis identified the most highly significant terms in
the greater than 2.0-fold upregulated genes as ‘‘defense response’’
(28 genes, FDR: P5 7.13 10207), the ‘‘extracellular region’’ or
‘‘extracellular space’’ (each 32 genes, FDR: P5 1.83 1023) and
‘‘receptor binding’’ (23 genes, FDR: P 5 5.7 3 1023). The
most highly significant terms in the less than 0.5-fold
downregulated genes were ‘‘lipid metabolic process’’ (52 genes,
FDR: P 5 6.6 3 10211), ‘‘small molecule metabolic process’’
(76 genes, FDR: P5 6.63 10211), and ‘‘organic acid metabolic
process’’ (44 genes, FDR: P 5 6.6 3 10211). The full list
is shown in Table E2 in this article’s Online Repository at
www.jacionline.org.
Analysis of the significantly upregulated genes identified
predicted protein interaction networks classified as ‘‘defense
response,’’ ‘‘extracellular region,’’ and ‘‘receptor binding’’ (see
Fig E3 in this article’s Online Repository at www.jacionline.org).
Significantly downregulated genes show predicted functional net-
works within ‘‘lipid metabolic processes,’’ ‘‘small molecule meta-
bolism,’’ and ‘‘organic acid metabolic processes’’ (see Fig E4 in
this article’s Online Repository at www.jacionline.org).FLG wild-type subjects show dysregulation of
genes involved with lipid metabolism and
upregulation of extracellular matrix terms
Analysis of the 8 FLG wild-type control subjects compared
with the 7 FLG wild-type cases identified 401 differentially
expressed genes with an FDR of less than 0.05, including 105
with a fold change of greater than 2.0 and 87 with a fold
change of less than 0.5 (the full list can be found in Table E3
in this article’s Online Repository at www.jacionline.org).
FIG 3. Network analysis of lipid metabolism genes differentially expressed in FLG wild-type AD cases
compared with FLG wild-type control subjects. Twenty-one significantly differentially expressed genes
(defined as FDR: P < .05 and fold change >2.0 or <0.05) were classified with the GO terms ‘‘lipid metabolic
process’’ (n5 13), ‘‘cellular lipid metabolism’’ (n5 13), ‘‘lipid particle’’ (n5 4), and ‘‘triglyceride catabolism’’
(n 5 3). Linear connectors indicate evidence for association in published data sets (STRING9.05; accessed
March 3, 2014).
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fold included ‘‘extracellular region’’ (17 genes, FDR: P 5 3.0 3
1023) and ‘‘lipid particle’’ (4 genes, FDR: P 5 3.0 3 1023).
Significantly downregulated transcripts (fold change <0.5) were
classified with the GO terms ‘‘cellular lipid metabolic process’’
(13 genes, FDR: P5 1.63 1023) and ‘‘lipid metabolic process’’
(13 genes, FDR: P 5 2.7 3 1022; the full list can be found in
Table E2). In silico protein network analysis of the differentially
expressed lipid metabolism genes shows a predicted network
involving both upregulated and downregulated transcripts (Fig 3).Case-control analysis stratified by FLG genotype
shows upregulated defense response cytokines and
downregulated ‘‘steroid metabolic process’’
Analysis stratified according to FLG genotype was
performed to investigate the mechanisms by which filaggrin
haploinsufficiency might predispose to the development of AD.
The 8 FLG wild-type control subjects were compared with the
7 compound heterozygous cases, revealing 816 differentially
expressed transcripts (FDR <0.05). These included 137 with a
fold change of greater than 2.0 and 266 with a fold change of
less than 0.5 (the full list can be found in Table E4 in this article’s
Online Repository at www.jacionline.org). Significant GO terms
in the upregulated transcripts included ‘‘defense response’’
(17 genes, FDR: P 5 2.3 3 1024) and ‘‘response to biotic
stimulus’’ (14 genes, FDR: P 5 2.3 3 1024), ‘‘chemokineactivity’’ (5 genes, FDR: P 5 1.3 3 1023), and ‘‘chemokine
receptor binding’’ (5 genes, FDR: P5 1.33 1023; full list shown
Table E2). In silico protein network analysis of the upregulated
transcripts demonstrated a functional network of chemokines
and cytokines in the defense response, including both TH1- and
TH2-associated transcripts: CXCL9, CXCL10, CCL13, CCL18,
SELE, IFI27, and IRF1 (see Fig E5, A, in this article’s Online
Repository at www.jacionline.org). The most significant GO
term in the transcripts downregulated less than 0.5-fold was
‘‘steroid metabolic process’’ (14 genes, FDR: P 5 3.6 3 1023,
see Table E2).
Analysis of the 8 FLG wild-type control subjects compared
with 12 FLG heterozygous cases revealed 1139 differentially
expressed transcripts (FDR, <0.05) in which 104 are
significantly upregulated (fold change, >2.0) and 313 are
significantly downregulated (fold change, <0.5; the full list can
be found in Table E5 in this article’s Online Repository at
www.jacionline.org). The upregulated transcripts showed
enrichment for GO terms in the ‘‘defense response’’ (16 genes,
FDR: P 5 7.6 3 1023) forming a predicted protein network
analogous to that seen in the wild-type control subject
versus compound heterozygous case comparison, with the
addition of GRIN2B, GRIK2, and MNDA (see Fig E5, B).
Genes classified for the ontology terms ‘‘receptor binding’’
(15 genes, FDR: P5 2.93 10212), ‘‘cytokine activity’’ (7 genes,
FDR: P 5 2.9 3 10212), and ‘‘extracellular region’’ (19 genes,
FDR: P 5 3.2 3 1026) were also significantly upregulated. The
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less than 0.5-fold were ‘‘small molecule metabolic process’’
(60 genes, FDR: P 5 3.1 3 10210), ‘‘carboxylic acid metabolic
process,’’ and ‘‘oxoacid metabolic process’’ (each 35 genes and
FDR: P 5 3.1 3 10210; the full list can be found in Table E2).FIG 4. Box plot showing FLGmRNA read counts in different AD phenotypesFLG mRNA shows a stepwise reduction in patients
with AD, and there might be upregulation of
expression in FLG wild-type atopic skin
FLG mRNA–normalized read counts show a stepwise
reduction from FLG wild-type to FLG heterozygous and
compound heterozygous patients with AD (Fig 4). This indicates
that a form of nonsense-mediated decay occurs in the context of
an FLG null mutation, although mature mRNA transcripts are
still detectable even in those subjects with 2 FLG null mutations
(Fig 4). Comparison of all cases with all control subjects showed
no significant difference in FLGmRNA levels (P >.05), but there
is significantly greater mRNA expression in wild-type AD cases
than wild-type control subjects (P 5 3.0 3 1023), suggesting
that there might be a compensatory upregulation of FLG
mRNA in atopic skin of FLG wild-type subjects.and FLG genotypes. Gene expression was normalized across all
samples with EdgeR: 8 wild-type control subjects, 7 wild-type AD cases,
12 heterozygous cases, and 7 compound heterozygous cases.
Differentially expressed transcripts at loci near to
regions identified by genome-wide association
studies indicate expression quantitative trait loci
Significantly differentially expressed transcripts in the
case-control analysis were compared with AD-associated single
nucleotide polymorphisms from published genome-wide
association studies (see the Methods section in this article’s
Online Repository). Seventeen putative expression quantitative
trait loci (cis-eQTLs) were identified on the basis of a transcript
proximity of less than 250 kb between the single nucleotide
polymorphism site and the 59 end of the transcript (see Table
E6 in this article’s Online Repository at www.jacionline.org).39
Four of the proposed cis-eQTLs correspond to previously
reported AD candidate genes (FLG, TNXB, C11ORF30, and
ZNF652), whereas 13 represent novel candidates (see Table E6).Analysis of cases stratified by FLG genotype shows
differential expression of cartilage intermediate
layer protein (CILP)
A comparison of the 26 cases stratified by FLG genotype was
performed to investigate filaggrin-associated mechanisms in
AD pathogenesis; this comparison also represents the most
closely matched samples to control for age-specific differences.
A total of 201 genes were differentially expressed (unadjusted
P < .01): 87 genes were differentially expressed in the FLG
wild-type cases versus compound heterozygous cases, and 127
were differentially expressed in thewild-type versus heterozygote
comparison (see Table E7 in this article’s Online Repository at
www.jacionline.org). Forty-one genes showed a fold change of
greater than 2.0 or less than 0.5. After controlling for multiple
testing, 2 genes showed a statistically significant difference in
expression: FLG (FDR: P 5 6.1 3 10212; fold change, 0.3) and
cartilage intermediate layer protein (CILP; FDR: P 5 .03; fold
change, 0.2). The differential expression of FLG, CILP, and
selected other transcripts was validated by using quantitative
PCR with aliquots of the previously extracted RNA samples(see Table E8 in this article’s Online Repository at www.
jacionline.org).
GO analysis of the 127 transcripts showing differential
expression between FLG wild-type and compound heterozygous
cases showed the highest number of genes to be associated
with ‘‘extracellular region’’ (28 genes, including FLG
and CILP; FDR: P 5 8.7 3 1023), ‘‘carbohydrate binding’’
(12 genes, FDR: P 5 5.6 3 1023), and ‘‘calcium ion binding’’
(14 genes, including FLG; FDR: P 5 .02; the full list can be
found in Table E9 in this article’s Online Repository at www.
jacionline.org).FLG expression correlates with gene expression in
the extracellular space and is anticorrelated with a
network of defense response genes
Correlation of gene expression with FLG expression was used
to investigate filaggrin-related mechanisms and pathways in
atopic skin. Twenty genes show strong correlation with FLG
expression (each r > 0.98 and P < .05), including 7 classified
within the extracellular region: CA2 (carbonic anhydrase 2),
COL12A1 (collagen, type XII, alpha 1), MUCL1 (mucin-like 1),
PIP (prolactin-induced protein), PRELP (proline/arginine-rich
and leucine-rich repeat protein), SCGB1D2 (secretoglobin,
family 1D, member 2), and ZG16B (zymogen granule protein
16 homolog B; the full list can be found in Table E10 in this
article’s Online Repository at www.jacionline.org).
The expression levels of 6 genes were strongly anticorrelated
withFLG expression (each r <20.98, see Table E10); 5 of these 6
genes formed a predicted network (Fig 5). Significant GO terms
associated with this network include ‘‘response to virus’’ (4 genes,
FDR: P 5 5.1 3 1023), ‘‘cellular response to type I interferon,’’
‘‘response to type I interferon,’’ and ‘‘type I interferon–mediated
signaling pathway’’ (each 3 genes, FDR: P 5 6.3 3 1023).
Combining these 6 anticorrelated and upregulated genes with
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genotype–stratified case-control analyses (see Table E2) shows
a common predicted functional network of ‘‘defense response’’
(20 genes, FDR: 5.6 3 10218; Fig 6).FIG 5. Network analysis of 6 genes with expression strongly anticorrelated
with FLG expression: TRIM22 (tripartite motif containing 22), KCNK1
(potassium channel, subfamily K, member 1), PARP9 (poly (ADP-ribose)
polymerase family, member 9), IFITM2 (interferon induced transmembrane
protein 2), IFITM1 (interferon induced transmembrane protein 1), and
STAT1 (STRING9.05; accessed October 27, 2013).DISCUSSION
The identification of genes involved in the pathogenesis of AD
represents a significant challenge because of the clinical
heterogeneity and complexity of multiple interrelated genetic
and environmental mechanisms in patients with this disease. The
identification of null mutations within the gene encoding filaggrin
(FLG) as a strong and significant risk factor for AD22 represented
a fundamental breakthrough in understanding pathogenesis.33
The strong effect of filaggrin haploinsufficiency can be used to
define AD subphenotypes clinically,40 and we have applied this
insight for stratification of the large and complex data set
generated by using transcriptomic analysis.
This study used DRS to quantify the whole transcriptome of
atopic skin in a unique collection of pediatric AD skin biopsy
specimens; it represents the largest collection of AD skin tran-
scriptomes reported to date. Skin offers the advantage of sampling
the tissue of interest, maximizing power to detect expression traits
correlating with clinical phenotype.41 Importantly, the histopathol-
ogy of clinically uninvolved atopic skin demonstrates an absence
of inflammatory cell infiltrate, and gene expression changes are
therefore likely to represent keratinocyte-related mechanisms
rather than those from any other cell type. The skin of patients
with AD shows epidermal barrier dysfunction, which can be
demonstrated in nonlesional (clinically uninvolved) skin, as well
as areas of active eczema.42,43 Nonlesional skin was sampled to
focus on the intrinsic biological abnormality in atopic skin and
to exclude, as far as possible, the secondary effects of inflammation
in patients with active dermatitis and secondary infection, which
would confound themRNAprofile.6,10 The cutaneous gene expres-
sion profile is known to vary by age, sex, and, most significantly,
body site.44 This study included case-case comparison for optimal
matching in age and skin site, and our case-control samples were
carefully matched for body site and sex. Age matching in the
case-control analysis was limited by the availability of skin biopsy
samples fromhealthy children; however, the data obtained frombi-
opsy specimens of teenage volunteers showed no clustering by age
(see Fig E2). Furthermore, the differentially expressed defense
response genes formed an overlapping network with the
age-matched case-case analyses. DRS allows accurate
quantification of mRNA species. The confirmation of findings
from previous microarray studies and consistency with our own
quantitative PCR studies provide support for the validity of DRS
as a novel technique for the investigation of AD pathogenesis.
We have shown that genes encoding proteins in the extracellular
space are differentially expressed in atopic skin, with upregulation
in patients with AD compared with that seen in control subjects
(see Table E2). Conversely, 7 genes encoding proteins in the extra-
cellular region are downregulated in strong correlation with FLG
expression (see Table E10). These genes are likely to contribute
to mechanisms by which a quantitative reduction in intracellular
filaggrin levels results in the paracellular barrier defect that is
observed in vitro.45,46 Expression of CILP shows the most signifi-
cantly reduced expression in FLG null cases compared with FLG
wild-type cases and might represent a novel AD candidate gene.
The protein encoded by CILP is expressed in many tissues,including skin and blood, as well as articular cartilage. It is
secreted into the extracellular space and sequesters growth factors,
cytokines, and matrix metalloproteases in the extracellular matrix.
Also, it has been shown to antagonize the actions of TGF-b1 and
insulin-like growth factor 1.47,48We hypothesize that a reduction in
expression of the cartilage intermediate layer protein permits
increased activity of insulin-like growth factor 1 and TGF-b1,
leading to cellular proliferation, whereas a reduction in the seques-
tration of proinflammatory cytokines and metalloproteases in the
extracellular space might simultaneously contribute to skin
barrier dysfunction in cases of AD associated with filaggrin
deficiency.
The second major finding of this global transcriptomic analysis
is the dysregulation of lipid metabolic pathways both in the
unstratified case-control comparison (see Fig E4, A) and in the
FLG wild-type case-control comparison (Fig 3). The demonstra-
tion of lipid dysregulation predominantly in the cases without
FLGmutations is in keeping with in vivo49 and in vitro50 findings
that filaggrin deficiency does not affect lipid composition in the
stratum corneum. Previous microarray analyses have shown a
reduction in expression of lipid homeostatic genes12 and reduced
intercellular lipid levels.15 Organotypic culture of primary
keratinocytes has shown increased expression of a cluster of
genes associated with lipidmetabolism throughout differentiation
in parallel with increasing barrier properties.51 Lipid raft
disruption produces transcriptomic changes in cultured
keratinocytes, including disruption of cholesterol biosynthesis,
that mimic changes seen in patients with AD.16 The predicted
functional network in Fig 3 comprises upregulated and
downregulated lipid metabolism genes and might offer insight
into the complex interplay of metabolic dysfunction with
systemic inflammation.52 Genes encoding proteins involved
with very long-chain fatty acid CoA ligase activity are
downregulated, which is in keeping with the observation that
ceramides and long-chain fatty acids play an important role in
skin barrier formation.49,53,54 Our stratified analysis indicates
that therapies aimed to restore skin lipid composition might be
most beneficial to FLG wild-type patients.
The FLG-stratified case-control and case-case comparisons
have identified an overlapping functional network of proteins
forming a type 1 interferon–mediated defense response (Fig 6).
The upregulation of this networkmight relate to the dysfunctional
cutaneous response to viral infection in patients with AD, which
FIG 6. Genes anticorrelated with FLG and upregulated in FLG mutant cases show a common network of
stress response. Six genes are anticorrelated (upregulated) with FLG expression, and 17 genes are
upregulated in the FLG genotype–stratified case-control analyses. Proteins encoded by genes classified
with the GO term ‘‘response to stress’’ are colored red (STRING9.05; accessed November 16, 2013).
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might represent a suboptimal, partially functional mechanism to
compensate for the increased frequency of viral infections,
including eczema herpeticum,55 seen in filaggrin-deficient
subjects. The signal transducer and activator of transcription
(STAT) encoded by STAT1 contributes to the transcriptional
control of several interferon-stimulated genes, including IFITM1,
IFITM2, IFI27, and GBP1. The Janus kinase/STAT signaling
pathway plays a key role in transmembrane signaling from
the TH2 cytokines IL-4 and IL-13, which predominate
in acute AD.56 IFITM1 and IFITM2 encode interferon-induced
transmembrane proteins, which contribute to the control of cell
growth through a multimeric complex involved in the transduc-
tion of antiproliferative and homotypic adhesion signals; they
are induced by IFN-g in primary keratinocytes in vitro and have
been proposed to play a role in keratinocyte apoptosis in patients
with AD.57 The chemokine network encoded by genes including
CCL13, CCL18, CXCL9, and CXCL10 has been implicated in the
pathogenesis of AD in some of the previous microarray
studies.9,11,13,58 Filaggrin haploinsufficiency increases the risk
of eczema herpeticum,59 and the functional network predicted
by transcriptomic analysis indicates a pathway that might be tar-
geted for therapeutic intervention in susceptible patients.
The quantitative reduction in filaggrin mRNA with FLG
null mutations (Fig 4) is consistent with previous studies
showing a stepwise reduction in filaggrin breakdown productsin FLG heterozygotes and FLG homozygotes or compound
heterozygotes.27,60 One previous microarray study has used
FLG genotype–stratified analysis8 and reported no significant
difference in FLG mRNA levels between FLG wild-type cases
and control subjects. In our analysis comparison of all cases
with all control subjects also showed no difference in FLG
mRNA counts (P > .05), but we have shown a significant
difference between FLG expression in wild-type control subjects
compared with wild-type cases (Fig 4). This is compatible with
the confidence range of data published previously8 but suggests
that theremight be compensatory upregulation ofFLG expression
in our pediatric AD cases. An alternative explanation is that
there might be lower filaggrin expression in our control
subjects, possibly reflecting the slightly older age, but detailed
studies of filaggrin expression changes with aging are not
currently available.
Intercellular edema (spongiosis) is a characteristic feature in
patients with AD, but the underlyingmechanisms are unclear. The
differential expression of genes encoding proapoptotic and
antiapoptotic proteins (including IGFBP6, CLU, IFITM1,
IFITM2, SELE, CXCL10, PRF1, and IRF1) might contribute to
the propensity to keratinocyte apoptosis that some authors
consider to be a key pathomechanism in atopic spongiosis.57,61,62
Alternatively, the dysregulation of proteins in cell death pathways
might reflect the specialized process of keratinocyte cell death,
cornification.63,64
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association studies are located within intergenic regions of
unknown function. Our analysis has offered insight into
possible genetic mechanisms associated with 14 of the previously
reported AD risk loci. We propose cis-eQTLs indicating a
range of pathomechanisms, including structural (FLG, LCE3E,
and TNXB), immune response (CST6, HLA-DRA, IRF1,
and PRRT1), transcriptional regulation (ATF6B, C11orf30,
RP11-21L23.4, RPL3P2, RPSAP47, SIPA1, and ZNF652),
mitochondrial (TST), and lipid biosynthetic (AGPAT1).
The use of DRS has allowed detailed study of tissue-specific
gene expression data from small amounts of tissue. This
transcriptomic analysis has provided new insight into the
mechanistic pathways in atopic skin, which are both
dependent and independent of FLG genotype. The strength of
using a functional genotype for phenotype stratification is
apparent, and this approach might prove useful for other
tissue-specific inflammatory disorders and personalized medicine
in the future.
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Key messages
d Atopic skin shows differential gene expression in
pathways classified in the extracellular space, lipid
metabolism, and stress response.
d Substratification of the whole transcriptome data set
according to FLG genotype reveals a type 1 interferon–
mediated stress response in filaggrin-deficient skin.
d These findings offer insight into the underlying
abnormalities in uninflamed atopic skin and might guide
future therapy development.REFERENCES
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TABLE I. Demographic data and FLG genotype results for 71
volunteers with clinically normal skin
Sex 43 male/28 female
Age (y), range (median) 22-70 (41)
FLG wild-type subjects (no.) 61
FLG heterozygotes (no.) 10
Total (no.) 71
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http://dx.doi.org/10.1016/j.jaci.2015.09.035Filaggrin genotype does not
determine the skin’s threshold to
UV-induced erythemaTo the Editor:
Profilaggrin and filaggrin play multiple roles in the formation
and function of the epidermal barrier, contributing to protection
against dehydration, mechanical stress, infection, and, it has been
proposed, photodamage.1 Loss-of-function mutations in the gene
encoding filaggrin (FLG) represent the strongest and most
significant genetic risk factor for atopic dermatitis (AD)
identified to date.1 Proteolysis of filaggrin releases histidine
and other amino acids into the stratum corneum. Histidine is
converted by the enzyme histidase (histidine ammonia-lyase)
to trans-urocanic acid (trans-UCA), which can then undergo
photoisomerization on absorption of UVB to produce cis-UCA
(see Fig E1 in this article’s Online Repository at www.
jacionline.org). There is experimental evidence to suggest that
cis-UCA has immunomodulatory and photoprotective effects. 2016 The Authors. Published by Elsevier, Inc. on behalf of the American Academy of
Allergy,Asthma& Immunology. This is an open access article under theCCBY license
(http://creativecommons.org/licenses/by/4.0/).The local and systemic immunosuppressive effects of cis-UCA
were initially demonstrated in murine models, and more recently,
histidinemic mice deficient in cutaneous UCA because of a
mutation in Hal, the gene encoding histidase, have been reported
to show increased propensity to UVB-induced DNA damage.2
Mice deficient in caspase-14 (an enzyme in the profilaggrin-
filaggrin proteolytic pathway) show accumulation of cyclobutane
pyrimidine dimers in response to UVB radiation and increased
apoptosis in the epidermis, indicating a role for caspase-14 in
UVB scavenging within the stratum corneum.3 The immunosup-
pressive effects of cis-UCA have been demonstrated in human
keratinocytes and leukocytes in vitro; knockdown of FLG in
organotypic culture results in increased susceptibility of kerati-
nocytes to UV-induced apoptosis.4 Loss-of-function mutations
and copy number variation in FLG are known to result in lower
levels of filaggrin breakdown products, including UCA, in human
stratum corneum. Therefore it has been postulated that FLG
genotype might in part determine the photoprotective capacity
of human skin (see Fig E1),1 but experimental evidence in vivo
is lacking.
We aimed to test the hypothesis that filaggrin deficiency
resulting from loss-of-function mutations in FLG is associated
with increased erythemal sensitivity to UV radiation. Cutaneous
response to UV radiation was assessed by using the minimal
erythema dose (MED; the lowest dose of UV causing just
perceptible skin redness) as a quantifiable surrogate end point
for cutaneous damage. We used detailed monochromator
phototesting of 71 adult volunteers of white European ethnicity
with clinically normal skin; the demographic characteristics are
summarized in Table I. A calculation performed before this study
commenced indicated that 7 or 8 FLG mutation carriers within a
total study size of 70 to 80 subjects would provide sufficient
statistical power to detect a 1.8-fold difference in MED. This
sample size estimation was based on known variability in
MEDs from previous studies and assuming comparisons of arith-
metic means of log-transformed data (therefore able to back–
transform differences into fold differences). Details of the power
calculation are shown in the Methods section in this article’s On-
line Repository at www.jacionline.org.
This work was approved by the East of Scotland Research
Ethics Committee (reference 14/ES/0030), and the study was
conducted in accordance with the Declaration of Helsinki.
Participants were screened for the 6 most prevalent loss-of-
function mutations in FLG in the white European population
(R501X, 2282del4, R2447X, S3247X, 3673delC, and
3702delG) by using published methodology.5 Ten (14%) of 71
FIG 1. Box plots showing monochromator phototesting MED results in healthy volunteers of different FLG
genotypes. The findings for 5 distinct wavebands are shown. Results for the 400 6 30 and 430 6 30 nm
wavebands showed no difference between FLG wild-type and heterozygotes (see Table E1); these data
are not displayed because the median MEDs and ranges are not quantifiable. Boxes indicate interquartile
ranges, and the bar within each box marks the median result. The difference in median MEDs (and 95%
CIs) are shown above each plot. All values are in millijoules per square centimeter. Median MEDs were
compared by using the Mann-Whitney U test. There were 61 FLG wild-type subjects and 10 FLG heterozy-
gous subjects tested in each group, with the exception of the 295 nm and 300 nmwavebands, in which data
were obtained on 53 FLG wild-type subjects and 8 FLG heterozygous subjects.
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FLG (Table I). Fitzpatrick sun-reactive skin phototype was
recorded for 45 of 71 subjects, and no difference was detected
(P 5 .14, x2 test) in skin phototypes between the genotype
subgroups.
Up to 7 separate wavebands from 295 to 430 nm, representing a
spectrum from UVB to UVA and visible light, were tested on the
71 subjects. A detailed description of phototesting methods is
given in the Methods section in this article’s Online Repository.
Subjects were grouped according to FLG genotype, and MEDs
were compared by using nonparametric rank-based methods
(because some MED values were greater than or less than test
dose ranges) with the Mann-Whitney U test (see the Methods
section in this article’s Online Repository) to derive CIs for
differences in medianMEDs (see Table E1 in this article’s Online
Repository at www.jacionline.org). We detected no significant
differences in MEDs (defined as P <_ .05) between the FLGwild-type and FLG heterozygous groups at any of the wavebands
tested (Fig 1 and see Table E1). The CIs for differences were suf-
ficiently narrow to make any large differences in MEDs between
the genotype groups unlikely.
It has previously been reported that AD might be associated
with photosensitivity,6 a lower threshold to UVB-induced ery-
thema,7 or both. Some epidemiologic data also suggest a higher
incidence of multiple nonmelanoma skin cancers in subjects
with a history of AD.8 Loss-of-function mutations in FLG are
strongly associated with AD, and there is widespread downregu-
lation of filaggrin expression in the skin of patients with atopic
eczema, which has been demonstrated at the transcriptome level
by means of direct RNA sequencing,9 and in the breakdown prod-
ucts of filaggrin in the stratum corneum, which was quantified by
means of HPLC.10 A partial reduction in expression of filaggrin
might result from the effect of circulating inflammatory
cytokines, whereas a more profound deficiency results from
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absence of profilaggrin in the homozygous or compound hetero-
zygous state. Therefore it can be hypothesized that filaggrin
deficiency contributes to the observed photosensitivity and/or
reduced threshold to UVB-induced erythema in patients with
AD. We have performed a detailed analysis of cutaneous
photoresponse in clinically normal skin to avoid the confounding
effects of atopic inflammation. Our findings have excluded a large
effect of FLG genotype on photosensitivity (>_1.8-fold difference
inMED) at any of thewavebands tested. In addition, the results of
our monochromator phototesting did not indicate a differential
erythemal sensitivity within the wavelengths representing UVB,
as would be predicted from the known absorption spectrum
of UCA.
One limitation of our study is that the healthy volunteers did not
include any subjects with ichthyosis vulgaris, and therefore we
have not excluded the possibility that FLG homozygous (or
compound heterozygous) subjects might show greater erythemal
sensitivity than wild-type subjects. However, FLG-null heterozy-
gosity has a significant effect on filaggrin expression in vivo,9,10
and therefore we would expect an effect to be observed in FLG
heterozygotes if this was substantial.
The fact that observations of UVB-induced damage in murine
and invitromodels have not been supported by clinical data suggest
that different mechanisms lead to cutaneous erythema in vivo than
the markers of UV damage studied in vitro and in mice. For
example, apoptosis is known to occur within areas of skin damaged
byUVexposure, and this is associatedwithcutaneous erythema, but
the relationship is nonlinear. Furthermore, the photoprotective
effect of the FLG wild-type genotype might be attributable to a
mechanical filtering of UV radiation by the stratum corneum rather
than by chemical photoimmunosuppression.
In conclusion, our FLG genotype–stratified analysis of
responses to UV and visible radiation in clinically normal skin
does not support the hypothesis that the breakdown products of
filaggrin play a major role in the sensitivity of human skin to
UV-induced erythema. This has relevance to the ongoing search
for predictors of patient response in phototherapy for AD and
for the development of personalized medicine.
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http://dx.doi.org/10.1016/j.jaci.2015.11.022Epidermal thymic stromal lympho-
poietin predicts the development
of atopic dermatitis during infancyTo the Editor:
To establish a primary prevention strategy for atopic dermatitis
(AD), it is important to identify biomarkers that can predict the
occurrence of AD. This study aimed to evaluate the expression
level of epidermal proteins by using a tape stripping method to
determine whether these proteins can be used as biomarkers
predictive of AD development in infants.
In this prospective birth cohort study, we followed 75 infants in
a risk group and 12 in a control group for 2 years (Fig 1). The con-
trol group consisted of infants with both parents who had neither
allergy nor immediate skin test reactivity to 8 common inhalant
allergens (Dermatophagoides pteronyssinus, Dermatophagoides
farinae, tree pollen mixture _ & II, weed pollen mixture, grass
pollen mixture, cat, and cockroach). The risk group was defined
METHODS
Assessment of MEDs of different wavebands in
healthy volunteers
Healthy adults with clinically normal skin of phototypes I to IIIE1 who had
previously participated in research studies within the National Photobiology
Unit (Dundee, Scotland, United Kingdom) were invited to participate in this
study. Exclusion criteria were history of skin allergy, eczema/AD, psoriasis
or polymorphic light eruption, immunosuppression caused by medications
or disease, photosensitizing medication, and a holiday abroad or sunbed use
within the preceding 4 weeks. A total of 71 subjects providedwritten informed
consent and a saliva sample for DNA extraction. Emollient application to skin
test sites was not allowed within the 48 hours before phototesting.
Detailed phototesting was undertaken by using an irradiation mono-
chromator, which is a diffraction grating device with a 1.6-kW or 450-W
xenon arc lamp.E2,E3 This instrument allows irradiation of small areas of the
skin over a range of wavebands, which are included in the solar spectrum
(UVB to UVA/visible). Monochromator phototesting was performed as fol-
lows. On day 1, approximately 1-cm2 areas of the skin on the volunteer’s
back were exposed to UVand visible light according to a standardized proce-
dure established in the National Photobiology Unit. A range of doses of UV
and visible light at specific narrow wavebands was used for all subjects
centered on (with half-maximum bandwidth) 295 6 5, 300 6 5, 305 6 5,
335 6 30, 365 6 30, 400 6 30, and 430 6 30 nm.
The MED, which was defined as the minimum dose producing just
perceptible erythema for each waveband tested, was determined 24 hours after
irradiation. The irradiation procedurewas repeated on day 2 on a separate area
of back skin using smaller dose increments (10% to 20%) across a narrower
range of doses at each waveband selected on the basis of the MEDs seen
24 hours after first irradiation to establish the MED precisely. Final MEDs
were assessed 24 hours later (day 3).
Power calculation
Our prestudy sample size calculation was performed to determine
how many subjects were likely to be needed to detect a clinically
important difference in MEDs between the FLG genotype groups within the
305 6 30 nm waveband. MED data derived from testing with a geometric
dose series do not follow a normal distribution, and therefore we based our
sample size on the minimum difference in arithmetic means of natural log-
transformed MEDs. This method was used because differences in arithmetic
means of log-transformed data can be ‘‘back-transformed’’ to fold
differences (eg, 1.8-fold), which is more understandable than the difference
in log-transformed MEDs that equates to this.
MEDs for the 305 6 5 nm waveband (representing a narrow waveband in
the UVB region, the waveband of interest) from 120 healthy volunteers tested
at the National Photobiology Unit were used to derive variance. These
nonnormal datawere log-transformed, and the numbers needed to detect a 1.5-,
1.8-, and 2-fold difference in geometric means were estimated by using Stata
12.1 software (StataCorp, College Station, Tex). Assuming that approximately
10% of the study participants would have 1 or more FLG loss-of-function mu-
tations,E4 to obtain an 80%powerwith aP value of .05,we required at least 7 or
8 subjects with FLG mutations (expected within a total sample size of 70-80
subjects) to detect a difference of 1.8-fold in mean natural log-transformed
MEDs at this waveband between the wild-type and FLG-null groups. Simi-
larly, 55 volunteers, including 5 or 6 FLG mutation carriers, were needed to
detect a 2-fold difference in mean natural log-transformed UVB MEDs.
Therefore the results arising from our sample size, including 71 volunteers
and 10 FLG mutation carriers, have sufficient statistical power to effectively
exclude an association with FLG genotype and erythemal response of a
1.8-fold or greater difference at the wavebands tested.
Statistical analysis of monochromator phototesting
data
When analyzing our data, we used nonparametric methods reliant on ranks,
rather than absolute values, instead of parametric methods based on trans-
formed data. This was for the practical reason that although we obtained ranks
for all MEDs, the precise values for some were unknown (greater than or less
than our test dose range). Some MEDs were determined to be greater than or
less than the test irradiation ranges. A small number was added to all MEDs at
greater than the top dose tested for wavebands of 305 nm and longer and a
small number was subtracted fromMEDs of less than the lowest dose tested to
allow appropriate rank-based analyses. The phototesting results were
compared with FLG genotype status (FLGwild-type or FLGmutant) by using
the Mann-Whitney U test to analyze these nonparametric data to test the null
hypothesis that therewas no association ofMEDswith genotype. Correspond-
ing CIs around medians were derived by using the methods of Altman and
Gardner.E5 We took a P value of .05 or less to be significant.
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FIG E1. Diagrammatic summary of factors affecting the profilaggrin–cis-UCA pathwayPrevious studies
have demonstrated the effects of variation within FLGE6-E8 and levels of TH2 cytokines
E9,E10 on filaggrin
expression. The role of caspase-14 in profilaggrin processing has been illustrated in mice.E11 Filaggrin is
degraded to release a pool of amino acids rich in histidineE12 in the stratum corneum, contributing to barrier
function through hydration and acidification.E13 The conversion of histidine to trans-UCA is catalyzed by
histidase,E14 and the trans-isomer is converted to cis-UCA by UVB.E15 UVB absorption might contribute
to cutaneous photoprotection, and cis-UCA might have additional immunomodulatory effects.E16-E20
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TABLE E1. Results of monochromator phototesting of 71 healthy volunteers stratified according to FLG genotype
Waveband
295 6 5 nm 300 6 5 nm 305 6 5 nm 335 6 30 nm 365 6 30 nm 400 6 30 nm 430 6 30 nm
Median MED (mJ/cm2)
FLG wild-type
subjects
10.0 (n 5 53) 18.0 (n 5 53) 47.0 (n 5 61) 5,600 (n 5 61) 24,000 (n 5 61) >82,000 (n 5 61) >82,000 (n 5 61)
FLG heterozygous
subjects
8.2 (n 5 8) 15.0 (n 5 8) 47.0 (n 5 10) 4,950 (n 5 10) 20,000 (n 5 10) 82,000 (n 5 10) >82,000 (n 5 10)
Difference 1.8 mJ/cm2
higher in
FLG wild-type
3.0 mJ/cm2
higher in
FLG wild-type
No difference 650 mJ/cm2
higher in FLG
wild-type
4,000 mJ/cm2
higher in FLG
wild-type
Not quantifiable Not quantifiable
95% CI for
difference
22.6 to 5.0 23.0 to 7.0 29.0 to 14.0 21,200 to 2,300 27,000 to 9,000 Not quantifiable Not quantifiable
P value (Mann-
Whitney U test)
.41 .35 .79 .62 .74 .58 .70
Some cells are ‘‘not quantifiable’’ because results of greater than the highest test dose were recorded.
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Abstract
 Atopic eczema is an itchy inflammatory disorderBackground:
characterised by skin barrier dysfunction. Loss-of-function mutations in the
gene encoding filaggrin ( ) are a major risk factor, but the mechanismsFLG
by which filaggrin haploinsufficiency leads to atopic inflammation remain
incompletely understood. Skin as an organ that can be modelled using
primary cells  provides the opportunity for selected genetic effects toin vitro 
be investigated in detail.
 Primary human keratinocytes and donor-matched primaryMethods:
fibroblasts from healthy individuals were used to create skin organoid
models with and without siRNA-mediated knockdown of  . BiologicalFLG
replicate sets of organoids were assessed using histological, functional and
biochemical measurements.
  knockdown leads to subtle changes in histology andResults: FLG 
ultrastructure including a reduction in thickness of the stratum corneum and
smaller, less numerous keratohyalin granules. Immature organoids showed
some limited evidence of barrier impairment with  knockdown, but theFLG 
mature organoids showed no difference in transepidermal water loss, water
content or dye penetration. There was no difference in epidermal ceramide
content. Mass spectrometry proteomic analysis detected >8000 proteins
per sample. Gene ontology and pathway analyses identified an increase in
transcriptional and translational activity but a reduction in proteins
contributing to terminal differentiation, including caspase 14, dermokine,
AKT1 and TGF-beta-1. Aspects of innate and adaptive immunity were
represented in both the up-regulated and down-regulated protein groups,
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represented in both the up-regulated and down-regulated protein groups,
as was the term ‘axon guidance’.     
This work provides further evidence for keratinocyte-specificConclusions: 
mechanisms contributing to immune and neurological, as well as structural,
aspects of skin barrier dysfunction. Individuals with filaggrin deficiency may
derive benefit from future therapies targeting keratinocyte-immune crosstalk
and neurogenic pruritus.
Keywords
Axon guidance, atopic dermatitis, eczema, filaggrin, gene ontology,
keratinocyte-immune crosstalk, organoid, proteomics
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Introduction
Atopic eczema (also termed atopic dermatitis or eczema1,2) is an 
itchy inflammatory skin disorder with complex and multifactorial 
aetiology3. The phenotype is heterogeneous and pathogenic 
mechanisms vary between affected individuals4. The pathogen-
esis may include differential contributions of: immune activation 
and skin barrier dysfunction; local and systemic effects; multiple 
genetic and environmental factors5. Loss-of-function muta-
tions in FLG, encoding filaggrin, cause the common Mendelian 
disorder of keratinization, ichthyosis vulgaris (OMIM # 146700). 
FLG null mutations are also strongly associated with increased 
risk of atopic eczema6,7 and multiple other atopic traits8–10.
Skin is an organ that can be modelled in vitro to effectively 
recapitulate the multi-layered structure and gene expression 
patterns of human skin in vivo11. This offers the opportu-
nity for selected molecular mechanisms to be investigated 
in relative isolation from a complex disease state, using 
relevant primary cells. Replicate experiments can be performed 
using primary cells with the same genetic background or cells 
from different donors12. Detailed functional and biochemical 
analyses may then be applied to define potential therapeutic 
targets12,13.
Filaggrin is a marker of keratinocyte differentiation; it is 
expressed in the granular layer of the upper epidermis as a 
polymer – profilaggrin – which undergoes post-translational 
modification and stepwise proteolysis to release monomeric 
filaggrin14. Profilaggrin and filaggrin have multiple functions, 
each of which have been described as contributing to the mechani-
cal, biochemical, immunological and microbiological aspects 
of skin barrier function15. Clinical studies have shown that filag-
grin haploinsufficiency is associated with xerosis and ichthyo-
sis (dry and scaly skin), keratosis pilaris (increased keratin 
within skin follicles), palmar hyperlinearity16 and increased 
transepidermal water loss17. Transcriptomic analysis of full thick-
ness skin biopsies have shown evidence of an abnormal defence 
response in FLG haploinsufficient atopic skin18; proteomic 
analysis to assess the effect of FLG knockdown in an epider-
mal organoid has also shown features of inflammation and stress 
protease activity19. However, in vitro studies have not shown 
consistent histological or functional effects of filaggrin defi-
ciency in the various different skin organoid models published 
to date20 and the multiple mechanisms by which filaggrin 
deficiency contributes to atopic disease remain incompletely 
understood5.
We have optimised a skin organoid model, with dermal and 
epidermal compartments cultured using donor-matched primary 
cells, for functional assessments and global mass spectrom-
etry proteomic analysis. The work aims to investigate in more 
detail the effect of FLG siRNA-mediated knockdown on one cell 
type - the keratinocyte - to increase understanding of the filag-
grin-deficient phenotype and to further define molecular 
mechanisms predisposing to atopic skin inflammation.
Methods
Source of primary human cells
Primary keratinocytes and primary fibroblasts were isolated 
from human skin tissue samples obtained, with written informed 
consent and Ethical Committee approval (East of Scotland 
Research Ethics Service reference 17/ES/0130 renewal 12/
ES/0083) under governance of the Tayside Biorepository. Surgical 
surplus samples of clinically normal skin from four adult donors 
(all females aged 29–65 years; one abdominal and three breast skin 
reductions) were used for the organoid cultures. Similar samples 
(n=5) were used for independent biological replicates to test 
for reproducibility of the functional effects of FLG knockdown.
Organoid culture methods
Primary keratinocytes and dermal fibroblasts were isolated 
from human skin by sequential trypsin EDTA and collagenase 
D digestion21. Using our previously reported methods12, the 
keratinocytes were co-cultured with mitomycin C inactivated 
3T3 feeder cells in RM media (3:1 DMEM : Hams F12, 10% 
FCS, 0.4µg/ml hydrocortisone, 5µg/ml insulin, 10ng/ml EGF, 
5µg/ml transferrin, 8.4ng/ml cholera toxin and 13ng/ml liothy-
ronine) (Sigma Aldrich, Gillingham, Dorset, UK)22. Epidermal 
growth factor (EGF) was omitted for the first day of culture. 
The fibroblasts were cultured in DMEM supplemented 
with 10% FCS under standard conditions.
Fibrin gel dermal equivalents12 were prepared using 0.5ml 
fibrinogen (35 mg/ml in NaCl) (Sigma Aldrich, Gillingham, 
            Amendments from Version 1
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level is demonstrated to a lesser degree than the knockdown 
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organoid culture.
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Dorset, UK) and 0.5ml thrombin (3U/ml in 2 mM CaCl
2
 / 1.1% 
NaCl) (Sigma Aldrich, Gillingham, Dorset, UK) combined on 
ice, with 200,000 fibroblasts and aprotinin (0.1 U/ml) (Sigma 
Aldrich, Gillingham, Dorset, UK) then transferred to a 12-
well plate. After 30 minutes incubation at 37°C, the gels were 
covered in medium (DMEM, 10% FCS, 0.1 U/ml Aprotinin) and 
cultured overnight (day 1). On day 2, the medium was replaced 
with RM excluding EGF, 0.1U/ml aprotinin and 2 × 106 
suspended keratinocytes. Culture medium was refreshed daily 
on days 3 and 4 using RM containing 0.1ng/ml EGF and 
0.1U/ml aprotinin. On day 5 the gels were carefully removed 
from wells and lifted onto custom-made steel grids lined with 
nylon gauze (Millipore, Livingston, Scotland, UK). RM medium 
supplemented with 0.1ng/ml EGF and 0.1U/ml aprotinin was 
added up to the base of the dermal equivalent so that the epidermis 
remained at the air-liquid interface. Medium was refreshed 
on alternate days sand the cultures were used for analysis up 
to day 12 (representing three, five and seven days after lifting 
to the air-liquid interface).
A diagrammatic summary of the process of skin organoid culture 
is shown in Figure 1.
Epidermis was separated from the fibrin gel using hyper-
tonic saline-induced split (4 hours, 1M NaCl, 4°C) to obtain a 
keratinocyte-only tissue sample for biochemical analyses.
FLG genotyping
DNA was extracted from donor skin samples using stand-
ard techniques and genotyping was performed for the four 
Figure 1. Diagrammatic summary of skin organoid culture. Dermal and epidermal equivalents produced using our published methodology 
optimised for skin barrier assessment12.
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most prevalent loss-of-function mutations in FLG in this white 
European population (R501X, 2282del4, R2447X and S3247X)23 
using validated KASPTM technology (LGC Genomics, Hod-
desdon, Hertfordshire, UK), as previously reported4,24. Briefly, 
KASPTM SNP genotyping consists of two competitive, allele-
specific forward primers and one common reverse primer. 
Each forward primer incorporates an additional tail sequence 
that corresponds with one of two universal FRET (fluores-
cent resonance energy transfer) cassettes (FAM and HEX). 
ROX™ passive reference dye, Taq polymerase, free nucle-
otides and MgCl2 in an optimised buffer solution make up 
the reaction master mix.
siRNA mediated knockdown
Keratinocytes were reverse transfected immediately prior to 
inclusion in the organoid cultures using RNAiMax transfec-
tion reagent (Life Technologies, Carlsbad, California, USA) 
according to manufacturer’s instructions. Briefly, siRNA com-
plexes were formed in OPTIMEM medium (20uM siRNA, 5µl 
RNAiMAX) and following 20 minutes incubation, combined with 
2 × 106 suspended normal human keratinocytes and trans-
ferred to the pre-prepared dermal substrate. A pool of four 
siRNA duplexes was used [FLG: LQ-021718-00-0002, Control: 
ON-TARGETplus non-targeting siRNA #4 D.001810-04-20] 
(Dharmacon, Lafayette, Colorado, USA).
Quantitative PCR
RNA was extracted from organoid epidermis using the Direct-
zol RNA kit (R2071, Zymo Research, Irvine, California, 
USA) following homogenisation in RNA-Bee (CS-104B, 
Amsbio, Abingdon, Oxfordhire, UK) using the TissueLyser LT 
(Qiagen, Manchester, UK) 5 mins at 50 Hz. cDNA was prepared 
from 1µg total RNA using random priming (2.5µM final) 
(Integrated DNA Technologies, Coralville, Iowa, USA) in com-
bination with Moloney murine leukemia virus (MMLV) enzyme 
(100 units) and buffer systems (28025013, Life Technologies, 
Carlsbad, California, USA). qPCR reactions were performed 
using exon spanning probe-based assays (FLG: 
HS.PT.58.24292320FAM, EF1A: HS.PT.58.24345862FAM) [Inte-
grated DNA Technologies, California, USA]) with TaqMan gene 
expression Mastermix (4369016, Life Technologies, Carlsbad, 
California, USA). Reactions were prepared and run using the 
Qiagility robot in combination with the Rotor-Gene Q 
(Qiagen, Manchester, UK). EF1A was used as a reference gene. 
PCR cycling conditions were: 95°C for 10 mins, [95°C for 
15 seconds, 60°C for 60 seconds] × 40 cycles. Fold changes 
were derived via the 2(-Delta Delta C[T]) method.
Western blotting
Organoid epidermis was homogenized in RIPA buffer (Cell 
Signalling Technologies, London, UK) using the TissueLyser 
LT (Qiagen, Manchester, UK) 5 mins at 50 Hz. Protein lysates 
were normalized by Pierce BCA assay (23225, Thermo Fisher, 
Waltham, Massachussets, USA) and resolved under reducing 
conditions using the NuPage® gel electrophoresis system (Life 
Technologies, Carlsbad, California, USA). Primary antibodies 
(monoclonal mouse filaggrin [RRID: AB_1122916, catalogue # 
sc66192, Santa Cruz Biotechnology, Texas, USA] and monoclonal 
mouse GAPDH [RRID: AB_2756824, catalogue # 97166, 
Cell Signalling Technologies, Boston, USA]) were prepared 
in 5% bovine serum albumin (BSA) and incubated overnight 
at 4°C with agitation. Immunoblots were developed using 
either goat anti rabbit (P0448, RRID: AB_2617138) or goat 
anti mouse (P0447, RRID: AB_2617137) peroxidase con-
jugated secondary antibodies (DAKO, Glostrup, Denmark, 
1:5000) in combination with chemiluminescent HRP substrate 
(Immobilon, Millipore, Billerica, Massachussets, USA) onto 
photographic film. Densitometry was performed using Fuji 
ImageJ (May 2017).
Structural assessments
(i) Histology
Formalin-fixed, paraffin embedded full thickness organoids 
were sectioned and stained using haematoxylin and eosin and 
imaged using Visiscope LT384P (VWR International, Lutterworth, 
UK).
(ii) Transmission electron microscopy (TEM)
Organoid skin samples were fixed in 4% paraformaldehyde, 
2.5% gluteraldehyde in 0.1M sodium cacodylate buffer (pH 
7.2) for one hour then cut into small pieces, washed in buffer 
and post-fixed in 1% osmium tetroxide in cacodylate buffer 
for one hour or 1% ruthenium tetroxide in cacodylate buffer 
for one hour. The pieces were dehydrated through alcohol 
series, into propylene oxide and embedded in Durcupan resin. 
Ultrathin sections were stained with 3% aqueous uranyl acetate 
and Reynold’s lead citrate and examined on a JEOL 1200EX 
electron microscope. TEM images were collected on a SIS 
Megaview III camera.
Functional assessments
(i) Trans-epidermal water loss (TEWL)
Organoid cultures were equilibrated at room temperature and 
atmospheric conditions for 30 minutes before TEWL was 
measured at two locations on the epidermal surface using an 
Aquaflux AF200 instrument (Biox Systems Ltd, London, 
UK) with a closed chamber and a custom (5mm diameter) 
probe head. TEWL measurements were taken every second 
for a minimum of 60 seconds until a stable reading, as 
determined by the software, was obtained. TEWL directly 
measures water evaporation from the skin surface but it may 
be considered as a measurement of ‘inside-outside’ barrier 
function25.
(ii) Capacitance
To inform the interpretation of TEWL, we measured electri-
cal capacitance; this is directly proportional to water content 
of the uppermost 10–20µm of tissue. Organoid cultures were 
equilibrated at room temperature and atmospheric condi-
tions for 30 minutes prior to measurement of epidermal surface 
capacitance, using a CorneometerTM and multiprobe adapter 
(CM825 and MPA2, Courage and Khazaka, Cologne, Germany). 
Three measurements were recorded from each organoid and the 
mean was calculated.
(iii) Fluorescent dye penetration
50µl of 1mM lucifer yellow dye (Sigma Aldrich) was 
added to the epidermal surface of the organoid and incubated at 
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37°C for 4 hours. Metal cloning rings were used to control 
uniform dosing on the epidermal surface. The lucifer 
yellow was removed and the organoids washed in PBS before 
formalin fix-paraffin embedding under standard conditions. 
4µM sections were deparaffinized, counterstained with DAPI 
(1µg/ml for 10 mins) (Life Technologies, Carlsbad, California, 
USA) and imaged by confocal Zeiss LSM710 microscope. 
Quantification of dye penetration in the upper dermis (average 
intensity in upper 40µm) was performed using Zeiss Zen Blue 
lite version 2.3 software and compared using paired t-tests. Dye 
penetration represents a measurement of the ‘outside-inside’ 
barrier function.
Mass spectrometry proteomic analysis
Frozen organoid epidermal samples were ground on dry ice, 
solubilized in 200µl of Cellular and Organelle Membrane 
Solubilizing Reagent (C0356-4BTL, also called Protein Extrac-
tion Reagent Type 4, Sigma-Aldrich, Gillingham, Dorset, UK), 
7.0 M urea, 2.0 M thiourea, 40 mM Trizma® base (Sigma Aldrich, 
Gillingham, Dorset, UK) and 1.0% C7BzO, pH 10.4 buffer 
with protease inhibitors. The lysate was acetone precipitated 
for 1 hour at -20°C and spun for 20 mins at 2°C at 15,000 rpm. 
The pellet was re-suspended in 200µl of 50mM ammonium 
bicarbonate. 100µl was taken for in-solution digest. 22µl of 
dithiothreitol was added and samples heated to 50°C for 15mins. 
24µl of iodoacetamide was added and the samples incubated 
at 22°C for 30 mins. 1µl of RapiGestTM (186001860, Waters, 
Herts, UK) was added, followed by 2.5µl of trypsin, for a 
12-hour digest. A further 1µl trypsin was added for an 
additional 4-hour digest. The peptide samples were fractionated 
into 24 fractions with high pH Reversed Phase C18 chromatog-
raphy, run on a Q Exactive Classic or Plus for 160 mins and the 
top 15 ions selected for sequencing. Mass spectrometry 
resolution was 70,000 and tandem mass spectrometry (MS/MS) 
resolution 17,500. Data were processed using MaxQuant 
(v1.6.0.13) and Human UniProt Database (Dec 2017) with a 
protein and peptide false discovery rate of 0.01.
Proteins identified as contaminants (trypsin and other lab 
originating proteins) and contained within the MaxQuant 
database were removed. To account for the possibility of 
keratin as a contaminant, we analysed the blank runs for 
keratin peptide intensity and subtracted this from the measured 
keratin intensities. A reversed database was used to identify false 
positives. The peptide and protein false discovery rate was set 
at 1%, and these were removed from further analysis.
Total intensities of the samples were normalized to total pro-
tein abundance, with adjustment to the lowest total protein 
yield. All samples were run in quadruplicate and reproducibility 
was assessed by Pearson correlation.
Mass spectrometry lipidomic analysis
Organoid samples were sonicated in phosphate buffered saline 
(pH7.4) and then extracted according to the method of Folch 
et al.26. The samples were analysed by liquid chromatography- 
mass spectrometry (LC-MS) on a Thermo Exactive Orbitrap 
mass spectrometer (Thermo Scientific, Hemel Hempsted, UK) 
coupled to a Thermo Accela 1250 ultra high pressure liquid 
chromatography (UHPLC) system. Samples were injected on to 
C18 column (Thermo Hypersil Gold, 2.1 mm x 100 mm, 1.9 µm) 
and separated using a water/acetonitrile/isopropanol gradient27. 
Ceramide 17:0 (Avanti Polar Lipids, Alabaster, AL, USA) 
was included as an internal standard. Ion signals correspond-
ing to individual ceramide molecular species were extracted 
from raw LC-MS data sets. Concentration of ceramide was 
expressed as pmol/mg after normalisation to mg of wet weight 
tissue.
Data analysis of qPCR, immunoblotting and functional 
assessments
Measurements were compared between non-targeting control- 
treated organoid models and FLG-siRNA-treated models, 
using paired t-test.
Histological sections of 10 replicate skin organoid experiments 
were measured using a standardized technique to minimize 
bias, as follows: three points were measured on each slide, at 
the right side, middle and left of each sample, across viable cell 
layers and stratum corneum; measurements were generated using 
Fuji ImageJ (May 2017) and the mean of the three measurements 
calculated.
Proteomic data analysis
The total intensities of the samples were normalised to total pro-
tein abundance, with adjustment to the lowest total protein yield. 
Log2 ratio of protein expression (log2 FLG knockdown – log2 
NT control) was visualised as a volcano plot, using GraphPad 
Prism (version 5) for human proteins detected in (three or all 
four) of the replicate experiments. P values were calculated 
by paired t-test applied to log 10 transformed data. Because 
of the burden of multiple testing in this large dataset, rather than 
defining arbitrary thresholds for ‘statistical significance’, our 
analyses focussed on changes that showed consistency across 
the biological replicate experiments. Approximately 1000 of the 
>8000 proteins were selected as showing consistently increased 
or decreased abundance, defined as follows:
Proteins were considered to be reduced in abundance if they 
showed a reduction in all four biological replicate experi-
ments comparing FLG-knockdown organoid samples to 
matched non-targeting controls and ratio ≤0.5 in three or four 
out of four of the replicates and reduced to undetectable levels 
of protein in a maximum of two replicates. Proteins were con-
sidered to be increased in abundance if they showed an increase 
in all four biological replicate experiments comparing FLG-
knockdown organoid samples to matched controls treated with 
non-targeting controls and ratio ≥1.2 in three or four out of four 
of the replicates. These magnitudes of change were used to 
define roughly equal proportions of up- and down-regulated pro-
teins for pathway analysis. The groups were then assessed using 
gene ontology and network analysis in STRING, version 1128 
and pathway prediction  using the Reactome Knowledge-
base, version 6829. This analysis, based on consistency of find-
ings across multiple biological replicate experiments was used 
in preference to a defined threshold of statistical significance, 
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Figure  2.  qPCR  analysis  of  epidermis  from  skin  organoids 
with and without FLG siRNA-mediated knockdown. Probes and 
primers are listed in Methods; n=8 biological replicates; error bars 
show SEM; *paired t-test p<0.05.
Figure  3.  Quantification  of  filaggrin  in  organoid  epidermis.  (A) Representative western blot. (B) Approximated quantification by 
densitometry. NT, non-targeting; n=7; ***p<0.0005 compared to non-targeting control.
with the aim to identify proteins and pathways of importance 
in the context of a common complex but heterogenous trait.
Lipidomic data analysis
The ratio of ceramide and omega-hydroxy ceramide species 
were compared between the FLG knockdown organoids and 
matched control samples in five biological replicate experiments.
Results
All samples are wild-type for the prevalent FLG null 
mutations and filaggrin shows knockdown at mRNA and 
protein level
Genotyping of DNA from tissue samples from the four skin 
donors did not detect any of the prevalent FLG null mutations30; 
this does not, however, exclude the possibility of rare 
(<0.01 allele frequency) null mutations.
FLG knockdown in the skin organoids persisted to day 10 
after siRNA transfection, as demonstrated by qPCR (Figure 2) 
and western blotting (Figure 3). We note the greater magni-
tude of knockdown quantified at mRNA than protein level in the 
organoid epidermis 10-days after transfection. This is likely to 
reflect the inherent differences in mRNA and protein stabilities: 
FLG mRNA has a half-life of ~2.2 hours31 whereas the half-lives 
of profilaggrin and filaggrin are approximately 6 and 24 hours 
respectively32.
FLG knockdown results in morphological changes in the 
epidermis
Histological examination confirmed a reduction of the 
granular layer, in keeping with a reduction in profilaggrin 
(Figure 4A). There was also a slight reduction in thickness 
of the stratum corneum (ratio 0.83 +/- 0.05 (mean +/- SEM), 
but no difference in thickness of the keratinocyte cell layers 
(Figure 4B).
Transmission electron microscopy (TEM) of the skin organoid 
model shows an effective recapitulation of the physiological 
layers of keratinocyte differentiation within skin, including a 
mature, multi-layered stratum corneum with corneodesmosomes 
and a granular layer with keratohyalin granules and desmo-
somes (Figure 5A). TEM of the FLG-knockdown organoid 
shows a similarly mature epidermis, but the stratum corneum 
has fewer layers and the granular layer contains keratohyalin 
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Figure 4. Structural changes in organoid models. (A) Histological examination (representative images from 8 biological replicates). NT, 
non-targeting. (B) Measurement of relative thickness of epidermal layers: VCL, viable cell layer and SC, stratum corneum; n=8; compared 
using paired t-test; **p<0.005.
Figure 5. Ultrastructural features of control and FLG knockdown organoids. (A) Control organoid sample, showing elements of normal 
human skin structure including stratified differentiation. (B) Organoid with FLG siRNA-mediated knockdown, showing thinner stratum corneum, 
reduced prominence if the corneodesmosomes and desmosomes, and smaller keratohyalin granules (organelles containing profilaggrin).
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Figure  6.  Transepidermal  water  loss  (TEWL)  measurements. 
TEWL measured under standard conditions at days 3, 5 and 7 after 
the organoid is lifted to the air-liquid interface, using an Aquaflux 
AF200 instrument (Biox Systems Ltd, London, UK) with a 5mm 
diameter probe head. NT, non-targeting; N=5; error bars show 
SEM.
Figure  7.  Epidermal  capacitance  measurements.  Electrical 
capacitance, directly proportional to water content of the uppermost 
10–20µm of tissue, was measured under standard conditions at days 
3, 5 and 7 after the organoid is lifted to the air-liquid interface, using 
a CorneometerTM (Courage and Khazaka, Cologne, Germany); the 
mean of three measurements is recorded. NT, non-targeting; N=5; 
error bars show SEM; paired t test **p<0.005.
Figure  8.  Lucifer  yellow  dye  penetration  of  organoid  samples. 
The hydrophilic lucifer yellow dye (Sigma Aldrich) was added 
to the epidermal surface of the organoid and incubated at 37°C 
for 4 hours before sectioning for microscopic examination. (A) 
Representative image from three of the five biological replicate 
experiments showing delayed maturation of barrier function. (B) 
Dot-plot of densitometry data from all five biological replicates. NT, 
non-targeting.
granules that are generally smaller and less numerous than in the 
control organoid (Figure 5B).
FLG knockdown shows some evidence of a barrier defect 
in the immature organoids but no functional effect on skin 
barrier in the mature organoid model
The organoid model described here shows progressive devel-
opment of skin barrier function after lifting to the air-liquid 
interface: there is a progressive reduction in TEWL (Figure 6), 
progressive reduction in capacitance (Figure 7) and the hydrophilic 
dye, lucifer yellow, is excluded from the epidermis by day 7 
in both the control and FLG-knockdown organoids (Figure 8).
Results from five biological replicate experiments showed there 
was no difference in the mean TEWL (Figure 6), or mean capaci-
tance measurements (Figure 7) between the mature organoid 
models with FLG knockdown and donor-matched non-targeting 
siRNA-treated controls. Capacitance was increased in the immature 
FLG-knockdown model (day 5 after air-exposure, Figure 7) 
and lucifer yellow dye was not fully excluded by the stratum 
corneum in some of the the FLG-knockdown replicate experi-
ments until day 7 (Figure 8). However, this delay in maturation 
of the ‘outside-to-inside’ barrier function was not consistently 
demonstrated in all biological replicates.
Mass spectrometry proteomic analysis identifies over 8000 
protein species per sample
After removal of contaminants and false positive results, >8000 
proteins were identified in each epidermal sample. The pro-
teomic data have been deposited to the ProteomeXchange 
Consortium via the PRIDE33 partner repository with dataset 
identifier PXD014875. Quality control analysis confirmed that 
similar distributions of proteins were identified in each experi-
ment (Figure 9A); protein extracts were analysed in quadru-
plicate to test for technical reproducibility and the Pearson 
correlations were 0.869-0.938 (Figure 9B).  The protein expression 
changes were visualised using a volcano plot (Figure 10).
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Figure  9.  Mass  spectrometry  proteomic  analysis  quality  control  assessments.  (A) Histograms showing the distribution of proteins 
quantified in each experiment. Bins on the x-axis contain the log2 intensity-based absolute quantification (iBAQ, sum of intensities of tryptic 
peptides for each protein divided by number of theoretically observable peptides); normalised counts of the proteins in each bin are shown on 
the y-axis; MS2, MS3, MS5 and MS6 are biological replicate experiments from different human donors; mock, untreated control organotypic; 
C4, non-targeting control treated organotypic; Filaggrin, FLG si-RNA treated organotypic. (B) Correlation of protein abundance from replicate 
analyses. x and y axes show iBAQ intensities of samples mapped against replicate analysis; biological replicates are highly correlated 
(Pearson correlation coefficient ≥0.86).
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Figure 10. Volcano plot to visualise changes in protein expression between control and FLG siRNA-treated organoids. Adjusted protein 
intensity data were filtered to include only human proteins detected in three or four replicate experiments. The log2 ratio (log2 FLG knockdown 
– log2 NT control) for each donor was calculated and averaged; p-values from paired t-test were derived from log10 transformed data and are 
unadjusted. Selected data-points with more extreme values are labelled using the abbreviated protein name. NT, non-targeting.
648 proteins show a consistent reduction in expression in 
skin organoids with FLG knockdown
648 human proteins showed a reduction in expression in all four 
of the replicates and ratio ≤0.5 in three out of four replicates. 
This list is available as Underlying data, uploaded to Figshare30.
645 of the proteins are identified in STRING and this group 
showed significant enrichment for interactions (p<1.0e-16) com-
puted by combining the probabilities from the different evi-
dence channels and corrected for the probability of randomly 
observing an interaction21. Gene ontology (GO) analysis in 
STRING showed evidence for functional enrichment of GO-
terms including RNA processing (false discovery rate (FDR) 
4.40e-11), catalytic activity (FDR 8.59e-08) and intracel-
lular component (FDR 3.88e-26). A list of the 10 most sig-
nificant GO analysis results in each of the GO domains is 
shown in Table 1 (see Underlying data)34.
Pathway analysis of down-regulated proteins identifies 
themes including RNA metabolism, adaptive immunity and 
axon guidance
Reactome detected 39 pathways in this set of proteins 
(Table 2, Underlying data)35. Descriptions include: metabo-
lism of RNA (including 67 out of the 652 genes in this pathway, 
FDR 3.36e-12); class I MHC mediated antigen processing and 
presentation (30/365 genes in pathway, FDR 0.0031); and axon 
guidance (34/541 genes, FDR 0.0207).
Down-regulated proteins indicate molecular mechanisms 
of relevance to atopic eczema
Manual searching of the list of down-regulated proteins iden-
tified several of specific interest based on a priori knowledge 
of eczema pathomechanisms. These highlight several puta-
tive therapeutic targets: the aryl hydrocarbon receptor plays 
a role in signalling pathways for skin barrier repair22 and has 
been proposed as a therapeutic target for the treatment of skin 
inflammation36; caspase 14 plays a role in filaggrin processing37 
and is required for epidermal protection against water loss and 
UVB-induced damage38; dermokine is a soluble regulator of 
keratinocyte differentiation39; sequence similarity to a murine 
protein (UniProtKB:Q8R1R3) indicates that StAR-related lipid 
transfer protein 7 may play a role in protecting mucosal tis-
sues from exaggerated allergic responses; a reduction in the 
cytokine TGF-beta 1 may predispose to atopic eczema40; 
and loss-of-function mutations in CYP4F22 cause lamellar 
ichthyosis41, suggesting that a reduction in CYP4F22 protein 
expression may contribute to the ichthyotic phenotype observed 
in ichthyosis vulgaris and atopic skin.
376 proteins show a consistent increase in expression in 
organoids with FLG knockdown
376 human proteins showed an increase in expression in 
all four of the replicates and ratio ≥1.2 in three or four out 
of the four replicates. This list is available as Underlying 
data, uploaded to Figshare30.
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374 proteins are identified in STRING and the group showed 
significant enrichment for interactions (p<1.0e-16). GO analy-
sis revealed enrichment of terms including translation (FDR 
4.12e-19), RNA binding (FDR 9.77e-12) and cytoplasmic 
part (FDR 9.64-36). A list of the 10 most significant GO 
analysis results in each of the GO domains is shown in Table 3 
(see Underlying data)42.
Pathway analysis of up-regulated proteins identifies 
themes including translation, innate and adaptive immunity 
and axon guidance
Reactome detected 113 pathways in this set of proteins with 
FDR p<0.05 (Table 4, Underlying data)43. Descriptions include: 
Translation (including 44 out of the 288 genes in this path-
way, FDR 1.17e-21); innate immune system (47/1012 genes in 
pathway, FDR 9.90e-7); cytokine signalling in immune system 
(32/654 genes in pathway, FDR 5.16e-05); and axon guidance 
(40/541, FDR 4.69e-11).
Up-regulated proteins indicate molecular mechanisms of 
relevance to atopic eczema
Manual searching of the list of up-regulated proteins identi-
fied several of relevance to atopic eczema, including: STAT1, an 
intracellular signalling molecule that shows increased expres-
sion in atopic eczema, and as part of the JAK-STAT pathway 
is targeted by several traditional herbal remedies44 as well as 
novel small molecule therapies45; carbonic anhydrase 2, which 
is increased in skin in a variety of forms of eczema46; 
and FK binding protein, which binds to tacrolimus, an 
established topical treatment for atopic eczema.
The type I keratins 10, 16 and 17 each show increased expres-
sion in the FLG-siRNA-treated organoid models with 
mean ratio 1.7, 1.3 and 1.3, respectively. Keratin 10 is an 
intermediate filament protein of structural importance in the 
skin; keratin 16 is an epidermis-specific keratin that plays a role 
in innate immunity in response to skin barrier breach47; kera-
tin 17 is expressed in epidermal appendages, including the hair 
follicle.
Finally, it is noteworthy that GAPDH, which is often considered 
to be a stable ‘housekeeping’ gene, is in the dataset of consist-
ently up-regulated proteins. However, in the context of this 
work, filaggrin knockdown is clearly apparent at a greater 
magnitude than the more subtle change in GAPDH (Figure 3).
Epidermal ceramide content shows no significant 
difference in FLG-knockdown organoids compared with 
controls
Ceramide and omega-hydroxy ceramide species in five bio-
logical replicate experiments showed no consistent difference 
between the FLG knockdown organoids and matched control 
samples (Figure 11).
Discussion
The functional and biochemical analyses of a filaggrin-deficient 
skin model have provided findings that are consistent with our 
and others’ previous analyses in vitro19 and in vivo48. We have 
included both epidermal and dermal compartments in this 
model (to allow for dermal-epidermal cross-talk49,50) and our 
more detailed proteomic analysis has revealed additional 
evidence of molecular mechanisms with relevance to atopic 
skin. These datasets are shared as a resource for the research 
community. 
Analysis of the immature organoid identified a delay in epi-
dermal maturation following FLG knockdown, but the lack of a 
replicable functional effect in our model, when mature, reflects 
previous reports in which epidermal equivalents created from 
FLG-null keratinocytes do not show impairment in barrier 
function20. This is in keeping with the observation that FLG-
null mutations are not fully penetrant with respect to ichthyosis 
vulgaris or atopic eczema16,51.
Because of the nature of our data, generated using biologi-
cal replicate samples, and the focus on modelling a common 
complex trait with considerable inter-individual variation, 
we elected to use the criterion of consistency across the bio-
logical replicates to define proteins of interest, followed by 
network and pathway analyses. We recognise that other, more 
complex data analytical approaches may be applied, and/or 
more focussed interrogation of specific pathways; we share 
the proteomics data and welcome such further analysis.
Our analysis has highlighted aspects of keratinocyte-immune 
signalling. This is an important component of the immuno-
logical barrier that may be overlooked in tissue with multiple 
different cell types. The predicted pathways entitled ‘innate 
immunity’ and ‘adaptive immunity’ included proteins showing 
Figure  11.  Ratio  of  ceramides  and  omega-hydroxy  ceramides 
in  organoid  epidermis.  Dots represent values for five individual 
experiments; bars show 95% confidence interval.
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both increased and decreased expression (Table 2 and Table 4, 
Underlying data)35,43. This immune dysregulation is likely to 
contribute to the predisposition to infection and inflammation 
observed in filaggrin-deficient skin in vivo: filaggrin-deficient 
patients show increased viral infection of the skin52 and increased 
incidence of irritant53,54 and allergic contact dermatitis55. 
The regulation of innate and adaptive immune pathways 
within keratinocytes (in addition to cells of the haematopoietic 
lineage) may therefore represent a worthwhile target for future 
therapeutic interventions.
The lack of effect of FLG knockdown on the ceramide content in 
the model epidermis is also consistent with previously reported 
findings in vitro56,57 and in vivo58. We did not analyse in detail 
the other epidermal lipids and therefore we cannot comment on 
whether there were relevant changes. Differences in lamellar 
body structure59 have been reported in FLG-mutant skin biopsies 
but this was not clearly observed in the organoid model. How-
ever, ultrastructural examination of the model stratum corneum 
did reveal abnormalities in the lamellar bilayer structure and 
less prominent corneodesmosomes (Figure 5), as previously 
reported in vivo59. It is also noteworthy that pathway analy-
sis in Reactome identified the terms ‘metabolism of lipids’ and 
‘phospholipid metabolism’ from the group of consistently 
down-regulated proteins (Table 4, Underlying data)43.
The most significant themes identified in the groups of pro-
teins showing increased expression upon FLG knockdown 
relate to RNA binding and translation; this is in contrast to RNA 
metabolism and RNA processing, which are demonstrated in 
the proteins showing decreased expression. The functional sig-
nificance of this increase in transcriptional and translational 
activity cannot be determined from the gene ontology and path-
way analysis. We may hypothesise that it reflects the increased 
‘stress’ response, as we have previously observed in FLG geno-
type-stratified transcriptome analysis of atopic skin biopsies18 
and/or the activation of innate and adaptive immune mechanisms.
It is tempting to speculate that the increased expression of 
keratins 10 and 16 may contribute to palmar hyperlinearity 
and keratin 17 may contribute to keratosis pilaris. These are 
characteristic features of ichthyosis vulgaris but their 
pathogenesis has not yet been explained as a direct result of 
filaggrin haploinsufficiency16,60.
Several of the proteins showing reduced expression relate 
to aspects of differentiation, including filaggrin itself, and 
caspase 14 which plays a role in the terminal degradation of 
filaggrin37. The aryl hydrocarbon receptor (AhR) is a ligand- 
activated transcription factor that responds to multiple different 
environmental and metabolic stimuli to control transcriptional 
pathways of relevance to atopic eczema, including immunity and 
differentiation61. Activation of AhR reduces skin inflammation62 
and enhances barrier repair63; therefore, a reduction in AhR 
expression in the FLG knockdown organoid would be antici-
pated to increase the eczema diathesis by opposing these effects. 
AKT1 activity is known to be reduced in atopic skin, leading 
to an alteration in protease expression and reduced filaggrin 
expression and processing64. This mechanism may further 
exacerbate the filaggrin deficiency in our FLG knockdown 
organoid. Dermokine acts as a soluble regulator of keratinocyte 
differentiation and mice deficient in the epidermal dermokines 
(beta and gamma isoforms) show defective cornification65. 
Transforming growth factor (TGF) beta-1 is a multifunctional 
protein: it regulates the growth and differentiation of multiple 
cell types, including keratinocytes and it can promote 
either Th17 or T-regulatory cell lineage differentiation in 
a concentration-dependent manner; it appears to have an 
immunosuppressive effect in atopic disease since a genetically-
determined lower production of TGF-beta-1 is associated with 
increased risk of atopic dermatitis40.
The Reactome term ‘axon guidance’ was detected in proteins 
showing increased and decreased expression. It has long been 
recognised that there is an increase in the density of sensory 
neurons in eczematous skin66 and nerve growth factor expres-
sion is upregulated in the keratinocytes of patients with atopic 
eczema67. Therefore, dysregulation of axon guidance may be 
of relevance to the pruritus that is so characteristic of atopic 
eczema and contributes substantially to the morbidity of this 
condition3. Antagonists of transient receptor potential vanilloid 
subfamily member 1 (TRPV1), expressed on sensory nerves 
and keratinocytes, are now being investigated for the control 
of pruritus68,69.
Taken together, our data demonstrate that filaggrin haploinsuf-
ficiency leads to abnormalities in both structural and immune 
features within the keratinocyte compartment of the epidermis. 
Keratinocytes display immune activity, producing multiple 
cytokines and chemokines in addition to their roles in innate 
immunity70,71. Together with the evidence of dysregulation in 
axon guidance, these findings indicate that patients with filaggrin 
deficiency – either haploinsufficiency or a reduction in filaggrin 
expression that occurs secondary to atopic inflammation72 – may 
derive clinical benefit from future therapies targeting 
keratinocyte-immune crosstalk mechanisms and neurogenic 
pruritus.
The skin organoid model described here represents a valu-
able opportunity to study genetic effects on keratinocytes in 
relative isolation. However, the lack of other cell types (nota-
bly T cells, B cells, dermal dendritic cells and innate lymphoid 
cells), the absence of complex dermal structures (including 
neurons and blood vessels) and skin appendages (for example 
hair follicles, sweat and sebaceous glands) is also a limitation 
in that it precludes assessment of the complex interactions that 
are likely to occur between different tissue compartments in skin.
In conclusion, we share these experimental results in detailed 
form, because of the additional insight provided by this in vitro 
analysis of filaggrin deficiency in a skin organoid model; 
our findings compliment and extend previous work in vitro 
and in vivo. Our  analyses have re-emphasised the role of 
keratinocyte-specific mechanisms in contributing to immune and 
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neurological as well as structural aspects of skin barrier func-
tion and offer new insight into molecular mechanisms for the 
ichthyosis vulgaris phenotype.
Data availability
Underlying data
Mass spectrometry proteomics data deposited in the Pro-
teomeXchange Consortium via the PRIDE partner repository33, 
Accession number PXD014875: https://identifiers.org/pride.
project:PXD014875
Figshare: Proteomic analysis of FLG knockdown in skin 
organoid. https://doi.org/10.6084/m9.figshare.c.4606052.v330.
This project contains the following underlying data:
-    TEM images (zip file containing raw, unedited TEM 
images in .tif format)
-    TEWL and corneometer readings (raw readings in .xlsx 
format)
-    Western blots (zip file containing unedited western blot 
scans, plus an annotated composite image with labels in .tif 
format)
-    Lucifer yellow dye penetration quantification.xlsx
-    Lucifer yellow dye penetration (zip file containing 
raw, unedited microscopy images for five replicates in 
.czi format)
-    Histology quantification (raw histology quantification 
data in .xlsx format)
-    H&E images (raw, unedited histology images for replicates 
1-11 in .bmp and .tif format)
-    Filaggrin densitometry (densitometry measurements for 
seven replicate experiments in .xlsx format)
-    FLG qPCR data (raw qPCR data in .xlsx format)
-    FLG genotyping results (raw genotyping results in .xlsx 
format)
-    Consistently down-regulated proteins in FLG kd organoids.
xlsx
-    Consistently up-regulated proteins in FLG kd organoids.
xlsx
Figshare: Table 1. Gene Ontology (GO) analysis of pro-
teins showing a consistent reduction in expression with FLG 
knockdown. https://doi.org/10.6084/m9.figshare.9710585.v134.
Figshare: Table 2. Reactome pathway analysis of down-regulated 
proteins. https://doi.org/10.6084/m9.figshare.9710666.v135.
Figshare: Table 3. Gene Ontology (GO) analysis of proteins show-
ing a consistent increase in expression with FLG knockdown. 
https://doi.org/10.6084/m9.figshare.9710738.v142.
Figshare: Table 4. Reactome pathway analysis of up-regulated 
proteins. https://doi.org/10.6084/m9.figshare.9710783.v143.
Data are available under the terms of the Creative Commons 
Attribution 4.0 International license (CC-BY 4.0).
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Elias  . investigated the effect of filaggrin deficiency in an optimized skin organoid model. Next to theet al
inside/out and outside/in barrier function assessed respectively by TEWL and penetration of a hydrophilic
dye, a global mass proteomic analysis has been done. As discussed by authors, the used model has
important advantage that the changes related to filaggrin deficiency could be studied in specific cells
(keratinocytes) and both epidermal and epidermal compartments were present. On the other side, the
model misses other relevant cell types. The study is well designed and presented.
 
Specific points 
1. Skin barrier function assessment
 
Although Lucifer yellow is a commonly used model penetrant it has to be realized that owing to its
hydrophilicity and a large molar mass (444 Da) it has quite low penetration rate and a long lag time. The
incubation time of 4 hours before microscopic examination is likely too short to detect penetration across
the SC unless the barrier damage is substantial. In general, it would be good to include in functional
studies both, hydrophilic and lipophilic penetrants and measure their penetration at different time points.
This might provide more detailed insight into alterations in the structure and composition of the SC and
relate them to the structural changes. As noted by the authors, the Flg-knock down ‘’reveal various
abnormalities: in the lamellar bilayer structure and less prominent corneodesmosomes’’ and furthermore
down-regulation of proteins involved in metabolism of lipids’ and ‘phospholipid metabolism’’ and thinner
stratum corneum. Though, no changes in either TEWL or dye penetration have been found. This model
would be of great value to further study functional consequences of filaggrin deficiency, including previous
damage of the skin e.g. by skin irritants. 
 
2. Other points
The authors note that ‘’FLG knockdown in the skin organoids persisted to day 10 after siRNA transfection,
as demonstrated by qPCR (Figure 2) and western blotting (Figure 3)’’. In Fig. 2 it is obvious that the
knock-down at the RNA level was not complete and lower than achieved in similar studies (van Dongelen 
., 2013 , Wang  ., 2017 ). On which day was the mRNA expression measured and what might beet al et al
reason for quite a low knock-down efficiency?
Ceramide analysis has been carried out in the model epidermis. Performing ceramide analysis in the
isolated stratum corneum might have been more relevant.
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Is the work clearly and accurately presented and does it cite the current literature?
Yes
Is the study design appropriate and is the work technically sound?
Yes
Are sufficient details of methods and analysis provided to allow replication by others?
Yes
If applicable, is the statistical analysis and its interpretation appropriate?
I cannot comment. A qualified statistician is required.
Are all the source data underlying the results available to ensure full reproducibility?
Yes
Are the conclusions drawn adequately supported by the results?
Yes
 No competing interests were disclosed.Competing Interests:
Reviewer Expertise: Skin barrier in inflammatory skin diseases, dermatotoxicology.
I confirm that I have read this submission and believe that I have an appropriate level of
expertise to confirm that it is of an acceptable scientific standard.
Author Response 19 Nov 2019
, Ninewells Hospital, Dundee, UKSara J. Brown
Specific points
 
1. Skin barrier function assessment
 
We agree that Lucifer yellow has a slow penetration rate hence our long incubation (4 hours,
compared to some other publications reporting 1 hour or less). We will, in future work, consider use
of a hydrophobic dye as an additional, complimentary assessment - thank you for this useful
suggestion.
 
2. Other points
 
The mRNA quantification was carried out 10 days after siRNA transfection and we agree it is
interesting to note this decay in knockdown at transcriptome level, whilst the protein knockdown
persists to a greater degree. This is likely to reflect the different half-lives of  mRNAFLG 
(approximately 2.2 hours ) whereas the half-lives of profilaggrin and filaggrin are approximately 6
and 24 hours respectively.  We have added this additional explanation to the updated manuscript.
Thank you for the knowledgeable advice about ceramide analysis. We agree that the stratum
corneum is the most relevant tissue layer in which to perform lipidomic analysis, but an accurate
separation of the whole stratum corneum (without upper epidermal cells) proved to be technically
challenging in the organoid model. We therefore chose to analyse full thickness epidermis to
1
2
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challenging in the organoid model. We therefore chose to analyse full thickness epidermis to
ensure consistency between the replicate experiments.
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Elias   present data on a manuscript titled "Proteomic analysis of a filaggrin-deficient skin organoidet al.
model shows evidence of increased transcriptional-translational activity, keratinocyte-immune crosstalk
and disordered axon guidance”.
In this study, primary keratinocytes from 4 female filaggrin wild-type genotyped individuals were subject to
siRNA   kd and a nontargeting siRNA control. These were grown in a skin equivalent model withFLG
matched donor fibroblasts, and then keratinocytes alone were harvested after the model had been in at
the air liquid interface for 7 days. This was used to carry out proteomic and lipidomic analysis. Additional
samples were used for validation work.
The work has been meticulously described in the methods and is an exemplar for human primary
keratinocyte research. Filaggrin knockdown was demonstrated at the transcriptomic and protein level,
and is evident in the mass spec data across all samples. A phenotype is seen on TEM and is elegantly
presented Fig 5. Barrier function as assessed by TEWL and dye penetration is not impaired following FLG
knockdown at Day 7, which is consistent with prior reports using skin equivalent models.
The key findings are the differentially expressed proteins in this novel model, and unlike prior skin
equivalent papers, here dermal fibroblasts are used, allowing for better modelling of human skin where
cross talk happens. Notably, lipidomic studies did not show a difference in epidermal ceramides.
Comments:
The authors highlight the proteins that have relevance to the known pathogenetic mechanisms of
eczema. It would be helpful to emphasise the novel findings detected in this model compared to
the prior proteomic analysis published on filaggrin knockdown keratinocytes (Elias  ., 2017 ),et al 1
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the prior proteomic analysis published on filaggrin knockdown keratinocytes (Elias  ., 2017 ),et al
as that model did not include matched donor fibroblasts.
 
Table 2 presents Reactome data and highlights Axon guidance, and it would be helpful to see this
in the context of the other pathways described. I would favour this being included in the PDF, rather
than Fig 9, which may be moved to supplementary data.
 
The volcano plot (Fig 10) is of interest, but more data could be presented here, for example, the 7
points which are log2 fold change >+5 could be identified to make this more informative for the
reader. I am uncertain if the colour scheme with p value cut offs is helpful; the authors carefully
justify using selected fold change thresholds in the methods section over arbitrary thresholds that
are p-value driven and this depiction is at odds with this.
 
Could the title be improved to reflect the more complete nature of this skin equivalent model that
incorporates fibroblasts? Also, how were the three elements "increased
transcriptional-translational activity, keratinocyte-immune crosstalk and disordered axon guidance”
selected or prioritised from the list of Reactome findings?
There is a minor typographical error on page 3. “Medium was refreshed on alternate day   the culturessand
were used for analysis up to day 12 (representing three, five and seven days after lifting to the air-liquid
interface)".
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I confirm that I have read this submission and believe that I have an appropriate level of
expertise to confirm that it is of an acceptable scientific standard.
Author Response 19 Nov 2019
, Ninewells Hospital, Dundee, UKSara J. Brown
Comments:
 
The authors highlight the proteins that have relevance to the known pathogenetic mechanisms of
eczema. It would be helpful to emphasise the novel findings detected in this model compared to
the prior proteomic analysis published on filaggrin knockdown keratinocytes (Elias et al., 20171),
as that model did not include matched donor fibroblasts.
 
Thank you for this insightful comment. The current work differs in several ways from the previous
work (performed by the same first author in different research institutions):
 
(i) The current work used FLG wild-type primary keratinocytes isolated from female breast skin and
co-cultured with 3T3 feeder cells in the presence of serum, whereas the previous publication used
keratinocytes isolated from foreskin donors and cultured in serum-free conditions.
(ii) The current work used a full-thickness skin organoid model ((Keratinocytes seeded on top of
donor matched fibroblasts embedded in a fibrin dermal matrix) whereas the previous work was
anepidermal equivalent model (Keratinocyes grown in a transwell) .
(iii) The current work benefited from advancements in proteomic technology and generated a more
extensive, detailed proteomic dataset.
 
The previous work provided, for the first time, evidence that filaggrin deficiency can alter the
expression levels of proteins relevant to the pathogenesis of AE, even without an external
inflammatory stimulus and the current work supports this.  
 
Mechanistic themes emerging from this study, including inflammatory, proteolytic and cytoskeletal
pathways, broadly overlap with findings from this previous work. However, novel findings detected
in the current model compared to the prior proteomic analysis (Elias et al., 2017) may be
summarised as follows:
Evidence that filaggrin-deficient keratinocytes are a source of immune signalling.
Filaggrin deficiency leads to an increase in transcriptional and translational activity but a
reduction in multiple markers of terminal differentiation.
There is a dysregulation of axon guidance (with elements of this pathway represented in
both the up- and down-regulated protein sets).
Table 2 presents Reactome data and highlights Axon guidance, and it would be helpful to see this
in the context of the other pathways described. I would favour this being included in the PDF, rather
than Fig 9, which may be moved to supplementary data.
 
Thank you for this suggestion. We agree that Table 2 is a valuable summary of the findings from
Reactome, but it is too large (including detailed lists of protein IDs, which we are keen to include) to
fit into the .pdf. We hope that readers will easily access the full table via the direct link provided to
FigShare. We have considered alternative methods to present our Reactome pathway analyses,
but the visualisation of pathways within a global over-view does not lend itself to our data where
relatively small numbers of pathways (39 and 113) show significant dysregulation.
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The volcano plot (Fig 10) is of interest, but more data could be presented here, for example, the 7
points which are log2 fold change >+5 could be identified to make this more informative for the
reader. I am uncertain if the colour scheme with p value cut offs is helpful; the authors carefully
justify using selected fold change thresholds in the methods section over arbitrary thresholds that
are p-value driven and this depiction is at odds with this.
 
Thank you for this advice. On further consideration we agree that the colour-coding is not helpful
and the addition of labels to the most extreme data points is informative for readers. These
changes have been made in a corrected version of Fig 10 in the updated manuscript.
 
Could the title be improved to reflect the more complete nature of this skin equivalent model that
incorporates fibroblasts? Also, how were the three elements "increased
transcriptional-translational activity, keratinocyte-immune crosstalk and disordered axon guidance”
selected or prioritised from the list of Reactome findings?
 
In response to your helpful suggestion we have added the words ‘full thickness’ to the title to
emphasise the nature of our model. Because the title was already very long we have truncated it,
since the main findings (‘increased transcriptional-translational activity, keratinocyte-immune
crosstalk and disordered axon guidance’) are clearly stated in the abstract.
 
These three elements were prioritised as noteworthy findings based on a combination of GO and
pathway analyses as follows:
 
(a) Aspects of transcriptional and translational activity are represented in all 10 of the most
significant GO terms for Biological process in the consistently down-regulated (Table 1) and
up-regulated (Table 3) proteins; ‘Metabolism of RNA’ is the top Reactome term in the
down-regulated protein dataset (Table 2) and the Reactome term ‘Translation’ is top in the
upregulated proteins (Table 4).  
 
(b) Keratinocyte-immune crosstalk is highlighted to emphasise that these experiments, in which
epidermal keratinocytes are isolated from other cells of the immune system, still generate signals
classified within the terms ‘innate’ and ‘acquired immunity’.  In the Reactome analyses of
consistently down-regulated proteins 7/39 enriched pathways are related to the immune or antiviral
systems and 15/113 enriched pathways in the up-regulated proteins relate to immune systems or
antiviral systems.
 
(c) Disordered axon guidance was represented by only one Reactome term in each of the up- and
down-regulated protein groups, but together these account for 74/541 (14%) of the proteins in this
pathway. This was prioritised as a novel signal of interest, likely to be relevant to AD
pathophysiology but not currently targeted for therapy.
 
There is a minor typographical error on page 3. “Medium was refreshed on alternate day sand the
cultures were used for analysis up to day 12 (representing three, five and seven days after lifting to
the air-liquid interface)".
 
Thank you, we have corrected this typo in the updated version of our manuscript. 
 No competing interests were disclosed.Competing Interests:
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© 2019 Werner S. This is an open access peer review report distributed under the terms of the Creative Commons
, which permits unrestricted use, distribution, and reproduction in any medium, provided the originalAttribution License
work is properly cited.
 Sabine Werner
Institute for Molecular Health Sciences, Department of Biology, ETH Zurich (Swiss Federal Institute of
Technology Zürich), Zürich, Switzerland
The authors generated and characterized 3D organotypic cultures using keratinocytes with filaggrin
knock-down or control keratinocytes. Although such cultures had been generated before, they had not
been used for proteomics studies. The proteomics analysis provides some insight into the molecular
mechanisms underlying the effect of filaggrin on keratinocyte function. The advantage of this system is
the focus on the keratinocyte phenotype. The disadvantage is the lack of the influence of other cell types
that are important for Atopic Dermatitis pathogenesis. Overall, this is an interesting study, although there
is no functional follow-up of any of the differentially expressed proteins. In addition, the statistical analysis
requires improvement.
 
Specific comments:
The filaggrin knock-down at the RNA level was only approximately 50%, whereas the knock-down
at the protein levels seems more robust. How do the authors explain this inconsistency? Why are
there no error bars in Fig. 2 NT-siRNA? The data should be confirmed by immunostaining of the
cultures for filaggrin. Staining of the cultures for loricrin would be helpful to confirm abnormalities in
the granular layer.
 
It is impossible to see obvious differences in Lucifer yellow penetration and there is also no
statistically significant difference. This should be expressed more carefully.
 
The proteomics data provide a very important resource. It would have been helpful to show the
validation of some of the data using independent samples and another method, e.g. Western blot
and/or immunohistochemistry. This would be easy for selected proteins, such as the different
keratins.
 
A comparison of the data with available transcriptomics data from AD patients would be
interesting.
 
For the proteomics analyses, it is not clear how the false discovery rate was exactly determined
(scrambled or reversed database?) and how false positives were removed. This requires
clarification. 
 
Statistical analysis to identify proteins with differential abundance between conditions lacks
stringency and appears asymmetric with regard to positive and negative effect sizes. Lack of
statistically significant hits upon multiple testing correction is a common problem with proteomics
datasets. Which multiple testing correction algorithm was applied? Bonferroni or
Benjamini-Hochberg? Did the authors try e.g. a limma moderated t-test that has proven useful for
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Benjamini-Hochberg? Did the authors try e.g. a limma moderated t-test that has proven useful for
proteomics data? Even without multiple testing correction, a statistical test appears more suitable
than selecting differentially abundant proteins only based on consistency between
comparisons/experiments. Moreover, the authors apply a cut-off of 2-fold (0.5) to identify proteins
with lower abundance upon filaggrin knockdown and of 1.2-fold (1.2) for those with higher
abundance in this condition. It appears this skewed effect size has been selected aiming at
equalizing hit numbers for pathway enrichment. This should be reconsidered. The terms ‘ratio’ and
‘fold-change’ are not used properly, since the authors report actual ratios as fold-changes, e.g. a
ratio of 0.5 would correspond to a fold-change of -2 and of 2 to a fold change of +2. Since
identifying proteins with statistically significantly differential abundance between conditions is
crucial, also for follow-up data analysis, the authors should re-evaluate this part of the study with
help of an expert in proteomics statistics.
Is the work clearly and accurately presented and does it cite the current literature?
Yes
Is the study design appropriate and is the work technically sound?
Yes
Are sufficient details of methods and analysis provided to allow replication by others?
Yes
If applicable, is the statistical analysis and its interpretation appropriate?
Partly
Are all the source data underlying the results available to ensure full reproducibility?
Yes
Are the conclusions drawn adequately supported by the results?
Yes
 No competing interests were disclosed.Competing Interests:
Reviewer Expertise: Skin Biology, Inflammatory Skin Disease, Wound Healing, Tissue Repair
I confirm that I have read this submission and believe that I have an appropriate level of
expertise to confirm that it is of an acceptable scientific standard, however I have significant
reservations, as outlined above.
Author Response 19 Nov 2019
, Ninewells Hospital, Dundee, UKSara J. Brown
Thank you for your interest in the skin organoid model and our analyses. We believe that a focus
on the keratinocyte phenotype is valuable, particularly in AD where the keratinocyte’s contribution
to barrier function is of particular interest. Whilst we agree that there are many other cell types
contributing to AD pathogenesis, we consider that the isolation of keratinocytes may be viewed as
an advantage in this experimental system because it provides an opportunity to investigate the
specific contribution of keratinocyte biology to features of atopic inflammation and other
pathomechanisms in this highly complex trait.
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pathomechanisms in this highly complex trait.
 
We agree that functional follow-up may be an important step and we have conducted extensive
validation in other applications of the skin organoid and a simpler epidermal model.  The detailed
dataset and our analyses reported here in   are shared as a resource forWellcome Open Research
the community, to allow others to review the differentially expressed proteins and follow up
selected candidates as indicated. We have further clarified this as the principle aim of our
publication in Version 2.
 
Specific comments:
 
The filaggrin knock-down at the RNA level was only approximately 50%, whereas the knock-down
at the protein levels seems more robust. How do the authors explain this inconsistency?
We agree, there was a 0.5-fold reduction in   mRNA compared to 0.36- and 0.25-fold reductionFLG
in pro-filaggrin and filaggrin proteins respectively. These differing levels of reduction in expression
reflect the use of siRNA which creates a transient knockdown. siRNA is our preferred methodology
because we aim to maintain the primary cells at low passage and to minimise non-physiological
experimental influences. The different degrees of knockdown reflect the long experimental time
points (10 days post transfection for a mature organoid) and the inherent differences in mRNA and
protein stabilities.  mRNA has a reported half-life of ~2.2 hours  whereas the half-lives ofFLG 
profilaggrin and filaggrin are approximately 6 and 24 hours respectively.  We have added this
additional explanation to the updated manuscript. Since our main experimental aim was to reduce
filaggrin at the protein level, we are satisfied that knockdown of the functional monomer is
maintained for the duration of our experiment and this degree of reduction is in keeping with the
reduction in expression observed in  -null heterozygotes or atopic skin.FLG
Why are there no error bars in Fig. 2 NT-siRNA?
The filaggrin expression presented in Figure 2 has been calculated in a pair-wise manner (FLG
-siRNA versus  -siRNA control) for each independent biological donor (N=8) and the replicateNT
data were then combined for statistical analysis. Since only one technical replicate was performed
per donor, the  -siRNA condition is calculated as 1 in each biological replicate and henceNT
displays no error in the combined dataset. This internally controlled method of analysis accounts
for differences in baseline filaggrin expression and technical variations between replicate
experiments.
The data should be confirmed by immunostaining of the cultures for filaggrin.
 
Thank you for this suggestion. We agree that immunostaining can represent a valuable
confirmatory approach, however the H&E stained section show a clear reduction in the granular
layer and the filaggrin knockdown at protein level was confirmed by mass spec proteomics (mean
0.27-fold, N=4) which is likely to be more sensitive for the detection of quantitative differences than
immunostaining.
 
Staining of the cultures for loricrin would be helpful to confirm abnormalities in the granular layer.
 
The electron microscopy (Figure 5) shows the granular layer in some detail, with a clear reduction
in the number and size of granules. We therefore did not elect to stain the organoid cultures for
loricrin specifically.
    
1,2
3
4
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It is impossible to see obvious differences in Lucifer yellow penetration and there is also no
statistically significant difference. This should be expressed more carefully.
 
Thank you for bringing this to our attention. We did observe a difference in Lucifer yellow dye
penetration in 3/5 of the biological replicates at day 3 but we agree this is not apparent in the
mature model at day 7 (example images shown in Figure 8A). We aimed to explain that our
quantification (in Figure 8B) shows all of the individual data points and, whilst some experiments
showed an increase in dye penetration in the immature organoid, we state “However, this delay in
maturation of the ‘outside-to-inside’ barrier function was not consistently demonstrated in all
biological replicates.” In light of your comment we have added further clarification to the text.
    
The proteomics data provide a very important resource. It would have been helpful to show the
validation of some of the data using independent samples and another method, e.g. Western blot
and/or immunohistochemistry. This would be easy for selected proteins, such as the different
keratins.
 
Thank you, we agree the proteomics data are a valuable resource and we are delighted to share
this resource. We also agree it will be relatively easy for other groups to validate proteins of interest
in their work; therefore, rather than carrying out validation ourselves for selected keratins (or
multiple different proteins as we have for our parallel proteomics analyses, recently published ) we
prefer to share the data for further independent validation.
 
A comparison of the data with available transcriptomics data from AD patients would be interesting.
We agree that this would be a very interesting analysis; it is not within the remit of this study but we
or others may pursue this in the future.
For the proteomics analyses, it is not clear how the false discovery rate was exactly determined
(scrambled or reversed database?) and how false positives were removed. This requires
clarification.
 
We apologise for the lack of clarity in this description. The false discovery rate was determined
using a reversed database. The peptide and protein false discovery rate was set at 1%, and these
identified peptides were denoted with REV_ and removed from further analysis. These details have
been added to the revised manuscript.
    
Statistical analysis to identify proteins with differential abundance between conditions lacks
stringency and appears asymmetric with regard to positive and negative effect sizes. Lack of
statistically significant hits upon multiple testing correction is a common problem with proteomics
datasets. Which multiple testing correction algorithm was applied? Bonferroni or
Benjamini-Hochberg? Did the authors try e.g. a limma moderated t-test that has proven useful for
proteomics data? Even without multiple testing correction, a statistical test appears more suitable
than selecting differentially abundant proteins only based on consistency between
comparisons/experiments.
 
We appreciate that there are no clear guidelines on methodology for the analysis of large
proteomics datasets (or indeed many other large datasets) and different expert opinions exist
regarding the most appropriate tools and thresholds to define ‘significance’. We have benefited
from the considerable expertise within our multidisciplinary collaboration, leading to the rather
1
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from the considerable expertise within our multidisciplinary collaboration, leading to the rather
simple data analysis that we have performed, whilst providing the full dataset for others to analyse
as they may wish.
 
A full Bonferroni correction does not identify any differentially expressed proteins because of the
large number detected in this global analysis. Because of the nature of our data, generated using
biological replicate samples (primary cells from 4 separate human donors), and the focus on a
common complex trait, we prefer to use the criterion of *consistency* across the biological
replicates, with filtering for fold change to provide similar numbers of up- and down- regulated
proteins, followed by network and pathway analyses.
 
Moreover, the authors apply a cut-off of 2-fold (0.5) to identify proteins with lower abundance upon
filaggrin knockdown and of 1.2-fold (1.2) for those with higher abundance in this condition. It
appears this skewed effect size has been selected aiming at equalizing hit numbers for pathway
enrichment. This should be reconsidered.
 
Thank you for highlighting this question. We have stated clearly and openly that we   selectdid
these cut-offs aiming to equalize protein numbers in this right-skewed dataset. Using the
thresholds of £0.5 and ³1.2 defines 1422 (~25%) and 1871 (~34%) of the total number of proteins.
This is an established approach in proteomic analysis; we appreciate other valid approaches can
be applied and we welcome further interrogation of our experimental data. We have further clarified
this in the discussion.
 
The terms ‘ratio’ and ‘fold-change’ are not used properly, since the authors report actual ratios as
fold-changes, e.g. a ratio of 0.5 would correspond to a fold-change of -2 and of 2 to a fold change
of +2.
 
We apologise for the inconsistency in this terminology and we have corrected this detail throughout
the manuscript.
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Abbreviations used
AD: Atopic dermatitis
DMEM: Dulbecco modified Eagle medium
EGF: Epidermal growth factor
FLG: Gene encoding filaggrin
GO: Gene ontology
GWAS: Genome-wide association study
Hi-C: Genome-wide chromosome conformation capture and high-
throughput sequencing to identify regions of DNA showing
interaction in 3-dimensional space
LRRC32: Leucine-rich repeat-containing 32 gene, encoding the
glycoprotein A repetitions predominant (GARP) protein
NHK: Normal human keratinocytes
NDF: Normal dermal fibroblasts
qPCR: Quantitative PCR
siRNA: Small interfering RNA
SNP: Single nucleotide polymorphism
TEWL: Transepidermal water loss
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ELIAS ET AL 471Objectives: We sought to apply a combination of genomic and
molecular analytic techniques to investigate which genes are
responsible for genetic risk at this locus and to define
mechanisms contributing to atopic skin disease.
Methods: We used interrogation of available genomic and
chromosome conformation data in keratinocytes, small
interfering RNA (siRNA)–mediated knockdown in skin
organotypic culture and functional assessment of barrier
parameters, mass spectrometric global proteomic analysis and
quantitative lipid analysis, electron microscopy of organotypic
skin, and immunohistochemistry of human skin samples.
Results: Genomic data indicate active promoters in the genome-
wide association study locus and upstream of EMSY; EMSY,
LRRC32, and intergenic variants all appear to be within a single
topologically associating domain. siRNA-knockdown of EMSY in
organotypic culture leads to enhanced development of barrier
function, reflecting increased expression of structural and
functional proteins, including filaggrin and filaggrin-2, as well as
long-chain ceramides. Conversely, overexpression of EMSY in
keratinocytes leads to a reduction in markers of barrier
formation. Skin biopsy samples from patients with AD show
greater EMSY staining in the nucleus, which is consistent with an
increased functional effect of this transcriptional control protein.
Conclusion: Our findings demonstrate an important role for
EMSY in transcriptional regulation and skin barrier formation,
supporting EMSY inhibition as a therapeutic approach. (J
Allergy Clin Immunol 2019;144:470-81.)
Key words: Atopic dermatitis, atopic eczema, EMSY, filaggrin, ge-
netics, genomics, organotypic, lipidomics, proteomics, siRNA
knockdown
Atopic dermatitis (AD; or eczema1) is a common inflammatory
skin disease with strong heritability.2 Genome-wide association
studies (GWASs) have identified multiple loci affecting AD
risk,3 including effects on the skin barrier and immune func-
tion,2,4 and it has been demonstrated in other complex traits
that molecular mechanisms defined by GWAS loci might repre-
sent effective therapeutic targets.5
The most widely replicated genetic risk for AD lies within the
epidermal differentiation complex on chromosome 1q21.33,6,7;
this includes FLG, which encodes the skin barrier protein filag-
grin.8 Expression levels of filaggrin and its metabolites in the
outer epidermis correlate with AD activity.9,10 However, this
mechanism has not been successfully targeted in therapy develop-
ment since its discovery more than 10 years ago.
An association peak within an intergenic region on chromo-
some 11q13.5 was identified in the earliest AD GWAS.6 This
locus has been replicated in subsequent GWASs11-13 and meta-
GWASs.3,7 In addition to AD, the region is associated with mul-
tiple atopic phenotypes14,15 and other disorders characterized by
epithelial barrier dysfunction, including polyallergen sensitiza-
tion,14,16 asthma,17 allergic rhinitis,18 food allergy,19,20 eosinophil
counts,21 eosinophilic esophagitis,22 inflammatory bowel dis-
ease,23 and the gut microbiome.24 The AD-associated single
nucleotide polymorphisms (SNPs) are in an intergenic region be-
tween LRRC32 (leucine-rich repeat-containing 32), and EMSY.
LRRC32 encodes the TGF-b activator LRRC32 (UniProtKB
Q14392), previously termed glycoprotein A repititions predomi-
nant (GARP), a membrane protein that binds latent TGF-b1 onthe surfaces of activated regulatory T cells.25 LRRC32 has been
proposed as a causal gene for atopic skin inflammation,26 but
the credible SNPs identified by GWASs at this locus are all inter-
genic,3 suggesting that regulatory rather than coding variants
drive the association.
EMSY, also known as BRCA2-interacting transcriptional
repressor and previously termed C11orf30, codes for the protein
EMSY (UniProtKB Q7Z589), which is expressed in multiple hu-
man tissues, including cerebellum, breast, lung, ovary, uterus, and
skin (GTEx RNA-seq, V7). EMSY has been characterized as a
transcriptional regulator, either repressing transcription as part
of a chromatin remodeling complex or activating transcription
as part of a histone H3–specific methyltransferase complex.27
EMSY amplification is associated with DNA damage and
increased risk of malignancy in breast and ovarian tissue.27
EMSY can also play a role in inflammation because the protein
kinase AKT1 regulates the interferon response through phosphor-
ylation of EMSY,28 but its role in skin remains undefined.
We set out to investigate, using genetic and genomic data,
whether EMSY, LRRC32, or both, showed evidence of activity in
human skin cells. We then investigated the mechanism of effect
using functional and multi-omics analysis of organotypic skin,
followed by immunostaining of AD biopsy samples.METHODS
Human tissues and cells
All human tissues were obtained with written informed consent from
donors under the governance of and with ethical approval from the NHS
Research Scotland Biorepository in Tayside. Primary keratinocytes and
donor-matched primary fibroblasts were extracted from skin samples
discarded from plastic surgery procedures. AD skin samples were identified
from the hospital pathology database as consecutive unselected cases.
Demographic details are provided in the Methods section in this article’s On-
line Repository at www.jacionline.org.Cell and skin organotypic cultures
Normal human keratinocytes (NHKs) and normal dermal fibroblasts
(NDFs) were isolated from healthy breast skin by means of sequential
collagenase D and trypsin EDTA digestion, as previously described.29 NHKs
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[DMEM]/Hams F12, 10% FCS, 0.4 mg/mL hydrocortisone, 5 mg/mL insulin,
10 ng/mL epidermal growth factor [EGF], 5 mg/mL transferrin, 8.4 ng/mL
cholera toxin, and 13 ng/mL liothyronine; Sigma-Aldrich, Gillingham,
Dorset, United Kingdom) along with mitomycin C–inactivated 3T3 feeder
cells.30 EGF was omitted for the first day of culture. NDFs were cultured in
DMEM supplemented with 10% FCS under standard conditions.
Fibrin gel dermal equivalents were prepared by using a protocol adapted
from published methods.31-33 A volume of 0.5 mL fibrinogen (35 mg/mL in
NaCl; Sigma-Aldrich) and 0.5 mL of thrombin (3 U/mL in 2 mmol/L CaCl2/
1.1% NaCl; Sigma-Aldrich) were combined on ice, supplemented with
200,000 NDFs and aprotinin (0.1 U/mL; Sigma-Aldrich), and transferred
to a 12-well plate. After 30 minutes of incubation at 378C, the gels were
covered in medium (DMEM, 10% FCS, and 0.1 U/mL aprotinin) and
cultured overnight (day 1). The following day, medium was replaced with
RM medium excluding EGF, 0.1 U/mL aprotinin, and 2 3 106 suspended
NHKs (day 2). This was refreshed daily for the next 2 days (day 3 and 4)
with RM medium containing 0.1 ng/mL EGF and 0.1 U/mL aprotinin. On
day 5, gels were carefully removed from wells by using a plastic spatula
and lifted onto custom-made steel grids lined with nylon gauze (Millipore,
Livingston, United Kingdom). RM medium supplemented with 0.1 ng/mL
EGF and 0.1 U/mL aprotinin was added up to the base of the grid, enabling
the fibrin gels to be nourished from below and the epidermis cultured at the
air-liquid interface. Medium was refreshed every other day until day 12
when the cultures were analyzed. Where required, the epidermis was iso-
lated from fibrin gel after hypertonic saline–induced split (4 hours, 1 mol/
L NaCl, 48C).Small interfering RNA–mediated knockdown
NHKs were reverse transfected immediately before inclusion in the
organotypic cultures by using RNAiMax transfection reagent (Life Technol-
ogies, Carlsbad, Calif), according to the manufacturer’s instructions. Briefly,
small interfering RNA (siRNA) complexes were formed in Opti-MEM
medium (20mmol/L siRNA and 5mL of RNAiMAX) and, after 20 minutes of
incubation, combined with 2 3 106 suspended NHKs and transferred to the
preprepared dermal substrate. A pool of 4 siRNA duplexes was used
(EMSY: LQ-004081-00-0002, FLG: LQ-021718-00-0002, control:
ON-TARGETplus nontargeting siRNA #4 D.001810-04-20; Dharmacon, La-
fayette, Colo).EMSY overexpression in primary keratinocytes
A second-generation lentiviral system was used, as follows. Pseudoviral
particles were prepared with psPAX2 packaging (catalog no. 12260;
AddGene, Watertown, Mass) and pMD2.G plasmid (catalog no. 12259;
AddGene), which were cotransfected with the control pLenti-C-mGFP-P2A-
puromycin–tagged cloning vector (catalog no. PS100093; OriGene, Rock-
ville, Md) plasmid or with the Lenti-ORF clone of mGFP-tagged-human
chromosome 11 open reading frame 30 (C11orf30; catalog no. RC216916L4;
OriGene) plasmid with Lipofectamine-3000 transfection reagent (catalog no.
L3000008; Invitrogen, Carlsbad, Calif), according to the manufacturer’s pro-
tocol, into 293T packaging cells for 16 hours. The nextmorning, the cells were
washed twice with PBS to remove excess plasmid DNA, and the medium was
replaced with virus-producing medium (20% FBS/DMEM). Forty-eight, 72,
and 96 hours after transfection, the first, second, and third viral supernatants
were harvested. Viral supernatants were spun down at 1200 rpm for 15minutes
and filtered with a 0.45-mm filter.
Primary human keratinocytes from donor skin were transduced twice.
The first transduction was in RMmedium without EGF. After treatment, the
keratinocytes with trypsin and 13 106 cells/well were mixed with 10mg/mL
Polybrene (hexadimethrine bromide; catalog no. H9268; Sigma-Aldrich)
and 1 or 2 mL of viral supernatant and then plated onto 6-well plates and
cultured overnight. The second transduction was performed in monolayer
culture using RM medium without EGF, 10 mg/mL Polybrene, and 1 or
2 mL of viral supernatant. Cells were incubated for 90 minutes at 378C, fol-
lowed by centrifugation at 1200 rpm. To eliminate excess virus, cells werewashed twice with PBS, and the medium was replaced with RM media
(3:1 DMEM/Hams F12, 10% FCS, 0.4 mg/mL hydrocortisone, 5 mg/mL in-
sulin, 10 ng/mL EGF, 5 mg/mL transferrin, 8.4 ng/mL cholera toxin, and
13 ng/mL liothyronine). Fresh RM medium was replaced every second
day, and samples were harvested on day 10 after transduction as a differen-
tiated culture.Fluorescent dye penetration
Fifty microliters of 1 mmol/L Lucifer yellow dye (Sigma-Aldrich) was
added to the epidermal surface of the organotypic culture and incubated at
378C for 4 hours. Metal cloning rings were used to control uniform dosing on
the epidermal surface. Lucifer yellow was removed, and the organotypic
cultures were washed in PBS before formalin-fixed paraffin embedding under
standard conditions. Four-micrometer sections were deparaffinized, counter-
stained with 49-6-diamidino-2-phenylindole dihydrochloride (1 mg/mL for
10 minutes; Life Technologies, Carlsbad, Calif), and imaged with a confocal
Zeiss LSM710 microscope (Zeiss, Oberkochen, Germany). Quantification of
dye penetration in the upper dermis (average intensity in the upper 40mm)was
performed with Zeiss Zen software and compared by using paired t tests.Transepidermal water loss
Organotypic cultures were equilibrated at room temperature and atmo-
spheric conditions for 30 minutes before transepidermal water loss (TEWL)
was measured at 2 locations on the epidermal surface with an AquaFlux
AF200 instrument (Biox Systems, London, United Kingdom) with a custom
(5 mm in diameter) probe head. TEWL measurements were taken every
second for a minimum of 60 seconds until a stable reading, as determined by
using the software, was obtained.Capacitance
Organotypic cultures were equilibrated at room temperature and atmo-
spheric conditions for 30 minutes before measurement of epidermal surface
capacitance as a measure of water content with a Corneometer (Courage and
Khazaka, Cologne, Germany). Three measurements were recorded from each
organotypic culture, and the mean was calculated.Protein data analysis
Network analysis was performed by using Ingenuity Pathway Analysis
(Qiagen Ingenuity, version 01-12; Qiagen, Hilden, Germany). Gene ontology
(GO) enrichment analysis was performed in the Gene Ontology Consortium
online tool by using PANTHER classification http://www.geneontology.org/
page/go-enrichment-analysis (accessed August 28, 2018). A volcano plot
was generated in R/ggplot2 by using human proteins detected in all 4 of the
replicates to calculate the fold change (nontargeting control/EMSY knock-
down) for each donor with log10 transformation and a t test for significance.Lipid staining
Frozen sections of skin organotypic samples were cut and air-dried onto
slides before formalin fixation and rinsing with 60% isopropranol. Oil Red O
(Sigma-Aldrich) working solution was freshly prepared, and sections were
stained for 15 minutes, rinsed with 60% isopropanol, and then lightly
counterstained with alum hematoxylin before a final rinse with distilled water.
Additional Methods are described in this article’s Online Repository at
www.jacionline.org.RESULTS
Genomic data support EMSY and LRRC32 as
candidate genes in skin
The AD-associated SNPs at the chromosome 11q13.5 locus are
approximately 27 kb downstream of EMSY (Human Genome
FIG 1. Regulatory features of the AD risk locus and adjacent genes on chromosome 11q13.5. Genes (blue)
flanking the locus with multiple disease-associated SNPs (green) were identified by using a GWAS. EMSY
has a protein-coding region spanning 106 kb, with 20 exons producing 18 splice variants. LRRC32 spans 13
kb, including 3 exons. The location of the credible set of AD-associated SNPs3 is marked. H3K27ac marks
(pink) and DNase I hypersensitivity data (gray) are from the Encyclopedia of DNA Elements (ENCODE; ac-
cessed June 2018). Regulatory features in the same region of chromosome 11 are from Ensembl
(GRCh38.12, accessed April 2019).
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approximately 77 kb downstream of LRRC32 (Human Genome
Nomenclature Committee: 137207, ENSG00000137507). The
credible set identified by mapping this locus lies entirely within
an intergenic region (Fig 1). Encyclopedia of DNA Elements
(ENCODE) and Ensembl data predict multiple regulatory fea-
tures within the region of disease risk SNPs, and there are putative
promoters upstream of each gene (Fig 1). Focusing on skin, there
are histone H3K27ac marks indicating active enhancers or pro-
moters in NHKs in the AD risk locus and at the 39 end of
EMSY but not LRRC32 (Fig 1).
Enhancer-promoter interactions can occur by proximity in
3-dimensional space34 and show cell lineage specificity35;
therefore we reanalyzed 2 sets of genome-wide chromosome
conformation capture and high-throughput sequencing (Hi-C)
data from NHKs, to identify regions of DNA showing
interaction in 3-dimensional space. Interrogation of Hi-C
data36 shows that the intergenic SNPs, as well as EMSY and
LRRC32 all lie within a single topologically associated domain
in keratinocytes (see Fig E1 in this article’s Online Repository
at www.jacionline.org), supporting a possible functional
interaction. Analysis of promoter-capture Hi-C37 in
differentiating keratinocytes showed evidence of interaction
between the promoter region of LRRC32 and the intergenic
SNP locus, but these data were not sufficiently detailed to
determine whether EMSY also shows conformational
interaction (see Fig E1).
Gene expression data38 and our own single-molecule
RNA-sequencing analysis39 confirm expression of each gene in
the skin, but there is no significant difference in EMSY or
LRRC32 mRNA abundance in atopic skin compared with
nonatopic control skin (P >.05, see Fig E2 in this article’s Online
Repository at www.jacionline.org). However, EMSY is more
highly expressed in skin than LRRC32 at the protein level
(https://www.proteinatlas.org/), and it has not previously been
studied in keratinocyte biology; therefore EMSY was selected
for further detailed investigation.EMSY knockdown in a skin organotypic model
enhances barrier function
To investigate a functional effect of EMSY in skin, we used
primary human keratinocytes seeded onto a dermal equivalent,
which forms an organotypic model with stratified layers that
effectively recapitulate the structure and gene expression
patterns of human skin.40 The model also demonstrates
functional parameters controlling the entry and exit of small
molecules, and this can be used to quantify effects on barrier
formation and function.41 siRNA knockdown of EMSY
expression was achieved by means of transfection of
keratinocytes immediately before seeding onto the dermal
equivalent. Knockdown was confirmed at the mRNA and
protein levels, persisting to 10 days in organotypic culture
(Fig 2, A-C). Equivalent effects were seen by using individual
and pooled siRNAs (see Fig E3 in this article’s Online
Repository at www.jacionline.org). EMSY knockdown
produced a marked phenotypic change (Fig 2, D), including
thickening of the epidermal cell layer and stratum corneum
(Fig 2, E). There was an increase in the number of layers
within the stratum corneum and the frequency of
corneodesmosomes (Fig 2, F). The stratum granulosum, the
site of filaggrin expression,8 was also more prominent
(Fig 2, D), and increased filaggrin expression was confirmed
by using quantitative PCR (qPCR; n 5 7 replicates,
mean 6 SEM fold change 5 2.00 6 0.41 compared with
the nontargeting control) and Western blotting (n 5 7,
mean fold change 5 1.97 6 0.22; Fig 2, G).
In our skin culture model stratum corneum hydration, TEWL,
and Lucifer yellow dye penetration progressively decrease as the
skin barrier is formed (see Fig E4 in this article’s Online Repos-
itory at www.jacionline.org).EMSY knockdown in the skin model
resulted in a reduction in stratum corneum hydration (Fig 3, A), a
reduction in TEWL (Fig 3, B), and a reduction in penetration of
the Lucifer yellow dye (Fig 3, C and D), which is in keeping
with enhanced and accelerated barrier development compared
with control siRNA treatment.
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FIG 2. Biochemical and histologic effects of EMSY knockdown in a skin organotypic model in vitro. A, qPCR
showing knockdown of EMSY mRNA after 10 days in culture (7 days after lifting to the air-liquid interface)
normalized to a nontargeting control–treated sample (n 5 7, mean 36% reduction compared with the non-
targeting control). B and C,Western blot showing knockdown of EMSY protein after 10 days in culture (Fig 2,
B) and densitometry to quantify protein knockdown normalized to a nontargeting control (Fig 2, C; n5 7).D,
Appearance of organotypic cultures showing an increased granular layer and thickened stratum corneum in
response to EMSY siRNA knockdown; representative images were replicated in 10 independent donor ex-
periments. Scale bar 5 25 mm. E, Relative thickness of epidermal layers (n 5 10). F, Transmission electron
microscopy of stratum corneum showing thickness of the stratum corneum (white arrows)with an increase
in the number of layers and number of corneodesmosomes (black arrowheads). G, Western blot showing
filaggrin expression in skin organotypic cultures untreated (mock) and treated with nontargeting siRNA,
FLG siRNA, and EMSY siRNA 7 days after lifting to the air-liquid interface. **P < .001 and ***P < .0001,
paired t test. GAPDH, Glyceraldehyde-3-phosphate dehydrogenase; NT, nontargeting control siRNA. Bars
show means and SEMs.
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FIG 3. Functional effects of EMSY knockdown in the skin organotypic model. A, Water content of the stra-
tum corneummeasured by capacitance on the skin surface (n5 5). ***P < .0001, paired t test. B,Water evap-
oration from the epidermal surface measured as TEWL (n 5 5). C, Visualization of fluorescent dye
penetration through the epidermis and dermis after 4 hours in skin organotypic cultures developed for 3,
5, and 7 days after lifting to the air-liquid interface. Representative images are from experiments replicated
in 5 independent donor experiments. D, Overexpression of EMSY in primary human keratinocytes and
concomitant reduction in expression of differentiation markers (n 5 5).
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FIG 4. Functional effects of EMSY knockdown in a skin organotypic model. Overexpression of EMSY in pri-
mary human keratinocytes (A) and concomitant reduction in expression of differentiation markers at the
mRNA (B) and protein (C and D) levels (n 5 3). Quantification of protein blots by using densitometry is
shown in Fig E5. GAPDH, Glyceraldehyde-3-phosphate dehydrogenase; GFP, green fluorescent protein.
FIG 5. Proteomic analysis of EMSY knockdown in a skin organotypic model. A, Volcano plot showing mean
fold change in 4 biological replicate samples comparing the nontargeting (NT) control siRNA–treatedmodel
with EMSY siRNA knockdown. t Test results are color coded red (P < .05), orange (fold change <_ 2.5 or >_ 0.5),
or green (P < .05 and fold change >_ 2.5 or <_ 0.5). B, Ingenuity Pathway Analysis (Qiagen) of proteins consis-
tently upregulated or downregulated (0.5 >_ fold change >_ 2.5) in 3 ormore of 4 biological replicates, showing
proteins defective in monogenic skin diseases with similarities to AD, including ichthyoses,42-45 hyperker-
atosis,46 or skin fragility47,48 (red asterisks) and an enhancement of pathways predicted to inhibit the devel-
opment of dermatitis, hyperkeratosis, and hair disorders (blue cogwheels).
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In contrast to the phenotype observed with EMSY knockdown,
overexpression of EMSY in primary human keratinocytes
resulted in a reduction in multiple markers of differentiation
and barrier formation at the mRNA and protein levels
(Fig 4 and see Fig E5 in this article’s Online Repository at
www.jacionline.org).Proteomic analysis reveals pathways inhibiting the
development of dermatitis
To assess in more detail the EMSY knockdown phenotype, we
applied tandem mass spectrometric global proteomic analysis
(MS/MS) to donor-matched control and EMSY knockdown
organotypic experiments from 4 independent donors. Total
epidermal protein extracts were fractionated by using high-pH
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FIG 6. Lipid and ultrastructural analyses of EMSY knockdown in the skin organotypic model. A, Lipid stain-
ing of skin organotypic samples treated with nontargeting (NT) siRNA control and EMSY siRNA and Oil Red
O stain neutral lipids B, Mass spectrometric lipid analysis showing a greater abundance of ceramides with
longer chain length in EMSY siRNA–treated organotypic skin compared with a nontargeting siRNA control.
The x-axis shows nonhydroxy fatty acid carbon chain length (n 5 5 biological replicate samples). Lines
show the best fit of the linear model and 95% CIs (shaded areas). P values are for the term in the linear model
for lipid chain length. C, Transmission electron microscopy: osmium tetroxide postfixed and stained,
showing increased size of desmosomal structures (arrows) in the EMSY knockdown skin model. Scale
bar 5 1 mm.
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etry, which identified more than 9000 proteins per sample (see
Fig E6 in this article’s Online Repository at www.jacionline.
org). qPCR and Western blotting confirmed knockdown of
EMSY in each sample. A greater proportion of proteins showed
increased rather than decreased expression on EMSY knockdown
(Fig 5, A), indicating that EMSY’s predominant role is as a tran-
scriptional repressor in this tissue.
Data were filtered for proteins showing changes in the same
direction consistently across all 4 biological replicates and fold
changes of 2.5 or greater (n5 154 proteins) or 0.5 or less (n5 130
proteins) in at least 3 of 4 of the biological replicates. Consistent
direction of change was used as a criterion to focus analysis on
changes of relevance toEMSY knockdown and showing reproduc-
ibility across different donors to minimize any effect of interindi-
vidual differences.
GO analysis of the upregulated proteins showed enrichment for
the biological processes termed establishment of the skin barrier
(GO: 0061436), skin development (GO: 0043588), regulation of
water loss through the skin (GO: 0033561), and cornification
(GO: 0070268; each false discovery rate: P <_ .037). GO analysis
of the downregulated proteins showed enrichment of cellularcomponents termed cytosol (GO: 0005829), the mitochondrial
membrane (GO: 0031966), and the Golgi membrane (GO:
0000139; each false discovery rate: P <_ .010). The full lists of
GO terms defined by using this analysis are shown in Fig E7 in
this article’s Online Repository at www.jacionline.org.
Pathway analysis (Ingenuity, version 01-12; Qiagen) identified
upregulation of pathways predicted to inhibit the development of
dermatitis and ichthyosis (Fig 5, B).42-48 Differential expression
levels of proteins from these pathways were tested for validation
by using qPCR,Western blotting, and/or immunostaining of orga-
notypic skin. All positive and negative findings and untested pro-
teins are displayed in Fig E8 in this article’s Online Repository at
www.jacionline.org.EMSY knockdown increases long-chain ceramides
Organotypic samples showed an increase in abundance of
epidermal lipid staining with EMSY knockdown (Fig 6,A), which
is in keeping with the increase in levels of proteins involved with
lipid metabolism (eg, STS, ALOXE3, ALOX12B, and APOE).
Mass spectrometric lipid analysis showed an increase in long-
chain ceramides and esterified omega-hydroxy-ceramides species
FIG 7. EMSY localization in skin of patients with and without AD. Immunohistochemistry showing EMSY
staining in a predominantly basal distribution in normal human skin in contrast to nuclear staining
extending throughout the epidermis in AD lesions. Representative images are taken from a tiled image of
the whole specimen viewed by using Deep Zoom. Scale bar 5 approximately 20 mm.
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are the ceramides that have previously been reported to show a
reduction in AD skin samples.49EMSY knockdown increases cell-cell adhesion
structures
Ultrastructural analysis demonstrated an increase in desmo-
some size (Fig 6, C), which is consistent with the observed in-
crease in desmocollin 1 levels. An increase in the number of
layers within the stratum corneum was also observed, which is
consistent with the increase in corneodesmosin levels (Fig 2, F,
and see Fig E9 in this article’s Online Repository at www.
jacionline.org).EMSY shows predominantly nuclear localization in
the skin affected by AD
To investigate EMSY expression in human skin samples, we
compared 18 normal control skin samples and biopsy specimens
from 14 patients with spongiotic dermatitis, AD, or both. Immu-
nohistochemistry showed considerable interindividual variabilityin EMSY staining, despite careful standardization of staining con-
ditions, and there was no consistent difference in total intensity
between cases and control subjects (see Fig E10 in this article’s
Online Repository at www.jacionline.org). However, all 14 AD
cases showed greater nuclear than cytoplasmic staining, and 12
(86%) of 14 cases showed predominantly nuclear staining extend-
ing throughout the epidermis compared with 2 (11%) of 18 con-
trol subjects (example images are shown in Fig 7, and all images
are shown in Fig E10). Similarly, control organotypic samples
showed EMSY staining in nuclei throughout the epidermis,
whereas the organotypic cultures with EMSY knockdown showed
expression predominantly in the basal epidermis in keratinocyte
nuclei. Thus increased nuclear expression is consistent with
increased activity of EMSY as a transcriptional regulator within
keratinocytes in lesional skin of patients with AD.DISCUSSION
GWASs have provided valuable insight into the pathogenic
mechanisms of many common complex traits, and some have
been exploited for targeted therapy development.5,50,51 Howev-
er, many of the loci identified by GWASs are intergenic, and
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performed in disease-relevant tissue to characterize important
pathomechanisms.52 Increasing understanding of the regulato-
ry features in intergenic DNA53,54 provides insight into
possible effector genes, either locally or distant from variants
identified by GWAS. Skin as an organ that can be cultured
in vitro offers an opportunity to investigate genetic mecha-
nisms using primary cells, quantification of barrier function,
and detailed molecular analyses. Cells extracted from normal
human skin have been used in our model to investigate the ef-
fect of a single candidate gene without the multiple genetic and
epigenetic effects that would be coinherited in cells harvested
from a patient with AD.2 Use of primary cells more closely
represents skin physiology than an immortalized cell line,
and replication in multiple donors is used to control for inter-
individual variation.
Our findings from genomic data and in vitro and ex vivo ana-
lyses converge to provide an understanding of the role of
EMSY in skin barrier function. The epigenetic regulatory mech-
anisms indicated by methylation and chromosomal confirmation
(Fig 1) provide a possible mechanism by which the intergenic
SNPs associated with AD can affect EMSYexpression. However,
additional epigenetic mechanisms,55 including other forms of his-
tone modification, micro-RNAs, and long noncoding RNAs,
might also play roles in EMSY transcriptional control. The greater
nuclear localization of EMSYin lesional skin of patients with AD
indicates increased activity of this transcriptional repressor. This
is in keeping with our findings in primary cell cultures, where
EMSY overexpression leads to a reduction in levels of multiple
proteins that have previously been shown to be biomarkers for
AD.56-58 Improvements in analytic capacity have increased un-
derstanding of the importance of lipid composition in epidermal
physiology and pathophysiology, including atopic disease,59
and the observed increase in relevant lipid species emphasizes
the role of EMSY in controlling multiple aspects of skin barrier
function.
It is interesting to note that EMSY knockdown increases filag-
grin expression, whereas EMSYoverexpression leads to a marked
reduction in profilaggrin levels. This might in part explain the
observation that the genetic risk variants in chromosome
11q13.5 and FLG show a multiplicative effect in population anal-
ysis.60 Chromosome 11q13.5 and the FLG locus also both show
their strongest associations within a subgroup of early-onset
and persistent AD in childhood,61 which is in keeping with their
combined effect leading to a more severe phenotype.
EMSY loss-of-function mutations are rare: they are detected in
1/60,000 unrelated subjects in the Exome Aggregation Con-
sortium,62 the minor allele frequency is approximately 0.001 in
the Exome Variant Server,63 and there are no homozygous loss-
of-function genotypes identified in gnomAD.64 This is consistent
with our finding that even a modest reduction in expression (mean
approximately 33% reduction in mRNA or protein in our experi-
mental model) results in a marked phenotypic change in organo-
typic cultures.
Together, these observations indicate that loss-of-function
mutations are likely to have a deleterious effect, and more
subtle modulation of EMSY expression is required for optimal
skin barrier function. Therefore it is tempting to speculate that
the control of FLG expression and skin barrier function
through EMSY might be a more sensitive mechanism to
exploit than targeting filaggrin directly. It might also be amore tractable target because the therapeutic effect would be
achieved by knockdown of EMSY rather than attempting to in-
crease expression of filaggrin.
Loci reaching statistical significance in genome-wide ana-
lyses might reflect the combination of more than 1 functional
association, and multieffect loci have been observed in patients
with AD, as well as other complex traits.12,65 Our finding of a
role for EMSY in keratinocytes does not preclude an additional
effect of EMSY through expression in T cells,66 which are known
to play a key role in AD pathogenesis.2 Intriguingly, immunohis-
tochemistry also reveals EMSY staining within the nuclei of
cells in the dermis (Fig 6 and see Fig E10). This might represent
an inflammatory infiltrate, including T cells, and warrants
further investigation. Similarly, the genomic promoter-capture
Hi-C analysis (see Fig E1) provides more support for a possible
promoter-promoter interaction between the GWAS locus and
LRRC32 than EMSY, suggesting that an effect through
LRRC32 expression in keratinocytes or T cells might also play
a role in the pathogenesis of AD. Further work, including
high-resolution 3C,67 could be used to finely map these impor-
tant regulatory interactions.
Expression quantitative trait locus analysis is an approach
that has been used to investigate genes responsible for risk
mechanisms attributable to intergenic loci.68 However, expres-
sion quantitative trait locus analysis relies on the genetic var-
iants having a quantitative effect on mRNA abundance of
sufficient magnitude to be detected with a suitably stringent
level of statistical significance.69 Other mechanisms can affect
disease risk without substantially altering the total amount of
mRNA, such as protein localization at a functional site, as ap-
pears to be the case for EMSY. Furthermore, EMSY has at least
7 isoforms produced by alternative splicing, as well as 14 an-
notated phosphorylation or glycosylation sites (https://www.
uniprot.org/uniprot/Q7Z589); it is likely that these mecha-
nisms also contribute to functional regulation in different
cell and tissue types.
Analysis of a single cell type, the keratinocyte, at different
stages of terminal differentiation represents a reductionist view of
the epidermis, but the skin organotypic model has proved to be a
valuable model for investigation of molecular mechanisms
controlling differentiation in this multilayered tissue.40,70
A limitation to the model is that the various dermal appendages
(eg, hair follicles, sweat glands, and sebaceous glands) are absent,
as are the dermal blood vessels and neurons, although these might
play a role in skin inflammation.71,72 Immune cells of the hemato-
poietic lineage are also missing from this model, but there is
increasing recognition of the role of keratinocytes in immune
signaling,73,74 and the organotypic culture displays innate immu-
nologic mechanisms.
The work presented here has identified EMSYas a therapeutic
target: knockdown in vivo is predicted to improve skin barrier
function and protect against AD. However, considerable further
work is needed, including high-throughput screening to identify
molecules capable of reducing the abundance of nuclear EMSY,
followed by preclinical testing, before these findings can be as-
sessed in clinical trials. The advent of biological therapy to target
the immune component of AD has transformed care for patients
with moderate-to-severe disease,75 but therapies designed to
improve skin barrier function are also required as an alternative
or complementary approach for this complex and therapeutically
challenging disorder.
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Key messages
d Genetic risk loci offer the opportunity for insight into the
cause of complex disease, but the mechanisms require
detailed molecular investigation.
d The AD-associated locus on chromosome 11q13.5 lies be-
tween 2 candidate genes: EMSY and LRRC32.
d Our genetic, proteomic, and immunohistologic analyses
have together demonstrated a role for EMSY expression
in the control of skin barrier formation and function,
which are of importance in patients with AD.
d Therefore EMSY represents a future therapeutic target in
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variable natural history. Longitudinal birth cohort studies
provide an opportunity to define subgroups on the basis of
disease trajectories, which may represent different genetic and
environmental pathomechanisms.
Objectives: We sought to investigate the existence of distinct
longitudinal phenotypes of AD and test whether these findings
are reproducible in 2 independent cohorts.
Methods: The presence of AD was examined in 2 birth cohort
studies including 9894 children from the United Kingdom
(ALSPAC) and 3652 from the Netherlands (PIAMA). AD was
defined by parental report of a typical itchy and/or flexural
rash. Longitudinal latent class analysis was used to investigate
patterns of AD from birth to the age of 11 to 16 years. We
investigated associations with known AD risk factors, including
FLG null mutations, 23 other established AD-genetic risk
variants, and atopic comorbidity.
Results: Six latent classes were identified, representing
subphenotypes of AD, with remarkable consistency between the
2 cohorts. The most prevalent class was early-onset-early-
resolving AD, which was associated with male sex. Two classes
of persistent disease were identified (early-onset-persistent and
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964with the AD-genetic risk score as well as personal and parental
history of atopic disease. A yet unrecognized class of mid-onset-
resolving AD, not associated with FLG mutations, but strongly
associated with asthma, was identified.
Conclusions: Six classes based on temporal trajectories of rash
were consistently identified in 2 population-based cohorts. The
differing risk factor profiles and diverse prognoses demonstrate
the potential importance of a stratified medicine approach for
AD. (J Allergy Clin Immunol 2018;141:964-71.)
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In clinical practice, atopic dermatitis (AD; eczema) demon-
strates a characteristic itchy erythematous rash1 but it has a
heterogeneous presentation with variations in timing of onset,
persistence,2,3 distribution, severity, association with allergic
sensitization,4 and comorbidity with other atopic diseases.5,6
Although the classification of eczema cases into atopic and
nonatopic forms is commonplace (in part because the underlying
etiology of these may be different4), the heterogeneity of
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resolve during childhood, some persist into adulthood. We
hypothesized that divergent temporal disease patterns may be
caused by different genetic and environmental etiological
mechanisms. Understanding these differences could influence
how AD is defined and treated, paving the way for a phenotype-
driven, more personalized approach to the management of
childhood AD.
AD is a strongly heritable condition. A total of 31 risk loci have
been identified in genetic association studies, including 24 loci
that were discovered in white European populations.7-13 The car-
dinal feature of an itchy erythematous rash is central to all case
definitions for AD, but large genetic studies have used a broad
case definition, including self-reported AD over a wide age range
of pediatric and adult patients. This broad case definition has been
necessary to allow collection of the large number of cases
required for genomewide analyses, but it does not allow for
detailed substratification of AD and dictates that such studies
are powered to detect variants common across subtypes of dis-
ease, while potentially missing variants with more specific effects
on subtypes of the disease.
The aim of our study was to investigate the existence of
longitudinal subphenotypes of AD and to test whether these
findings are reproducible in 2 independent birth cohorts. We used
longitudinal latent class analysis (LLCA), a statistical technique
that can be used to model potential subgroups within a data set, to
identify different longitudinal patterns of disease. We applied
LLCA to cohorts from the United Kingdom and the Netherlands
from birth to 16 years or 11 years, respectively. We tested each
latent class for association with known genetic and nongenetic
risk factors for AD and atopic comorbidities, to investigate the
existence of distinct subgroups of disease having different
etiological and prognostic profiles.METHODS
Avon Longitudinal Study of Parents and Children
The Avon Longitudinal Study of Parents and Children (ALSPAC) is a
longitudinal population-based birth cohort study of 14,701 children fromAvon,
United Kingdom. The study protocol has been described previously14 and
further details are in this article’s Online Repository at www.jacionline.org.
Information regarding the presence/absence of rash consistentwithADwas
extracted from questionnaires completed by the mothers when the children
were aged between 6 months and 16.5 years (at 6, 18, 30, 42, 57, 69, 81, 103,
128, 140, 166, and 198 months). At each time point AD was defined as a
positive response to 1 of the following questions: ‘‘Has your child had an itchy,
dry, oozing or crusted rash on the face, forearms or shins?’’ (at age 6 months);
‘‘Has your child had a skin rash in the joints and creases of their body (e.g.
behind the knees, elbows, under the arms) in the past 6-12 months?’’ (18-
166 months); ‘‘Has your child had an itchy rash which was coming and going
for at least 6 months in the past 12 months and confined to the creases of the
knees/ankles/elbows or wrists?’’ (at 16 years).Nongenetic risk factors were selected on the basis of existing evidence for
association with AD15 and data availability in the 2 cohorts. Parental history of
AD and asthma was parent-reported in questionnaires completed by the parents
or guardians. Breast-feeding was coded as a binary variable of never versus any
breast-feeding as reported by the mother when the child was 15months old. Cat
exposurewas coded as a binary variable of 0 or 11 cats in the home, as reported
by the mother at 8 weeks’ gestation. Children were classified as asthmatic at 7
and 13 years if a parent answered ‘‘yes’’ to ‘‘Has your child had asthma in the
past 12 months?’’ Total IgE level was measured in venous blood at 7 years
and total IgE level of more than 75 kU/L was defined as elevated.
DNAwas obtained from blood and genotypes were determined according
to methods described in this article’s Online Repository at www.jacionline.
org. Individuals were categorized into 2 groups: those with and those without
any of the 4 gene encoding filaggrin (FLG) null mutations tested (ie, FLG2/2
and FLG1/2 vs FLG1/1).16 Genotypes for the remaining 23 established (and
replicated) European AD risk variants13 were combined into a score, with the
value representing a sum of the risk alleles carried across the 23 variants.
Prevention and Incidence of Asthma and Mite
Allergy
Prevention and Incidence of Asthma andMite Allergy (PIAMA) is a Dutch
multicenter birth cohort of 3963 children from allergic and nonallergic
mothers. The study protocol has been described previously17 and further de-
tails are in this article’s Online Repository at www.jacionline.org.
The International Study of Asthma and Allergies in Childhood–based
questionnaires were used to report symptoms ofADbetween age 3months and
11 years (3, 12, 24, 36, 48, 60, 72, 84, 96, 132months). At each time point, AD
was defined as a positive response to both of the following 2 questions: ‘‘Has
your child had an itching rash that was variably present in the last 12months?’’
(or ever at 3 and 12 months) and ‘‘Was this rash present around the eyes/ears,
foreside ankles, inner side knees or inner side elbows?’’ (also neck at 3 and
12 months).
Parental history of asthmawas taken from questionnaires that asked ‘‘Have
you ever had asthma?’’ Any versus never breast-feeding was assessed by
questions on infant feeding in the questionnaires administered at age 3 months
and 1 year. Cat exposure was coded as a binary variable of 0 or 11 cats in the
home at 3 months after birth. Asthma at 7 and 11 years was defined as a
parental report of a doctor’s diagnosis of asthma at any time and a parental
report of asthma in the last 12months at age 7 and 11 years. Total IgE level was
measured in venous blood at age 8 years and a level of more than 75 kU/L was
defined as elevated.
DNA was obtained from blood and mouth swabs and genotypes were
determined according tomethods described in this article’s Online Repository.
FLG genotype categorization and the non-FLG genetic risk score were con-
structed, as for ALSPAC.
Statistical analysis
LLCAwas used to investigate heterogeneity in patterns of AD. As the name
suggests, this method is applied in longitudinal settings,18,19 where the aim is to
identify distinct subgroups in longitudinal multivariate categorical data. This is
akin to cluster analysis, but is more appropriate for binary data and allows for
assignment based on probability, rather than definitive partitioning of individ-
uals into classes. Starting with a single latent class, additional classes are added
until measures that estimate model fit are optimized. Several statistical criteria
(including low Bayesian information criterion, Vuong-Lo-Mendell-Rubin like-
lihood ratio test, and entropy) were assessed to determine the optimal number of
classes; full details are given in this article’s Online Repository at www.
jacionline.org. Model fitting was carried out in Mplus version 7.0.20
Model fit was primarily assessed using only those individuals for whom
there was no missing AD symptom data. However, to optimize the use of
available data and maximize the cohort size, results were compared with
analyses that included individuals for whom data were available for 50% or
more of the time points studied (>_6 of the 12 time points in theALSPAC cohort
and >_5 of the 10 time points in the PIAMA cohort). Association analyses
primarily focused on this larger (although incomplete) data set, but results
were compared with models from the smaller but more complete data set.
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tested using a manual implementation of the bias-adjusted 3-step analysis.21
This method accounts for uncertainty in class assignment (see this article’s
Online Repository at www.jacionline.org). Associations with established
risk factors (sex, family history of atopy, breast-feeding, presence of pet cat
in the household, FLG loss-of function mutation, genetic risk score of 23 es-
tablished white European AD variants) were tested using multinomial regres-
sion, whereas atopic comorbidities (asthma at ages 7 and 11 or 13 years;
elevated IgE level at age 7 or 8 years) were tested using logistic regression.FIG 1. Prevalence and frequency of AD in UK and Dutch longitudinal
cohorts. Plot of frequency (right-hand axis) of AD cases (gray bars) and
controls (white bars) and AD prevalence (black points and left-hand axis)
over 12 time points in ALSPAC and 10 time points in PIAMA. AD is defined
by the presence of typical rash.RESULTS
LLCA in the ALSPAC cohort
The prevalence of AD in the ALSPAC cohort declined over
time (Fig 1, A) from 27% in the first year of life to 7% at age
16.5 years. Data were available from all 12 time points for a total
of 3480 individuals. The 6-class model was considered the best fit
to the data (as defined by the lowest Bayesian information crite-
rion); however, only small improvements were seen between
the 4-class and the 6-class models (see Table E1 and Fig E1 in
this article’s Online Repository at www.jacionline.org). We pre-
sent the results of the 6-class model as the primary analysis, but
show the results for the simpler 4-class model in this article’s On-
line Repository at www.jacionline.org, which for most analyses
produced very similar results.
A total of 9894 individuals had data available from at least 6 of
the 12 time points and the model fit parameters were broadly
consistent with the smaller but more complete data set (Table E1).
Comparison of models from the larger incomplete and smaller but
complete data sets showed that the prevalence patterns of AD by
class were very similar (see Table E3 in this article’s Online Re-
pository at www.jacionline.org) and only 3% of children (116 of
3480) changed best-fit class between the 6-class models in each
analysis (see Table E2 in this article’s Online Repository at
www.jacionline.org).
Fig 2,A, shows the estimated prevalence of a rash characteristic
of AD at each time point across the 6 classes in the analysis of
9894 individuals. Descriptions of the classes alongside the labels
we gave each class are given in Table I.
The estimated prevalence of a rash characteristic of AD at each
time point for the 4-class model is displayed in Fig E3 in this ar-
ticle’s Online Repository at www.jacionline.org. The 4 classes
can be described as follows: unaffected individual or transient
AD (61.9%); early-onset-persistent AD (10.7%); early-onset
AD resolving by age 11 years (16.5%); later-onset AD after age
3.5 years (10.9%). These 4 classes show substantial overlap
with the 6-class assignment (see Table E4 in this article’s Online
Repository at www.jacionline.org).LLCA in the PIAMA cohort
The prevalence of AD in the PIAMA cohort declined only
slightly from 18% in the first year of life to 14% by age 11 years
(Fig 1, B). Data were available from all 10 time points for 2063
individuals. A total of 3652 individuals had data available from
at least 5 of these time points, and we present the results from
the analysis of this larger incomplete data set. LLCA model fit
was similar to ALSPAC, with lowest Bayesian information
criteria achieved between the 4-class and 6-class models (see
Table E5 and Fig E2 in this article’s Online Repository at www.
jacionline.org), the resulting class patterns following a remark-
ably similar pattern to ALSPAC (Fig 2, B; see Fig E4 in thisarticle’s Online Repository at www.jacionline.org), with compa-
rable class prevalences (Table I and Fig 1, B).
As for ALSPAC, we present association results for the 6-class
model as the primary analysis because this showed best fit.
Comparison of assignment between 4- and 6-class models is
shown in Table E7 in this article’s Online Repository at www.
jacionline.org and association results from the 4-class model
are also shown in this article’s Online Repository.Associations between latent classes with family
history and selected environmental risk factors
The associations of 6 classes with potential AD risk factors are
summarized in Table II. The results from the smaller but complete
data set and the 4-classmodels are presented in Tables E9 and E10
in this article’s Online Repository at www.jacionline.org. Similar
conclusions could be drawn from these models, unless otherwise
specified.
In ALSPAC, taking the ‘‘unaffected or transient AD’’ class as
the baseline category, being female was a risk factor for the early-
onset-persistent, mid-onset, and late-onset classes, the strongest
association being with the late-onset class (odds ratio [OR], 1.90;
95% CI, 1.48-2.44; P5 43 1027). However, male sex was a risk
factor for the early-onset-early-resolving class (OR, 1.33; 95%
CI, 1.10-1.61; P 5 .004). A similar pattern was observed in
PIAMA, where the strongest association with female sex was
observed with the late-onset group (OR, 1.87; 95% CI, 1.21-
2.90; P5 .005) and there was evidence of an association between
male sex and early-onset-early-resolving class.
Maternal history of AD was associated with all classes in
ALSPAC,with the strongest association in the persistent class (OR,
3.16; 95% CI, 2.60-3.83; P5 43 10231). A similar pattern (albeit
with weaker evidence for all classes) was observed in ALSPAC for
FIG 2. Longitudinal classes identified using LLCA in 2 independent birth cohorts: A, ALSPAC (n5 9894) and
B, PIAMA (n 5 3652).
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PATERNOSTER ET AL 967maternal history of asthma, where again the strongest association
was with the persistent class (OR, 1.54; 95% CI, 1.22-1.95;
P5 33 1024). Paternal history of asthma showed a similar asso-
ciationwith this class (OR, 1.59), but the smaller sample sizemeant
there was less evidence for this result (P5 .139). Paternal asthma
also showed association with the early-onset-late-resolving class
(OR, 2.53; 95% CI, 1.30-4.91; P 5 .006). In PIAMA the
associations with maternal and paternal history of asthma
were similar, with strong associations with the persistent and
early-onset-late-resolving groups for maternal history (OR, 1.94,
95% CI, 1.11-3.40, P 5 .021, and OR, 3.14, 95% CI, 1.76-5.61,
P 5 1 3 1024, respectively) and with the persistent group for
paternal history (OR, 2.69; 95% CI, 1.66-4.36; P5 63 1025).
In ALSPAC, breast-feeding was associated with a higher risk of
persistent and early-onset-late-resolving AD (OR, 1.42, 95% CI,
1.11-1.81, P5 .006, and OR, 1.53, 95% CI, 1.12-2.08, P5 .008,
respectively). There was little evidence of association with mid-
or late-onset classes. In PIAMA, there was little evidence for
breast-feeding being associated with any class.
Early-life exposure to a pet cat was not associated with any of
the latent classes in the primary analyses for ALSPAC or PIAMA.
However, this was the only risk factor in which a difference was
seen in the complete-case results in ALSPAC, where there was
some evidence of a protective effect of early-life cat exposure on
the early-onset-early-resolving class only (OR, 0.64; 95% CI,0.46-0.90; P5 .010; Table E9). The same direction of effect was
observed in PIAMA but with a weaker and less precise estimate
(OR, 0.72; 95% CI, 0.50-1.04; P 5 .081).Associations between latent classes and atopic
traits and comorbidities
The associations of AD classes with elevated total IgE and
asthma are displayed in Table III. Raised IgE level was associated
with the AD classes showing prevalent disease at the time of
testing, that is, age 7 to 8 years (the persistent, early-onset-late-
resolving, and mid-onset classes in ALSPAC and the persistent
class in PIAMA).
In ALSPAC, all classes showed association with asthma at age 7
and13 years. The associationswere strongest for the persistent class
(7 years: OR, 5.50, P 5 5 3 10241; 13 years: OR, 7.19;
P 5 3 3 10246) in which 29% reported asthma at age 7 years
(compared with 8% of the normal/transiently affected class),
increasing to 31% at 13 years (compared with 7% of the normal/
transient class). The early-onset-early-resolving class showed the
smallest increased risk of asthma at age 7 and 13 years (ORs, 1.56
and 1.79, respectively). In PIAMA, the persistent and early-onset-
late-resolving group showed association with asthma at age 7 years
(persistent OR, 14.27; P5 53 10215). At age 11 years, all but the
mid-onset-resolving group were associated, again the strongest
TABLE I. Descriptions and prevalences of the classes in 2 independent cohorts
Class Description of class in ALSPAC ALSPAC prevalence PIAMA prevalence
Unaffected individuals or transient AD 64% of this class never had reported rash, others had 1 or 2
isolated occasions of rash; ;10% reported rash consistent
with AD at 6-18 mo and this declined with age
58.0% 62.9%
Early-onset-persistent AD At age 30 mo, ;85% of this class had reported rash, increasing
to >90% prevalence until 12 y; it then steadily declined to
;50% at 16.5 y
7.3% 4.9%
Early-onset-late-resolving AD In this class the prevalence of rash rose steeply to >95% at
30 mo and then steadily declined to ;10% by 16.5 y
7.0% 3.8%
Early-onset-early-resolving AD ;60% of children in this class had reported rash at 18 and
30 mo; this declined to 10% by 6-7 y
12.9% 15.4%
Mid-onset-resolving AD In this class there was a 10%-20% prevalence of rash until
30 mo, steeply rising to 75% prevalence at 5-6 y, and steadily
declining to <10% prevalence by 16.5 y
7.0% 6.5%
Late-onset-resolving AD In this class, ;30% reported rash at 18 mo, declining to ;10%
prevalence at 5-6 y, steadily rising to ;70% prevalence by
12 y and finally declining to 10% by 16.5 y
7.9% 6.5%
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P5 33 10211).Associations between latent classes and genetic
risk variants
In ALSPAC, all classes other than the mid-onset class
showed association with FLG null mutations (Table IV). The
strongest association was for the persistent group (OR, 4.31;
95% CI, 3.29-5.63; P5 23 10226); the other associated classes
had ORs of about half this (2.14-2.30). In PIAMA, only the
early-onset-late-resolving class was associated with FLG null
mutations (OR, 5.63; 95% CI, 2.65-11.95; P 5 7 3 1026);
however, the approximate number of FLG2/1 or FLG2/2
individuals in the PIAMA analyses was very low (between 7
and 14 individuals per class), so power was limited to identify
associations.
The combined genetic risk score encompassing all other AD
variants was associated with all but the early-onset-early-
resolving and the late-onset classes in the 6-class model in
ALSPAC. The association was strongest with the persistent class
(OR, 1.17; 95% CI, 1.12-1.22, for each additional risk allele;
P5 23 10213). A similar pattern was observed in PIAMA, with
the persistent class showing the strongest association and an
almost identical effect size to that seen in ALSPAC (OR, 1.17;
95% CI, 1.07-1.28; P 5 5 3 1024).
The associations for individual AD risk single nucleotide
polymorphism are presented in Table E11 in this article’s
Online Repository at www.jacionline.org. These analyses are
not well powered and should be interpreted with caution, but
some patterns are noteworthy. Most variants had the strongest
effects in the persistent class and 3 variants showed consistent
associations in ALSPAC and PIAMA: These were rs17881320
in STAT3, rs479844 near OVOL1, and rs6010620 in RTEL1.
One variant (rs1057258) showed evidence in ALSPAC for
association in the opposite direction to that reported previously
for AD with the late-onset and early-onset-early-resolving
classes (OR, 0.73, 95% CI, 0.57-0.93, P 5 .011, and OR,
0.80, 95% CI, 0.65-0.99, P 5 .039, respectively).
A consistent direction of effect (though with weak statistical
evidence) was observed for the late-onset class and this singlenucleotide polymorphism in PIAMA (OR, 0.74; 95% CI,
0.45-1.20; P 5 .218).DISCUSSION
Our results provide novel insights into the heterogeneity of AD
in childhood. We report 6 latent classes, representing subpheno-
types of AD with remarkable consistency between 2 independent
cohorts. The most prevalent class was early-onset-early-resolving
AD (13%-15%), which was associated with male sex. This class
has a favorable prognosis and is only very weakly associated with
asthma in later life. Two classes of persistent disease were
identified (early-onset-persistent and early-onset-late-resolving);
theseweremost strongly associated with anAD-genetic risk score
as well as personal and parental history of atopic disease.
Importantly, these classes display strong comorbidity with
asthma. A yet unrecognized class of mid-onset-resolving AD,
not associated with FLG mutations, but strongly associated with
asthma, was described. In this class, AD prevalence increases
sharply from age 2.5 years peaking at approximately 6 years.
The etiological factors in this class remain unclear because the
subgroup was not strongly associated with many of the known
risk factors, but does show strong association with asthma
comorbidity.
The clinical application of this LLCA is based on the clear
demonstration of distinct classes of AD phenotype with different
disease trajectories. The substantial diversity of disease that is
defined as ‘‘AD’’ (or ‘‘eczema’’) has long been recognized, and
clearer subdivisions are an essential prerequisite for the develop-
ment of stratified medicine approaches that will be needed for the
optimal application of novel biological therapies in the more
severe subgroups of AD. Therefore, further studies are needed to
define the most appropriate combinations of biomarkers and risk
factors to detect these subgroups prospectively and at an early
age.
There was some evidence of differential strength and presence
of associations with risk factors and comorbidities between the
classes. The early-onset-persistent class showed the strongest
associations (compared with other classes) with most well-
established risk factors and markers of severe atopic phenotype,
including FLG null mutations and a genetic risk score of other
TABLE II. Association results between risk factors and AD classes identified by LLCA
Trait
Exposed/
Total Wald P Early-onset persistent
Early-onset late-
resolving
Early-onset early-
resolving
Mid-onset
resolving
Late-onset
resolving
ALSPAC 7.3% 7.0% 12.9% 7.0% 7.9%
Female 4805/9875 6 3 10217 1.56 (1.29-1.89)
P 5 6 3 1026
0.97 (0.77-1.22)
P 5 .811
0.75 (0.62-0.91)
P 5 .004
1.79 (1.40-2.29)
P 5 4 3 1026
1.90 (1.48-2.44)
P 5 4 3 1027
Maternal eczema 3154/9722 3 3 10243 3.16 (2.60-3.83)
P 5 4 3 10231
1.68 (1.32-2.14)
P 5 2 3 1025
2.00 (1.65-2.44)
P 5 4 3 10212
1.66 (1.29-2.13)
P 5 8 3 1025
1.75 (1.36-2.25)
P 5 1 3 1025
Maternal asthma 1554/9721 2 3 1024 1.54 (1.22-1.95)
P 5 3 3 1024
1.43 (1.08-1.91)
P 5 .014
1.23 (0.95-1.58)
P 5 .112
1.10 (0.79-1.53)
P 5 .566
1.02 (0.73-1.44)
P 5 .891
Paternal asthma 245/1568 .030 1.59 (0.86-2.93)
P 5 .139
2.53 (1.30-4.91)
P 5 .006
1.58 (0.86-2.89)
P 5 .139
0.94 (0.38-2.33)
P 5 .893
1.72 (0.83-3.57)
P 5 .146
Breast-feeding 7019/9198 9 3 1024 1.42 (1.11-1.81)
P 5 .006
1.53 (1.12-2.08)
P 5 .008
1.22 (0.97-1.54)
P 5 .093
1.04 (0.78-1.37)
P 5 .803
1.04 (0.78-1.38)
P 5 .800
Pet cat 2963/9511 .179 0.88 (0.71-1.09)
P 5 .226
1.14 (0.89-1.45)
P 5 .291
0.92 (0.74-1.13)
P 5 .427
0.81 (0.61-1.06)
P 5 .125
1.26 (0.98-1.62)
P 5 .073
PIAMA 4.9% 3.8% 15.4% 6.5% 6.5%
Female 1759/3652 .025 1.06 (0.75-1.49)
P 5 .743
0.63 (0.40-1.00)
P 5 .051
0.89 (0.64-1.24)
P 5 .494
0.94 (0.65-1.37)
P 5 .753
1.87 (1.21-2.90)
P 5 .005
Maternal asthma 259/3645 .001 1.94 (1.11-3.40)
P 5 .021
3.14 (1.76-5.61)
P 5 1 3 1024
1.33 (0.70-2.51)
P 5 .385
0.96 (0.41-2.24)
P 5 .932
1.38 (0.65-2.93)
P 5 .406
Paternal asthma 272/3633 .002 2.69 (1.66-4.36)
P 5 6 3 1025
0.91 (0.34-2.46)
P 5 .854
1.19 (0.63-2.25)
P 5 .585
1.72 (0.94-3.14)
P 5 .076
1.17 (0.53-2.61)
P 5 .697
Breast-feeding 2984/3614 .888 1.00 (0.63-1.56)
P 5 .983
1.34 (0.70-2.57)
P 5 .377
1.19 (0.75-1.89)
P 5 .461
0.97 (0.60-1.56)
P 5 .886
0.88 (0.52-1.48)
P 5 .634
Pet cat 1213/3651 .151 0.73 (0.50-1.06)
P 5 .098
0.80 (0.50-1.29)
P 5 .367
0.72 (0.50-1.04)
P 5 .081
1.0 (0.68-1.47)
P 5 .996
0.67 (0.42-1.07)
P 5 .094
‘‘Wald P’’ is for the overall omnibus test. Individual P values and effect sizes (OR and 95% CI) comparing each class with the ‘‘unaffected/transient’’ class are also shown; results
P < .05 are shown in boldface.
TABLE III. Association results between AD classes identified by LLCA and comorbidities
Trait Cases/Total Wald P
Early-onset
persistent
Early-onset
late-resolving
Early-onset
early-resolving
Mid-onset
resolving
Late-onset
resolving
ALSPAC 7.3% 7.0% 15.4% 7.0% 7.9%
Asthma at age 7 y 904/7859 2 3 10250 5.50 (4.28-7.05)
P 5 5 3 10241
3.08 (2.22-4.27)
P 5 2 3 10211
1.56 (1.09-2.24)
P 5 .015
2.23 (1.53-3.26)
P 5 3 3 1025
1.89 (1.26-2.83)
P 5 .002
Asthma at age 13 y 784/6752 7 3 10258 7.19 (5.48-9.42)
P 5 3 3 10246
3.59 (2.51-5.12)
P 5 2 3 10212
1.79 (1.20-2.65)
P 5 .004
3.41 (2.35-4.96)
P 5 1 3 10210
2.01 (1.30-3.12)
P 5 .002
Elevated IgE
level at age 7 y
2057/4790 8 3 10216 2.62 (1.98-3.47)
P 5 1 3 10211
1.92 (1.38-2.68)
P 5 1 3 1024
1.15 (0.88-1.51)
P 5 .310
1.55 (1.10-2.18)
P 5 .013
1.38 (0.99-1.93)
P 5 .059
PIAMA 4.9% 3.8% 15.4% 6.5% 6.5%
Asthma at age 7 y 94/3349 2 3 10215 14.27 (7.33-27.78)
P 5 5 3 10215
5.92 (2.31-15.16)
P 5 2 3 1024
3.03 (1.08-8.47)
P 5 .035
0.60 (0.03-13.62)
P 5 .750
1.73 (0.38-7.88)
P 5 .478
Asthma at age 11 y 102/2639 7 3 10211 15.35 (6.86-34.35)
P 5 3 3 10211
9.12 (3.49-23.82)
P 5 6 3 1026
4.91 (1.66-14.55)
P 5 .004
2.10 (0.42-10.53)
P 5 .366
5.70 (1.98-16.43)
P 5 .001
Elevated IgE
level at age 8 y
723/1707 1 3 1024 3.00 (1.85-4.86)
P 5 8 3 1026
1.58 (0.86-2.89)
P 5 .140
1.57 (0.97-2.56)
P 5 .067
1.42 (0.83-2.46)
P 5 .203
0.97 (0.53-1.77)
P 5 .914
‘‘Wald P’’ is for the overall omnibus test. Individual P values and effect sizes (OR and 95% CI) comparing each class with the ‘‘unaffected/transient’’ class are also shown; elevated
IgE level is defined as total IgE level of >75 kU/L; results P < .05 are shown in boldface.
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parental history of atopic disease. The associations with asthma at
ages 7 and 11 and 13 years were strongest with the persistent
class, but all AD classes showed evidence of some increased
risk of asthma at these ages. Our data did not support the presence
of a specific trajectory from AD to asthma (the so-called atopic
march), which is in keeping with a previous report from the Man-
chester Asthma and Allergy Study (MAAS) and earlier analyses
in ALSPAC.6 The associations observed with elevated total IgE
level were most marked during active and persistent disease, inkeeping with previous reports.22 Within the class of early-onset
disease that resolved before the time of IgE measurement, a
smaller proportion of individuals had IgE levels above the
threshold defined as ‘‘elevated,’’ in comparison with the class of
early-onset disease that was still active. Further investigation
with earlier IgE measures is required to explore whether such in-
dividuals would have had raised IgE level at the time of active
disease.
Although being female was more strongly associated with the
early-onset persistent and late-onset classes, there was some
TABLE IV. Association results between genetic risk factors and AD classes identified by LLCA
Study and genetic risk
factor
No. with risk
genotype/total Wald P
Early-onset
persistent
Early-onset late-
resolving
Early-onset early-
resolving
Mid-onset
resolving
Late-onset
resolving
ALSPAC 7.3% 7.0% 12.9% 7.0% 7.9%
FLG null mutation 813 of 7570 4 3 10228 131 of 570 (23%)* 78 of 514 (15%)* 111 of 832 (13%)* 54 of 467 (12%)* 70 of 499 (14%)*
4.31 (3.29-5.63)
P 5 2 3 10226
2.23 (1.53-3.26)
P 5 3 3 1025
2.14 (1.54-2.98)
P 5 7 3 1026
1.48 (0.92-2.39)
P 5 .109
2.30 (1.57-3.38)
P 5 2 3 1025
Genetic risk score
(all other
variants)
Total N 5 6497 8 3 10217 1.17 (1.12-1.22)
P 5 2 3 10213
1.08 (1.04-1.13)
P 5 4 3 1024
1.02 (0.99-1.06)
P 5 .222
1.06 (1.00-1.12)
P 5 .042
1.01 (0.96-1.06)
P 5 .758
PIAMA 4.9% 3.8% 15.4% 6.5% 6.5%
FLG null mutation 117 of 1516 6 3 1024 7 of 74 (10%)* 14 of 60 (23%)* 11 of 159 (7%)* 7 of 96 (7%)* 10 of 95 (11%)*
1.34 (0.49-3.67)
P 5 .563
5.63 (2.65-11.95)
P 5 7 3 1026
0.87 (0.25-3.03)
P 5 .821
0.95 (0.26-3.45)
P 5 .942
1.87 (0.76-4.62)
P 5 .174
Genetic risk score
(all other
variants)
Total N 5 1964 6 3 1025 1.17 (1.07-1.28)
P 5 5 3 1024
1.0 (0.91-1.11)
P 5 .968
1.16 (1.08-1.25)
P 5 1 3 1024
1.11 (1.03-1.20)
P 5 .004
1.08 (0.98-1.18)
P 5 .111
‘‘Wald P’’ is for the overall omnibus test. Individual P values and effect sizes comparing each class with the ‘‘unaffected/transient’’ class are also shown; results P < .05 are shown in
boldface; genetic risk score is defined by the total number of risk alleles across the 23 AD-associated loci (other than FLG) identified by genome-wide association study meta-
analysis to date; OR represents the change in odds per risk allele for the genetic risk score or between carriers compared with noncarriers for the FLG mutations.
*To demonstrate the approximate numbers of individuals with FLG null mutations in each class, individuals were assigned to the most likely class. Given that the actual association
analysis accounted for uncertainty in assignment of classes, these values are approximations for purposes of highlighting where power might be low. The approximate number with
FLG null mutations/approximate total with FLG genotype data (%), within each class are shown. The ‘‘unaffected/transient’’ groups had 8% (;369 of 4712) and 7% (;68 of 1032)
with FLG mutations in ALSPAC and PIAMA, respectively.
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onset-resolving classes. It is tempting to speculate that the late-
onset class might represent AD induced by behavioral changes in
the adolescent child (including increased bathing/showering and
the use of fragranced products), which might differ between
males and females, but this hypothesis remains to be tested. The
male preponderance in AD cases ascertained in infancy has
previously been reported23-26 but the mechanisms accounting for
this sex difference are unknown.
There is conflicting epidemiological evidence indicating that
breast-feedingmay be either a risk factor or a protective factor in the
etiology of AD27 and our analyses have not been able to add clarity
to this important question. In the ALSPAC cohort, breast-feeding
was associated with the 2 classes of most long-lasting disease
(early-onset-persistent and early-onset-late-resolving AD) but in
the PIAMA cohort there was little evidence of breast-feeding being
associated with any of the latent classes. This apparent difference
could be explained in several different ways: It may be stochastic
(given that all 95% CIs overlap between the 2 cohorts); it may be
a result of the substantially higher prevalence of breast-feeding in
the Dutch population compared with the UK population; or it
may result from reverse causation in the ALSPAC cohort, if, for
example, mothers with a strong history of atopic disease are more
likely to breast-feed their infants.
We found little evidence for early-life exposure to a pet cat
being associated with any of the classes in the main analysis.
However, in the complete-case data set in ALSPAC, there was
some evidence that cat exposure may have a protective effect on
early-onset-early-resolving AD, which is somewhat at odds with
previous reports of cat exposure increasing the risk of AD.28,29
This may indicate a specific beneficial effect of early cat exposure
on this more transient phenotype and warrants further
investigation.
There was evidence that FLG null mutations were associated
with all classes; however, as reported previously,30,31 the associ-
ation was strongest in the group with early-onset-persistentdisease. The genetic risk score of the other established AD vari-
ants showed a similar pattern, whereby the association was stron-
gest for the early-onset-persistent class, with a striking increase in
the burden of risk of approximately 17% per additional risk allele.
Of note, 3 variants showed consistent patterns of effects across
both cohorts, with stronger associations in the early-onset persis-
tent group, and weaker associations with the other classes. The
functional mechanisms of these loci have not been fully defined,
but rs17881320 is within STAT3 (encoding a signal transducer and
activator of transcription, an acute-phase response protein);
rs479844 is near toOVOL1 (which encodes zinc-finger containing
transcription factor); and rs6010620 is withinRTEL1 (regulator of
telomere elongation helicase 1). This heterogeneity of effect of
genetic variants on different disease profiles emphasizes the
need for patient stratification in future genetic studies. Stratifica-
tion may be used to increase the power to detect variants associ-
ated with specific classes; stratification could also allow the
identification of phenotype-specific mechanistic pathways as
future therapeutic targets.
The similarity and high frequency of AD symptom ascertain-
ment in ALSPAC and PIAMA are strengths of our study. The
phenotype definitions used within the cohorts comprised pro-
spective questions to capture diagnostic features of eczema
including the changing distribution of skin involvement from
infancy to later childhood. One key difference is that PIAMA had
a shorter follow-up (11 years vs 16 years), which could have
limited the ability to detect classes with differences at later ages.
Despite this, the class patterns are remarkably similar between
ALSPAC and PIAMA (Fig 2). However, neither cohort allowed
for investigation of variable AD patterns in adulthood, more sub-
tle AD patterns (such as the transient cases that were indistin-
guishable from the unaffected individuals in our study), nor in
people of ancestries other than white European. We also studied
only a limited number of environmental factors and so this
work could be extended to investigate the association between
latent classes and other potential risk factors.
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certainty (see Table E8 in this article’s Online Repository at www.
jacionline.org), the LLCA 3-step method models this uncertainty
and allows for the inclusion of individuals with incomplete data
to maximize sample size and minimize any loss to follow-up
bias. We note that our analysis does not formally test for causal di-
rection and some risk factors studied do not entirely precede the
onset of disease. Therefore, although the observational associations
are interesting, furtherwork shouldbe conducted to investigate cau-
sality. A further challenge is that by stratifyingAD into smaller sub-
phenotypes of disease,we inevitably lower the power of association
testing. Few studies have such detailed longitudinal data and so to
increase sample sizes in future studies, it will be necessary to
extrapolate these data-driven phenotypes into settings where less
detailed data are available, such as large data registries.32
In conclusion, we have identified longitudinal subgroups of AD
that have both shared and distinctly different risk factor profiles.
Future studies of the etiology and treatment of this complex trait
should take these subgroups of disease into account and, in turn,
this may offer valuable stratified medicine approaches to refining
prognostic predictions and therapeutic strategies.
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Clinical implications: AD ranges from a transient condition to
lifelong morbidity. This study has identified distinct subpheno-
types of AD in children, which could indicate the importance of
a stratified approach to the management of this complex
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Atopic dermatitis and psoriasis are the two most common immune-mediated inflammatory disorders affecting the skin. Genome-wide
studies demonstrate a high degree of genetic overlap, but these diseases have mutually exclusive clinical phenotypes and opposing im-
mune mechanisms. Despite their prevalence, atopic dermatitis and psoriasis very rarely co-occur within one individual. By utilizing
genome-wide association study and ImmunoChip data from >19,000 individuals and methodologies developed from meta-analysis,
we have identified opposing risk alleles at shared loci as well as independent disease-specific loci within the epidermal differentiation
complex (chromosome 1q21.3), the Th2 locus control region (chromosome 5q31.1), and the major histocompatibility complex (chro-
mosome 6p21–22). We further identified previously unreported pleiotropic alleles with opposing effects on atopic dermatitis and pso-
riasis risk in PRKRA and ANXA6/TNIP1. In contrast, there was no evidence for shared loci with effects operating in the same direction on
both diseases. Our results show that atopic dermatitis and psoriasis have distinct genetic mechanisms with opposing effects in shared
pathways influencing epidermal differentiation and immune response. The statistical analysis methods developed in the conduct of
this study have produced additional insight from previously published data sets. The approach is likely to be applicable to the investi-
gation of the genetic basis of other complex traits with overlapping and distinct clinical features.Introduction
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Despite a lifetime prevalence of ~2% for psoriasis and
10%–20% for AD,3,4 these diseases rarely co-occur within
an individual5—an observation attributed to opposing im-
mune response patterns.6 However, it has been reported
that both Th1-cell-dominated autoimmune and Th2-cell-
dominated allergic diseases aggregate within families7
and that parental psoriasis might increase the risk of AD
in offspring.8 Furthermore, genome-wide linkage and asso-
ciation studies have shown genetic risk loci in each disease
that map to similar regions of the genome. The epidermal
differentiation complex (EDC) on chromosome 1q21.3 in-
cludes AD and psoriasis risk loci in close proximity.9–12
Null mutations in the gene encoding filaggrin (FLG [MIM
135940]) represent the strongest known risk factor for
AD13,14 and account for at least a proportion of AD risk
within the EDC, but FLG-null mutations are not associated
with psoriasis.15,16 A deletion of the late cornified envelope
genes LCE3B-LCE3C (MIM 612614, 612615) represents a
genetic substrate for psoriasis within the EDC,17,18 but
this deletion is not associated with AD.19 The cytokine
cluster encoded at 5q23.1–5q31.1 includes variants
showing association with both diseases,10,20,21 and an in-
tergenic region of chromosome 20q13.2 has also shown as-
sociation with both AD and psoriasis.22,23 Finally, a recent
genome-wide association study (GWAS) on AD identified a
strong association within the margins of the major histo-
compatibility complex (MHC)20 on chromosome 6p21.3,
less than 2.4 kb from a variant associated with HLA-Cw6
(MIM 142840),24 the strongest known psoriasis-risk locus.
In order to gain insight into overlapping and specific
genetic mechanisms, we systematically compared and con-
trasted AD and psoriasis via analytical techniques devel-
oped from meta-analysis.Subjects and Methods
Study Subjects
Genome-wide genotype data were obtained on samples from six
case-control cohorts (three each of AD and psoriasis), totaling
2,262 AD and 4,489 psoriasis case subjects and 12,333 control sub-
jects (Table S1 available online).
The German AD case subjects were recruited from tertiary
dermatology clinics at Munich, as part of the GENEVA study, Uni-
versity of Kiel, University of Bonn, and the University Children’s
Hospital of Charité Universitätsmedizin Berlin. AD was diagnosed
by experienced dermatologists and/or pediatricians according to
the UK Diagnostic Criteria.25 German control subjects were ob-
tained from the PopGen biorepository,26 the population-based
KORA study in southern Germany,27 and the German part of
ISAAC II to assess the prevalence of asthma and allergies in school-
children.28 The Irish AD case collection was recruited from the sec-
ondary and tertiary pediatric dermatology clinic at Our Lady’s
Children’s Hospital, Crumlin, Dublin. Irish control individuals
were obtained from healthy adult blood donors as part of the
Trinity Biobank, Dublin.29
The German psoriasis case subjects were recruited from the ter-
tiary dermatology clinic at the University of Kiel and German con-
trols were again obtained from the PopGen biorepository and theThe AmerKORA study (independent from those used as controls for AD).
The British psoriasis case-control study is part of the Welcome
Trust Case Control Consortium 224 and the US psoriasis study
has been described elsewhere.21
ImmunoChip data on 2,425 AD case subjects, 3,580 psoriasis
case subjects, and 9,061 control subjects were obtained from pre-
vious studies,11,12 including data on a subset of case and control in-
dividuals also analyzed by GWAS. Results of analysis of the four
most prevalent FLG (RefSeq accession number NM_002016.1)
loss-of-function mutations were obtained for a total of 2,865 case
subjects and 5,540 control subjects as data generated for previous
studies;11,20 the FLG mutations in these analyses are as follows:
p.Arg501* (c.1501C>T), p.Ser761Cysfs*36 (c.2282_2285del),
p.Arg2447* (c.7339C>T), and p.Ser3247* (c.9740C>A) (R501X,
2282del4, R2447X, and S3247X, respectively).
The institutional review board in each contributing center
approved these studies. All participants (or their parents or guard-
ians) gave written informed consent.Study Design
The study design is summarized in Figure 1.Quality Control
Quality control and standard GWAS analysis of genotyped single-
nucleotide variants (SNVs) was carried out with PLINK30 and R.
Samples with extensive missing data (rate >5%), excess of hetero-
zygosity or homozygosity, and discrepant gender determined on
the basis of average X-chromosomal heterozygosity compared to
the gender recorded in the database were excluded.We then exam-
ined identity-by-state (IBS) sharing and estimated identity-by-
decent (IBD) on a pruned SNV set between all pairs of individuals
and deleted resulting duplicates or closely related samples with
PI_HAT > 0.1875 (halfway between expected IBD for third- and
second-degree relatives). Multidimensional scaling (MDS) of the
pairwise IBS matrix was carried out to identify and delete outliers
of unusual ancestry and to calculate genome-wide principal-
component scores for each individual. We excluded 894 samples
because of SNVs showing a missing rate of >5%, deviation of
Hardy-Weinberg equilibrium pHWE < 10
8, or minor allele fre-
quency (MAF) <5% (summarized in Table S2). After quality con-
trol, the resulting SNVs and samples were analyzed for association
via logistic regression with age, sex, and principal-component
scores as covariates. Results from each panel were investigated to
determine whether established GWAS loci were identified for the
respective trait of interest, and genomic control inflation factors
were calculated.Imputation of SNVs and Classical HLA Alleles
Any SNVs showing significant association were checked (e.g., by
visual inspection of the intensity cluster plots and investigation
of consistency of LD with surrounding markers) and those SNVs
deemed unreliable were removed. The final data sets of high-qual-
ity SNVs were prephased with SHAPEIT31 and subsequently used
to perform imputation with IMPUTE2,32 the 1000 Genomes refer-
ence panel (integrated variant set, release March 2012).33 In the
Irish AD collection (Table S1), case and control subjects were gen-
otyped on different platforms, and therefore only the 131,692
SNVs in common between the platforms were used to inform
imputation.
Postimputation SNVs with low imputation quality (info score <
0.4), call rate <95%, deviation from pHWE < 10
8, or MAF < 5%ican Journal of Human Genetics 96, 104–120, January 8, 2015 105
Figure 1. Study Design
Abbreviations are as follows: CCMA, case
control meta-analysis; MANTRA, meta-
analysis of trans-ethnic association studies;
BFD, Bayesian false discovery; PO, prior
odds; *conditional analysis for the MHC
was also carried out with imputed classical
HLA-allele (detailed in the Subjects and
Methods).were excluded. A final data set of approximately 5.2 million SNVs
in 2,079 AD case subjects, 3,867 control subjects, 4,212 psoriasis
case subjects, and 8,032 control subjects were eligible for subse-
quent analysis (Table S3).
Classical alleles for HLA-A, HLA-B, and HLA-C were imputed for
each case-control cohort separately by HLA*IMP34,35 and best
guess genotypes with probability >0.9. Additional classical HLA-
DQA1, HLA-DQB1, and HLA-DRB1 alleles were imputed in each
case-control cohort with the exception of the Irish samples, in
which there were insufficient informative SNPs. Alleles with a fre-
quency>1%were put forward for analysis. For each individual, al-
leles were coded as having no, one, or two copies of the respective
allele via allele probability >0.9. We obtained high-quality data at
the four-digit level with call rates of 92%–100% and accuracy of
92%–98%.
Statistical Analysis
Meta-GWAS was performed on each disease, via standard method-
ologies. To analyze these findings further, we developed two
different meta-analysis-based approaches to filter SNVs andmodel
the contrasting effects in each disease. The first was a compare and
contrast meta-analysis (CCMA) approach inspired by a subset-
based method.36 The second used transethnic meta-analysis im-
plemented in the MANTRA software,37 combining all six studies
by using prior clustering to reflect the ethnic difference and the
disease type. The MHC region was reserved for separate analysis
because of its unique and complex variability and patterns of
strong linkage disequilibrium (LD).
The CCMA approach is based on an adaptation of an idea of
Bhattacharjee et al.,36 who modeled association with heteroge-
neous traits. With METAL,38 we calculated z-scores signed positive
or negative with respect to the same reference allele for two meta-
analyses, T1, combining AD studies only, and T2, combining pso-
riasis studies only. We then calculated the overall test statistic Tmax
with the formula Tmax ¼ maxðjT1j; jT2j; jT12sharedj;

T12opposing

Þ,
where T12shared ¼ ðT1 þ T2Þ=
ffiffiffi
2
p
and T12opposing ¼ ðT1  T2Þ=
ffiffiffi
2
p
. We
categorized the effect of each SNV as corresponding to an effect106 The American Journal of Human Genetics 96, 104–120, January 8, 2015on AD only, to an effect on psoriasis
only, to a shared effect (in the same di-
rection on AD and psoriasis), or to op-
posing effects, according to which of the
four test statistics ðjT1j; jT2j; jT12shared j;

T12opposing

Þ was the largest. In order to
derive a p value for Tmax, we worked out
an empirical null distribution by simu-
lating 10,000,000 realizations of two nor-
mally distributed random variables, Z1
and Z2. Then we calculated Z12shared ¼
ðZ1 þ Z2Þ=
ffiffiffi
2
p
, Z12opposing ¼ ðZ1  Z2Þ=
ffiffiffi
2
p
,
and Zmax ¼ maxðjZ1j; jZ2j; jZ12shared j;

Z12opposing

Þ. The emprical p values can be derived as
Pemp ¼ ð#ðZmax > TmaxÞ þ 1Þ=ð# simulationsþ 1Þ.
In a separate simulation of 1,000,000,000 replicates, we derived
a calibration curve for the p values and found it suitable up to a p
value of 109. Hence with the calibration curve we can derive Zmax
thresholds corresponding to standard genome-wide ‘‘suggestive’’
(105) and genome-wide ‘‘significant’’ (108) thresholds, corre-
sponding to Tmax values of approximately 4.7 and 6.0, respectively
(Figure S1).
In the second approach we used the MANTRA software37 devel-
oped for transethnic meta-analysis. MANTRA uses a Bayesian
partition model for grouping studies according to their ethnicity.
We adopted this idea and worked out a prior distribution to cluster
studies according to both our phenotypes of interest and the ge-
netic distance between the studies derived from our MDS analysis
based on the pairwise IBSmatrix:DTotal¼DDiseaseþDEthnicity, where
DEthnicity is a diagonal matrix of Euclidean distances between study
centers. To distinguish the two diseases (psoriasis and AD),
we set the corresponding cells of the DDisease matrix to Dij ¼ 2 3
max(DEthnicity) and to account for the different subphenotype in
AD (AD in general versus childhood AD), we set the corresponding
cells of the DDisease matrix to Dij ¼ max(DEthnicity), resulting in the
prior components shown in Table S4.
We calibrated the resulting log10BFMANTRA¼ log10(Bayes Factors)
from the MANTRA software in order to find a threshold for
filtering SNVs, which were compared with the CCMA top SNVs
and subsequently carried forward to multinomial regression
modeling. To perform this calibration, we calculated the Bayesian
False Discovery Probability proposed by Wakefield39 with diverse
prior odds (PO) in favor of H0:
BFDP ¼ BFMANTRA 3PO
1þ BFMANTRA 3PO:
Sensitivity analysis was performed with only the DEthnicity as prior
matrix and we observe high correlation (r2 > 0.99) of the top-
ranked SNVs (BFDP < 0.05; PO ¼ 99) with our analysis (data not
shown).
Finally, we carried forward a filtered set of SNVs fromCCMA and
MANTRA for modeling via a multinomial regression model,
adjusted for sex and the first four genome-wide principal-com-
ponent scores. The multinomial model involves three outcome
categories: the ‘‘baseline’’ category into which all controls are cate-
gorized, a ‘‘psoriasis’’ case category, and an ‘‘AD’’ case category
(modeled through regression coefficients bPSO and bAD, respec-
tively). This analysis makes use of individual-level genotypes and
is thus more computationally intensive (although arguably more
powerful and more statistically satisfactory) than CCMA and
MANTRA. We calculated p values for tests that were designed to
be sensitive to the following situations: an overall SNV effect (on
either or both diseases, in either direction), an individual SNV ef-
fect on one disease (but not on the other), a shared SNV effect
(operating in the same direction for both diseases), and a contrast-
ing SNVeffect (operating in opposing directions between both dis-
eases), by performing Wald tests of the following linear
hypotheses:
Overall effect : H0 :
bPSO þ bAD
bPSO  bAD ¼
0
0
; H1 :
bPSO þ bAD
bPSO  bAD s
0
0
Psoriasis effect : H0 : bPSO ¼ 0; H1 : bPSOs0
AD effect : H0 : bAD ¼ 0; H1 : bADs0
Shared effect : H0 : bPSO þ bAD ¼ 0; H1 : bPSO þ bADs0
Opposing effect : H0 : bPSO  bAD ¼ 0; H1 : bPSO  bADs0
The overall significance of the SNV was assessed through the 2
degree of freedom (df) test of overall effect, which compares the
null hypothesis that the SNV has no effect on either psoriasis or
AD with the alternative hypothesis that it has an effect on one
or both diseases. The other four 1 df tests were used to categorize
the effect (in analogy to CCMA) in four categories—AD only, pso-
riasis only, shared effect, and opposing effects—by categorizing ac-
cording to the minimum of the p values: pMNM ¼ min(pAD, pPSO,
pSHARED, pOPPOSING). The rationale for the use of the minimum
of these 1 df tests for categorization is as follows: if a SNV is asso-
ciated with one disease but not the other, the test of a nonzero
regression coefficient for that disease (even while unnecessarily
also allowing for a nonzero coefficient for the other disease, as is
done in the psoriasis effect and AD effect tests), should be more
powerful than a test that erroneously groups together the coeffi-
cients of the associated and the nonassociated disease (as is done
in the shared and opposing effect tests). This is on account of
the fact that grouping together these coefficients will incur a pen-
alty in terms of increasing the variance, while not incurring any
greater expected magnitude of effect since the expected value of
the regression coefficient for the nonassociated disease is zero. If,
on the other hand, the SNV has effects that operate in the same
direction on both diseases, then a test based on adding together
these effects (as is done in the shared effect test) should be more
powerful than considering each effect on its own, or subtracting
one effect from the other (as is done in the opposing effect test),
because adding together the coefficients induces the greatest
magnitude of effect. Finally, if the SNV has effects that operate
in opposite directions in the two diseases, then a test based on sub-
tracting one effect from the other (as is done in the opposing effect
test) should be most powerful because it induces the greatest
magnitude of effect.The AmerAll analyses if not explicitly stated were carried out with R. For
the purposes of this analysis, we distinguished between a shared
genetic ‘‘region’’ and a shared genetic ‘‘locus.’’ We arbitrarily desig-
nated a shared region as a block of genomic DNA spanning 2 Mb
with association signals for both traits. We defined a genetic locus
as the lead SNV and all SNVs with r2 > 0.5.
Predicted Protein Network Analysis and Gene
Ontology Analysis
Functional protein association networks were investigated in silico
and gene ontology analyses were performed with STRING9.1.Results
Filtering Variants to Define Risk Effects
Quality control and imputation generated 5.2 million
SNVs with a minor allele frequency >0.01 for further anal-
ysis (Figure 1). GWASs within each cohort resulted in
genomic inflation factors l between 1.03 and 1.08. Meta-
GWAS performed on each disease confirmed previously
reported risk loci in AD and psoriasis and illustrated areas
of colocalization on chromosomes 1, 5, and 6 (Figure 2A).
Excluding the MHC, 2,210 SNVs were identified with
shared (by which we mean alleles having effects operating
in the same direction in both diseases), opposing, and dis-
ease-specific SNVs with CCMA test statistic Tmax> 4.7. This
threshold was defined to correspond to a suggestive signif-
icance of p< 105 in order to reduce the probability of false
negatives. The 2,210 SNVs were condensed to 142 distinct
loci after an LD-based clumping procedure30 with the
following parameters: distance % 250 kb and r2 R 0.5.
Analysis with MANTRA revealed 3,304 SNVs with
Bayesian false discovery probability (BFDP) < 0.05 with
prior odds (PO) 1/99 resulting in 76 distinct loci after
clumping. The overlap of CCMA and MANTRA gave
2,183 SNVs and the union of both methods resulted in
3,331 SNVs that were carried forward for multinomial
regression modeling (MNM), which was adjusted for sex
and the first four genome-wide principal-component
scores. The results are displayed in Figure 2B, in which dis-
ease-specific, shared, and opposing loci are coded by color.
SNVs showing genome-wide significance in at least one of
the three methods of analysis (Tmax > 6, BFDP < 0.05 with
PO ¼ 1/999, or pMNM < 108) map to 144 distinct loci (Ta-
ble S5). Comparison of effect classification (AD, psoriasis,
shared, opposing) in CCMA and MNM (Figure S2) showed
an agreement of 94.8% when excluding the MHC region
(Figure S3). For further investigation, we considered only
loci containing more than one SNV and an effect classified
in the same direction by CCMA and MNM.
Validation of Previously Reported AD- and
Psoriasis-Risk Loci
15 European and 9 Asian loci have previously been re-
ported in GWASs on AD, and 44 European and 9 Asian
loci have been reported in association with psoriasis (Table
S6). In our disease-specific meta-analysis individuals ofican Journal of Human Genetics 96, 104–120, January 8, 2015 107
A
B
Figure 2. Genome-wide Comparison of
AD and Psoriasis
(A) Mirrored Manhattan plots showing re-
sults of AD meta-GWAS (top) and psoriasis
meta-GWAS (bottom).
(B) Comparative analysis of AD and psoria-
sis in which SNVs are color coded to show
AD-specific effect (black), psoriasis-specific
effect (red), shared effects defined as alleles
operating in the same direction (green),
and opposing effects (blue). The genome-
wide significance level is marked at p ¼
0.5 3 108 (Tmax ¼ 6.0).white European descent, 14 of the European AD loci as well
as 43 of the psoriasis loci are replicated. Furthermore, 4 AD
and 4 psoriasis loci so far reported only in Asians showed
evidence for association in European populations (p <
103): CCDC80 (MIM 608298)/CD200R1L at 3q13.2,
CARD11 (MIM 607210) at 7p22.2, ZNF365 (MIM
607818) at 10q21.2, and BCAS1 (MIM 602968) at
20q13.2 in AD;CSMD1 (MIM 608397) at 8p23.2, SERPINB8
(MIM 601697) at 18q22.1,MAMSTR (MIM 610349)/RASIP1
(MIM 609623) at 19q13.33, and ZNF816A at 19q13.41 in
psoriasis (Table S6).
New Opposing-Effect Loci Identified by Genome-wide
Comparative Analysis
Excluding the MHC, 25 loci showed a genome-wide sig-
nificant association with either skin disorder, defined
by all three methods of analysis (CCMA Tmax > 6 and
MANTRA BFDP < 0.05 with PO ¼ 1/999, and pMNM <
108) including six loci that were coassociated with both
AD and psoriasis. Each coassociated locus displayed
opposing effects and two of these loci (2q31.2, 5q33.1)
have not previously been reported as showing coassocia-
tion with AD and psoriasis (Table 1).
2q31.2 demonstrates an opposing effect at rs62176107
(MNM p ¼ 1.08 3 1034; Table S5); this variant is within
exon 6 of PRKRA (MIM 603424) and also within
microRNA 548n (MIR548N) and a noncoding transcript,
AC009948.5. PRKRA encodes protein kinase interferon-
inducible double-stranded RNA-dependent activator
(PACT), a cellular dsRNA-binding protein originally identi-
fied as a binding partner and activator of PKR in response
to extracellular stress.46 More recently, it has been shown
to be an essential factor in the PKR-independent initiation108 The American Journal of Human Genetics 96, 104–120, January 8, 2015of RIG-I-induced antiviral response.47
Of note, individuals with AD are
known to be susceptible to viral skin
infections, but cutaneous infec-
tions rarely occur in psoriasis.48
MicroRNAs play a role in posttran-
scriptional regulation of gene expres-
sion by affecting the stability and
translation of mRNAs, but the specific
role of miRNA548n has not been
defined. Themost significantly associ-ated (‘‘lead’’) SNV at 2q31.2 (rs62176107, G>A, having the
smallest p value from MNM) is a synonymous SNV with
predicted effects on 12 transcripts, including PRKRA splice
variants’ UTR and intronic regions and a variant predicted
to undergo nonsense-mediated decay (Ensembl release 75).
Gene expression profiling data show downregulation of
both PRKRA mRNA and miRNA548n in psoriatic lesions
compared to nonlesional skin, but no significant differ-
ences in AD (Table S7).
The most highly significant variant at 5q33.1
(rs17728338) shows opposing effects on AD and psoriasis
(MNM p ¼ 3.96 3 1038; Table S5) and lies 2 kb upstream
of ANXA6 (MIM 114070) and 8 kb downstream of TNIP1
(MIM 607714). LD analysis in 1000 Genomes (release
August 2009) via LocusZoom49 showed that rs17728338
is located within a 25-kb block containing both TNIP1
and ANXA6. The locus has previously been associated
with psoriasis in European and Chinese populations
but has not been implicated in AD. TNIP1 is involved in
TNF signaling and regulation of the transcription factor
NF-kB;21,50 it shows increased expression both in AD and
psoriatic lesions compared to control skin (Table S7). In
contrast, ANXA6, which encodes a calcium-dependent
membrane and phospholipid binding protein, shows
significant upregulation of expression in atopic skin
compared to control skin (fold change 1.3, FDR p ¼
0.016) and lesional to nonlesional AD skin (fold change
2.4, p ¼ 0.027), whereas expression is decreased in psori-
atic versus healthy skin (fold change 0.7, p ¼ 6.38 3
1013) (Table S7). Clearly, further finemapping is necessary
to identify the causal variant that exerts opposing effects
on AD and psoriasis, but we speculate that ANXA6 might
be a switch-point differentiating AD from psoriasis that
Table 1. Loci Showing Genome-wide Significant Association with Either AD or Psoriasis Defined by All Three Methods of Comparative Analysis
Chr Band
Reference SNV
Number(s) Position (hg19) Nearest Gene(s) or Transcript(s)
Effect Observed
in GW Analyses
Estimated Odds Ratio (95% CI)
Previous Report(s) of Association at
This LocusAD Psoriasis
1p31.3 rs77614545 (del) 67749581 retro-DNAJB6 and IL23R (MIM 607562) psoriasis 0.99 (0.92–1.07) 1.21 (1.15–1.28) psoriasis: 1p31.3 locus, IL28RA21,24,40
1q21.3a rs55879323 152168740 within FLG-AS1 opposing 0.76 (0.70–0.82) 1.05 (1.00–1.12) AD and psoriasis: 1q21.3 locus, HRNR,
FLG;41 FLG;20,42 LCE3B, LCE3C,18 LCE
gene cluster;17 LCE3D24
rs11205006,
rs12144049
152440176,
152440910
RP1-91G5.3, CRNN (MIM 611312),
LCE5A (MIM 612619)
AD 1.52 (1.41–1.64),
1.53 (1.42–1.64)
0.97 (0.92–1.03),
0.98 (0.92–1.03)
AD: 1q21.3 locus,HRNR, FLG;41 FLG20,42
rs471144 152454255 LCE5A (MIM 612619) AD 1.54 (1.37–1.73) 1.03 (0.94–1.14) AD: 1q21.3 locus,HRNR, FLG;41 FLG20,42
rs10888499 152532742 LCE3E (MIM 612617) AD 1.49 (1.38–1.61) 0.98 (0.93–1.04) AD: 1q21.3 locus,HRNR, FLG;41 FLG20,42
rs4112788 152551276 LCE3D (MIM 612616) psoriasis 0.97 (0.90–1.05) 1.22 (1.15–1.28) psoriasis: LCE gene cluster;17 LCE3D24
rs1581803 152592281 LCE3A (MIM 612613) psoriasis 0.97 (0.90–1.04) 1.22 (1.15–1.30) psoriasis: LCE gene cluster17
rs77199844 (del) 152757094 LCE1E (MIM 612607) [AD] 2.01 (1.72–2.35) 1.16 (1.01–1.33) AD: 1q21.3 locus,HRNR, FLG;41 FLG20,42
psoriasis: LCE gene cluster17
rs4363385 152989321 SNORA31, SPRR3 (MIM 182271),
SPRR1B (MIM 182266)
[opposing] 1.23 (1.15–1.32) 0.89 (0.85–0.94) AD: SPRR3 repeat number variant43
2p16.1 rs35741374 61072567 within lincRNA AC010733.4 psoriasis 1.09 (1.01–1.63) 1.20 (1.15–1.27) psoriasis: REL;24 NR23
2q31.2 rs62176107 179300971 exonic PRKRA and within miRNA548n
and AC009948.5
opposing 0.55 (0.46–0.65) 1.42 (1.32–1.53) –
5q31.1a rs1295686 131952222 intronic IL13 (MIM 147683) and within
AC004041.2
[opposing] 1.27 (1.17–1.38) 0.88 (0.82–0.94) AD and psoriasis: IL13;21 KIF3A, IL13;22
KIF3A, IL4, IL13-RAD50;10 multiple
effect locus RAD50/IL13;20 C5orf56
rs6596086 131995843 intronic RAD50 (MIM 604040) opposing 1.30 (1.20–1.41) 0.85 (0.8–0.91) AD and psoriasis: IL13-RAD50;10
multiple effect locus RAD50/IL1320
5q33.1 rs17728338 150478318 ANXA6 (MIM 114070) opposing 0.70 (0.59–0.84) 1.77 (1.61–1.95) psoriasis: TNIP121,42
5q33.3 rs10515778, rs7715173,
rs7719425b
158658012, 158664631,
158670938
within CTB-11I22.1 psoriasis 1.07 (0.98–1.17) 1.29 (1.21–1.38) psoriasis: 5q33.3 locus, IL12B17,21,24,44;
AD: PTTG142
rs11135056,
rs4921442b
158687281, 158694100 intronic UBLCP1 (MIM 609867) psoriasis 0.97 (0.89–1.05) 1.45 (1.35–1.56)
rs2546890 158759900 within AC008697.1 psoriasis 1.01 (0.94–1.06) 1.39 (1.32–1.47)
rs5872599 (indel) 158859989 lincRNA AC008703.1, IL12B
(MIM 161561)
psoriasis 0.82 (0.73–0.93) 1.54 (1.45–1.64)
6q21 rs9487605 111582885 intronic KIAA1919 psoriasis 1.06 (0.98–1.14) 1.27 (1.20–1.35) –
rs240993 111673714 intronic REV3L (MIM 602776) psoriasis 1.05 (0.97–1.13) 1.29 (1.22–1.36) –
rs9481169 111929862 TRAF3IP2 (MIM 607043) psoriasis 0.98 (0.86–1.11) 1.58 (1.45–1.72) psoriasis and psoriatic arthritis:
TRAF3IP224,44,45
(Continued on next page)
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110 The American Journal of Human Genetics 96, 104–120, January 8reflects the importance of calcium-dependent effects in
keratinocyte differentiation.
Opposing effect loci were also identified within regions
characterized by complex patterns of LD within the EDC
(Figure S4), the cytokine cluster on 5q31.1 (Figures S4
and S5), and the MHC. These regions were therefore inves-
tigated further via conditional analysis.
Stepwise Conditional Analysis within 1q21.3 and
5q31.1 Identifies Opposing and Disease-Specific Risk
Variants
Coverage of the EDC was achieved via GWAS data
(Figure 3), whereas ImmunoChip data provided better
coverage for the cytokine cluster on 5q31.1 (Figures 4
and S5).
Within 1q21.3 we identified seven LD blocks with dis-
ease-specific or opposing signals (Figure 3A). Stepwise
conditional analysis on the four most prevalent FLG-
null mutations and variants tagging the LCE3B-LCE3C
deletion identified one AD-specific locus mapping to
FLG, a psoriasis-specific locus mapping to LCE3B-LCE3C,
and a locus with opposing effects on both diseases map-
ping to RPTN (MIM 613259)/HRNR/FLG-AS1 (Figure 3B
and Table 2). After conditioning on the four FLG-null mu-
tations and the LCE3B-LCE3C deletion, the G allele of the
lead MNM SNV rs12130219 decreases the risk for AD
(ORADcond ¼ 0.812, pADcond ¼ 0.0018) and increases the
risk for psoriasis (ORPSOcond ¼ 1.119, pPSOcond ¼ 3.68 3
104) (Table 2). Filaggrin, repetin, and hornerin are all
members of the S100 fused-type protein family and each
contribute to the cornified cell envelope, a functional
component of the epidermal barrier. Both FLG and
HRNR show reduced expression in AD51–53 whereas
RPTN shows no significant difference (Table S7). In psori-
asis HRNR expression can be downregulated53 or upregu-
lated,54 RPTN expression might be upregulated, and FLG
expression might be downregulated55 or dysregulated15
(Table S7). The function of FLG-AS1 (FLG antisense
RNA1) is currently undefined, but its proximity to FLG
and HRNR suggests a role in coordinating keratinocyte
terminal differentiation. FLG-AS1 expression is increased
in psoriasis lesional compared with nonlesional skin,
whereas in AD lesional skin, expression is reduced (Table
S7). Together, our results confirm the role of the LCE3B-
LCE3C deletion in psoriasis and support the presence of
genetic risk mechanisms for AD within the EDC in addi-
tion to the predominant effect of FLG-null mutations,
with opposing effects on psoriasis.
Conditional analysis at 5q31.1 revealed three indepen-
dent loci specifically contributing to AD risk: IL13 (MIM
147683, rs848, ORADfull ¼ 1.12, p ¼ 0.0204), KIF3A (MIM
604683, rs 2299009, ORADfull ¼ 1.16, p ¼ 4.1 3 104),
and SLC22A4 (MIM 604190)/C5orf56 (rs74458173, ORAD-
full ¼ 1.57, p ¼ 2.0 3 104) (Figure 4A, Table 2). None of
these loci showed significant effects on psoriasis. However,
a fourth independent locus has opposing effects on AD
and psoriasis. The most highly significant variant maps, 2015
A
B
Figure 3. Regional Association within the Epidermal Differentiation Complex at 1q21.3
(A) Multinomial regression model with GWAS and ImmunoChip data. Seven blocks of linkage disequilibrium are indicated by curly
brackets; black circles indicate AD-specific association, red circles indicate a psoriasis-specific association, blue circles represent opposing
effects in AD and psoriasis, and green circles indicate shared effects. Vertical lines have been drawn tomark the positions of known genes
and transcripts (identified from UCSC Genome Browser, GRCh37/hg19 accessed Feb. 2009) and the horizontal dotted lines indicate
thresholds of suggestive and genome-wide significance (p ¼ 105 and 108). The horizontal gray bands at the bottom indicate the
coverage of the region by GWAS SNVs (upper row) and ImmunoChip SNVs (lower row).
(B) Conditional regional association plot of stepwise logistic regression using GWAS and ImmunoChip data. The different colored sym-
bols indicate association results after each step of analysis, as follows. Unconditioned results are shown by black dots to indicate asso-
ciation with AD and red dots to indicate association with psoriasis; blue triangles and blue crosses represent results after conditioning on
the known disease-associated variants, FLG in AD and LCE3B-LCE3C deletion in psoriasis; SNVs indicated by the same symbol are in LD
(legend continued on next page)
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to RAD50 (MIM 604040, rs6596086, ORADfull ¼ 1.17, ORP-
SOfull¼ 0.88, p¼ 6.33 107); this variant is associated with
increased risk of AD but is protective against psoriasis
(Figure 4B, Table 2).
Analysis of the MHC Confirms Multiple Psoriasis-Risk
Loci and Identifies Opposing Effects
In the extended HLA region, we took forward 23,479 SNVs
with Tmax > 4.7 or BFDP < 0.05 (PO ¼ 1/99) and 75 vari-
ables representing the classical HLA alleles obtained from
HLA imputation for multinomial modeling, of which
18,515 SNVs were classified as specific to psoriasis by
CCMA and MNM. To reduce the data set for post hoc anal-
ysis, we considered only SNVs with effect classification in
the same direction by CCMA and MNM, meeting the p <
105 threshold in MNM. Within the psoriasis-specific
markers, we excluded all tagging SNVs (r2 > 0.8 with the
lead SNV), resulting in 1,503 SNVs, including those previ-
ously reported for AD.20
The strongest and most significant association was
observed for psoriasis, a variant (rs111576655 ORPSOfull ¼
3.32, p ¼ 3.2 3 1065) tagging the well-known psoriasis-
risk allele HLA-C*06:02 (ORPSOfull ¼ 3.59, p ¼ 8.7 3
10154). Conditional analysis revealed two additional inde-
pendent loci contributing to psoriasis risk at MICA (MIM
600169, rs201374403, ORPSOfull ¼ 1.65, p ¼ 1.0 3 1026)
and HLA-A (MIM 142800, rs113573479, ORPSOfull ¼ 1.41,
p ¼ 2.7 3 1017), as well as two loci with opposing effects
at HLA-C (MIM 142840, rs1793889, ORADfull ¼ 0.6, ORPSO-
full ¼ 1.18, p ¼ 1.1 3 109) and HLA-DRB1 (MIM 142857,
rs28383201, ORADfull ¼ 0.61, ORPSOfull ¼ 1.18, p ¼ 6.5 3
109) (Figure 5, Table 3). Conditional analysis with
imputed classical alleles identified five independent HLA-
class I alleles contributing to psoriasis risk in addition to
HLA-C*06:02 and two alleles with opposing effects: HLA-
C*03:03 (ORADfull ¼ 0.71, ORPSOfull ¼ 1.27, p ¼ 2.3 3
105) and HLA-DQA1*02:01 (ORADfull ¼ 0.64, ORPSOfull ¼
1.09, p ¼ 6.0 3 108; r2 ¼ 0.405 with rs28383201)
(Table 3).
Ontology and Network Analysis of Genes Indicate
Effects in the Skin Barrier and Immune Response
Genes implicated from genome-wide and conditional ana-
lyses (identified from Tables 1, 2, and 3) were investigated
via predicted protein network and gene ontology (GO)
analysis. The results are summarized in Figure S6. The
GO term ‘‘keratinocyte differentiation’’ (GO:0030216) is
enriched in genes implicated in AD and psoriasis risk
(FDR p ¼ 4.3 3 104 in AD; p ¼ 6.9 3 104 in psoriasis;
and p ¼ 2.7 3 103 in opposing effects). The GO term
‘‘response to interferon-gamma’’ (GO:0034341) is also
significantly enriched in psoriasis (FDR p ¼ 1.9 3 103).with the lead SNV of each stepwise conditional analysis (defined as r
genes and transcripts (identified from the UCSC Genome Browser GR
cate significance thresholds of p¼ 0.005, 105, and 108. The horizon
GWAS SNVs (upper row) and ImmunoChip SNVs (lower row).
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This genome-wide comparative analysis confirms a high
degree of genomic coincidence between AD and psoriasis,
suggesting that common molecular mechanisms are
involved. This agrees with the central role of epidermal
barrier defects and T-cell-dominated inflammation in
both diseases.48 Within the six regions of colocalization,
we demonstrate coassociated and independent disease-
specific loci. Of note, all coassociated loci display opposing
(antagonistic) effects on AD and psoriasis, in agreement
with the epidemiological observations of lower-than-
expected coincidence between these diseases in the popu-
lation.5 Within these loci, specific variants including
chromosome 2q31.2 (rs62176107), chromosome 5q33.1
(rs17728338), and within RAD50 on chromosome 5q33.3
(rs6596086) demonstrate opposing effects on risk of AD
and psoriasis. This raises the intriguing possibility that
the same biological mechanisms might act differentially
on AD versus psoriasis. However, our current data cannot
distinguish this specific opposing mechanism from the
possibility that each lead variant is in LD with other vari-
ants having opposing effects in each disease.
Themajority of the opposing effect loci are implicated in
pathways related to adaptive immunological functions,
which potentially mirrors the polarized immune mecha-
nisms.6 It might further be speculated whether the
presence of multiple opposing alleles reflects balancing
selection as a response to heterogeneity in environmental
pressures. Balancing selection is particularly common
within the extended MHC region and has been proposed
as a potential explanation for antagonistic effects at multi-
ple loci in different autoimmune diseases.56
Two of the loci displaying opposing effects (ANXA6/
TNIP1 and PRKRA) have not previously been reported in
association with psoriasis and/or AD. Formal external vali-
dation is limited by the requirement for additional inde-
pendent, population-matched GWAS data for AD and pso-
riasis, but data available from RNA sequencing and
microarray analyses provide some support for the differen-
tial expression of ANXA6/TNIP1 and PRKRA in AD and pso-
riasis, relative to normal or uninvolved skin. The lead
variant within PRKRA might mediate opposing effects in
AD and psoriasis via miRNA processing and/or cellular
response to environmental stress, and we hypothesize
that this reflects the striking differential susceptibility to
viral and bacterial skin infections observed in AD and pso-
riasis. The opposing effect of variation in ANXA6 suggests a
role for calcium-dependent effects in defining patterns of
skin inflammation.
On chromosome 1q21.3, apart from well-established
AD-associated FLG mutations and psoriasis-associated2 R 0.5). Vertical lines are drawn to mark the positions of known
Ch37/hg19 accessed Feb. 2009), and horizontal dotted lines indi-
tal gray bands at the bottom indicate the coverage of the region by
, 2015
A
B
Figure 4. Regional Association within the Cytokine Cluster at 5q31.1
(A) Multinomial regression model with GWAS and ImmunoChip data. Black circles indicate AD-specific association, red circles indicate
psoriasis-specific association, blue circles represent opposing effects in AD and psoriasis, and green circles indicate shared effects. Vertical
gray shading marks the positions of known genes (identified from the UCSC Genome Browser GRCh37/hg19 accessed Feb. 2009), and
horizontal dotted lines indicate suggestive and genome-wide significance thresholds (p¼ 105 and 108, respectively); results are shown
for SNVs in LD with the lead SNV (defined as r2 R 0.5). The horizontal bands at the bottom indicate the coverage of the region by GWAS
SNVs (upper row) and ImmunoChip SNVs (lower row).
(B) Conditional regional association plot of the EDC bymultinomial regression of GWAS and ImmunoChip data. Different symbols indi-
cate association results after each step of analysis, as follows. Unconditioned results are shown by blue circles representing opposing ef-
fects in AD and psoriasis; black dots showAD-specific association results after conditioning on the lead SNV in RAD50 (a gene reported to
(legend continued on next page)
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deletion of LCE3B-LCE3C, FLG-AS1 is a plausible candidate
to mediate differential AD/psoriasis risk via the network of
regulatory elements coordinating gene expression.57 Natu-
ral antisense transcripts contribute to gene regulation via a
variety of transcriptional and posttranscriptional mecha-
nisms58 and include effects on human epidermal differen-
tiation.59 The proximity of FLG-AS1 to FLG and HRNR,
combined with data showing coordinated differential
expression of these genes, supports a role in control of ker-
atinocyte terminal differentiation.
On chromosome 5q31.1, antagonistic signals for AD and
psoriasis have previously been attributed to IL13.10,11,21
We here show that IL13 polymorphisms specifically influ-
ence AD risk, whereas opposing signals map to RAD50. The
Rad50 protein, a component of the MRN complex (Mre11,
Rad50, and Nbs1), is involved in DNA double-strand break
repair but has no known function directly related to AD or
psoriasis. However, RAD50 mRNA shows significantly
increased expression in psoriasis lesional skin and a trend
to reduced expression in AD lesional skin (Table S7). Of
note, RAD50 is located in the center of the Th2-cytokine
cluster and its 30 end is part of a locus control region regu-
lating expression of these cytokine genes.60 AD and psori-
asis represent opposing extremes of Th2 cell dysregulation,
and therefore we hypothesize that RAD50 polymorphisms
might exert opposing effects on AD and psoriasis through
variation in DNA repair resulting in a differential skew in
Th2 cell response.
Our dissection of the MHC locus confirms the presence
of multiple independent psoriasis-risk loci. Markers
tagging HLA-Cw*0602 generate the strongest effects,
which is in line with previous reports.17,21,24,44,61 CD8þ
T cells are increased in the epidermis of lesional psoriatic
skin, and the association of psoriasis susceptibility primar-
ily with class I HLA alleles might reflect the critical role of
psoriasis-associated (auto-)antigen presentation to patho-
genic CD8þ T cells.62 CD8þ T cells are also increased in
the epidermis of AD skin, but with strikingly different cyto-
kine profiles compared to psoriasis.63 The opposing effects
of class II HLA alleles in AD and psoriasis might represent
the differential responses to pathogenic and allergenic
peptides presented to CD4þ T cells.64 GWASs in AD by uni-
variate and multivariate models have reported association
signals in the MHC class I and II regions22,65 and two spe-
cific HLA class II haplotypes, HLA-DRB1*0701 (a protective
effect) and HLA-B*4402 (a risk effect).20 Our analysis con-
firms the association of classical HLA class II alleles with
AD, but in the conditional analysis, only HLA-DQA1*
02:01 remained, showing a significant protective effectbe associated with AD and psoriasis); black squares indicate the resid
RAD50 and IL13 (genes reported to be associated with AD); and blac
tionally conditioning on the lead SNV in KIF3A (a gene reported to be
with the lead SNV of each stepwise conditional analysis (defined as r2
(identified from the UCSCGenome Browser GRCh37/hg19 accessed F
olds of p ¼ 0.005, 105, and 108; results are shown for SNVs in LD w
bottom indicate the coverage of the region by GWAS SNVs (upper ro
114 The American Journal of Human Genetics 96, 104–120, January 8on AD and a significant opposing effect on psoriasis. A
further opposing locus mapped to HLA-C*03:03 (Table 3).
The reported observation of AD occurring within the
offspring of parents with psoriasis8 is not supported by
our findings, and the observation that both Th1-cell-domi-
nated autoimmune and Th2-cell-dominated allergic dis-
eases can show aggregation within families7 also presents
a discrepancy with our analyses. It is possible that there
are shared risk loci for AD and psoriasis that were not de-
tected in our current study because of lack of power, if
the shared effect is not strong; alternatively, there might
be hereditary risk factors associated with predisposition
to any chronic inflammatory (auto-)immune disease. It is
also possible that diagnostic misclassification occurs,
particularly in pediatric cases, where the clinical signs of
psoriasis are more difficult to distinguish from AD than is
the case in adult disease,66 or by recall bias for disease in
parents.
It is interesting to estimate the extent to which our find-
ings can explain the mutual exclusivity of AD and psoria-
sis, but an accurate assessment is hindered by the lack of
published data on the proportion of AD and psoriasis cases
where the diseases do and do not co-occur. Henseler et al.
report a 25-fold lower prevalence of AD occurring in psori-
asis cases5 and assuming a prevalence of 10% and 2% for
AD and psoriasis, respectively,3,4 we estimate that the ef-
fects at the six opposing loci listed in Tables 1, 2, and 3
would result in a reduction in prevalence of AD from
10% to 8% within the group of individuals with psoriasis.
This 2% reduction contrasts with the 25-fold reduction re-
ported by Henseler et al.,5 which is equivalent to a reduc-
tion of 9.6%, from 10% in the population to 0.4%. Our re-
sults have therefore explained approximately 21% (2/9.63
100) of the mutual exclusivity of AD and psoriasis.
Taken together, our comparative analyses of AD and pso-
riasis support a paradigm in which genetic factors deter-
mining keratinocyte differentiation and cutaneous barrier
function have particularly strong effects on AD risk,
whereas in psoriasis genetic factors influencing (auto-)anti-
gen recognition are of paramount importance. Further-
more, multiple pleiotropic loci with antagonistic effects
contribute to opposing mechanisms of adaptive immunity
in both AD and psoriasis.
The meta-analysis-inspired methodology developed in
the course of this study has demonstrated the power to
leverage additional information from GWAS and high-
density SNV data and to dissect cross-phenotype associa-
tions. AD and psoriasis are particularly well suited to the
compare/contrast approach, but this methodology willual AD-specific association after conditioning on the lead SNVs in
k triangles indicate the residual AD-specific association after addi-
associated with AD). SNVs indicated by the same symbol are in LD
R 0.5). Vertical gray shading marks the positions of known genes
eb. 2009), and horizontal dotted lines indicate significance thresh-
ith the lead SNV (defined as r2 R 0.5). The horizontal bands at the
w) and ImmunoChip SNVs (lower row).
, 2015
Table 2. Conditional Analysis of the 1q21.3 and 5q31.1 Regions Showing Disease-Specific and Opposing Risk Effects in AD and Psoriasis
Data
Source Effect SNV Pos (hg19) Allele
Candidate
Genes
AD Psoriasis
poverall
a
AD Psoriasis
Poverall
aOR (95% CI) p OR (95% CI) p OR (95% CI) p OR (95% CI) p
Chromosome 1q21.3
Unconditioned Analysis Conditional Analysisb
GWAS Opposing rs12130219 152162106 G/A FLG-AS1/
RPTN/HRNR
0.66
(0.60–0.73)
1.1 3 1016 1.15
(1.09–1.224)
4.0 3 106 1.2 3 1023 0.812
(0.71–0.93)
0.0018 1.119
(1.05–1.19)
3.68
3 104
2.4 3 106
GWAS AD rs12144049 152440910 C/T FLG 1.53
(1.42–1.64)
2.7 3 1030 0.98
(0.92–1.03)
0.4140 3.0 3 1030 – – – –
GWAS Psoriasis rs1581803c 152592281 G/T LCE3B/
LCE3D
0.97
(0.90–1.04)
0.4396 1.22
(1.16–1.30)
1.5 3 1012 1.6 3 1012 – – – –
GWAS Opposing rs35722864 153040505 G/GA SPRR cluster 0.81
(0.75–0.88)
1.0 3 107 1.129
(1.07–1.20)
2.1 3 105 4.8 3 1013 0.851
(0.71–0.93)
0.0019 1.074
(1.01–1.14)
0.0211 1.3 3 104
Chromosome 5q31.1
Conditional Modelsd Full Model
Ichip Opposing rs6596086 131952222 C/T RAD50 1.31
(1.22–1.41)
1.7 3 1013 0.86
(0.80–0.92)
1.7 3 105 5.7 3 1021 1.17
(1.07–1.28)
4.04 3 104 0.88
(0.81–0.96)
0.0023 6.3 3 107
Ichip AD rs848 131996500 A/C IL13 1.20
(1.10–1.30)
5.6 3 105 0.96
(0.89–1.04)
0.3375 4.14 3 105 1.12
(1.02–1.23)
0.0197 0.96
(0.88–1.05)
0.3515 0.0204
Ichip AD rs2299009 132042813 G/T IL4/KIF3A 1.14
(1.06–1.23)
7.9 3 104 0.99
(0.92–1.06)
0.7392 0.0018 1.16
(1.07–1.25)
2.03 3 104 0.99
(0.92–1.06)
0.6657 4.1 3 104
Ichip AD rs74458173 131621731 A/C SLC22A4 1.57
(1.26–1.96)
6.1 3 105 1.02
(0.80–1.30)
0.8590 2.14 3 104 1.57
(1.26–1.96)
5.71 3 105 1.02
(0.80–1.30)
0.8683 2.0 3 104
Full model incorporates the combined effects of independent SNVs identified by stepwise analyses.
apoverall represents the overall opposing signal calculated using the T12opposing statistic and derive the p value from the normal distribution.
bConditional analysis of chr1q21.3 was conditioned on FLG for AD and LCE3B/LCE3D for psoriasis.
crs1581803 tags the previously reported psoriasis SNV rs4112788 (r2 ¼ 0.995).
dStepwise conditional analysis at chr5q31.1 was carried out usingmultinomial regression models and resulted in three additional signals for AD; this table shows only independent loci (r2< 0.5) and the SNV with the strongest
association; the effect allele is underlined.
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Figure 5. Conditional Regional Association within the Major Histocompatibility Complex at 6p21–22 via GWAS and ImmunoChip
Data
Symbols indicate association results after each step of analysis, as follows. Unconditioned psoriasis-specific results are shown by red dots;
red triangles show psoriasis-specific association results after conditioning on C*06:02 (known to be strongly associated with psoriasis);
red3s indicate psoriasis-specific association after conditioning on C*06:02 andMICA; blueþs indicate the association after conditioning
on C*06:02, MICA, and HLA-A with opposing effects on AD and psoriasis; and blue squares indicate the residual association after con-
ditioning on C*06:02,MICA, HLA-A, and HLA-DRB1with opposing effects on AD and psoriasis. SNVs indicated by the same symbol are
in LD with the lead SNVof each stepwise conditional analysis (defined as r2 R 0.5). Vertical shadingmarks the positions of known genes
(identified from the UCSC Genome Browser GRCh37/hg19 accessed Feb. 2009) and HLA classes; horizontal dotted lines indicate signif-
icance thresholds of p ¼ 105 and p ¼ 108; results are shown for SNVs in LD with the lead SNV (defined as r2 R 0.5). The horizontal
bands at the bottom indicate the coverage of the region by GWAS SNVs (upper row) and ImmunoChip SNVs (lower row).be applicable to many other complex traits with overlap-
ping and disease-specific phenotypic features. Character-
izing shared and opposing molecular mechanisms across
complex phenotypes will expand our understanding of
biology and disease and will have implications for treat-
ment and drug discovery.Supplemental Data
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Table 3. Conditional Analysis of the MHC Region on 6p21–22 Showing Psoriasis-Specific and Opposing Risk Effects in AD and Psoriasis
Data
Source Effect SNV Pos (hg19) Allele
HLA Allele/
Candidate
Genes
Conditional Modelsa Full Model
AD Psoriasis
poverall
AD Psoriasis
poverallOR (95% CI) p OR (95% CI) p OR (95% CI) p OR (95% CI) p
GWAS PSO rs111576655 31242731 A/T C*06:02 0.84
(0.74–0.95)
0.0053 4.41
(4.10–4.74)
3.1 3 10376 9.8 3 10380 1.12
(0.81–1.54)
0.5071 3.32
(2.90–3.81)
2.3 3 1069 3.2 3 1065
GWAS PSO rs201374403 31383754 T/TAG MICA 0.78
(0.7–0.88)
6.4 3 105 1.68
(1.56–1.8)
7.9 3 1048 2.2 3 1053 0.81
(0.67–0.96)
0.0174 1.65
(1.50–1.81)
1.8 3 1025 1.0 3 1026
GWAS PSO rs113573479 29842444 A/G HLA-A 0.89
(0.81–0.97)
0.0109 1.39
(1.30–1.49)
6.6 3 1025 1.0 3 1026 0.92
(0.81–1.04)
0.1948 1.41
(1.30–1.52)
2.8 3 1017 2.7 3 1017
GWAS opposing rs28383201 32574869 C/G HLA-DRB1 0.59
(0.51–0.68)
4.6 3 1013 1.15
(1.06–1.24)
4.5 3 104 3.3 3 1016 0.61
(0.52–0.71)
3.4 3 1010 1.18
(1.08–1.28)
1.0 3 104 6.5 3 1014
GWAS opposing rs1793889 31222181 A/G HLA-C 0.60
(0.50–0.73)
2.5 3 107 1.18
(1.07–1.31)
0.0011 1.1 3 109 0.60
(0.50–0.73)
2.5 3 107 1.18
(1.07–1.31)
0.0011 1.1 3 109
Data
Source Effect HLA Allele
HLA Allele
Frequency in
Ps/AD/Controls
Conditional Modelsa Full Model
AD Psoriasis
poverall
AD Psoriasis
poverallOR (95% CI) p OR (95% CI) p OR (95% CI) p OR (95% CI) p
GWAS PSO C*06:02 0.271/0.075/0.089 0.81 (0.71–0.91) 8.48 3 104 4.28 (3.98–4.61) 2.9 3 10362 1.30 3 10368 0.97 (0.82–1.15) 0.7475 3.59 (3.26–3.95) 2.1 3 10159 8.7 3 10154
GWAS PSO A*02:01 0.28/0.227/0.239 0.95 (0.88–1.03) 0.1793 1.32 (1.24–1.40) 4.1 3 1020 1.1 3 1020 0.99 (0.90–1.08) 0.7739 1.32 (1.24–1.41) 1.8 3 1017 1.1 3 1016
GWAS PSO B*57:01 0.13/0.017/0.032 0.61 (0.46–0.80) 3.83 3 104 1.63 (1.44–1.84) 8.0 3 1015 5.8 3 1020 0.60 (0.42–0.85) 0.0039 1.58 (1.38–1.81) 3.8 3 1011 1.1 3 1013
GWAS PSO C*12:03 0.048/0.044/0.038 0.87 (0.74–1.03) 0.1169 1.74 (1.54–2.00) 5.2 3 1018 3.5 3 1019 0.86 (0.72–1.04) 0.1295 1.85 (1.62–2.11) 7.5 3 1020 1.8 3 1020
GWAS PSO B*27:05 0.032/0.02/0.025 0.80 (0.63–1.01) 0.0619 1.59 (1.37–1.86) 2.9 3 109 3.2 3 1010 0.74 (0.55–1.00) 0.0499 1.50 (1.28–1.76) 7.3 3 107 1.8 3 107
GWAS PSO A*01:01 0.221/0.154/0.166 1.03 (0.94–1.13) 0.5475 1.25 (1.17–1.35) 2.3 3 1010 1.7 3 109 1.08 (0.96–1.21) 0.2013 1.23 (1.14–1.33) 6.8 3 108 4.0 3 107
GWAS opposing C*03:03 0.037/0.025/0.038 0.66 (0.54–0.81) 9.71 3 105 1.30 (1.13–1.49) 2.5 3 104 5.9 3 108 0.71 (0.56–0.90) 0.0040 1.27 (1.10–1.47) 0.0011 2.3 3 105
GWAS opposing DQA1*02:01 0.186/0.055/0.098 0.64 (0.54–0.76) 3.44 3 107 1.09 (1.01–1.19) 0.0385 6.0 3 108 0.64 (0.54–0.76) 3.4 3 107 1.09 (1.01–1.19) 0.0385 6.0 3 108
Effect allele is underlined. Abbreviations are as follows: PSO, psoriasis; AD, atopic dermatitis. Table shows only independent loci (r2 < 0.5) and the SNV with the strongest association.
aStepwise conditional analysis was carried out with multinomial regression models and resulted in three psoriasis-specific and two opposing signals.
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